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ABSTRACT 
Huntington’s disease (HD) is a neurodegenerative movement disorder caused by 
abnormal cytosine-adenine-guanine (CAG) expansion on the HTT gene. As both a proteinopathy 
and the most common PolyQ disease, HD shares key features with several disorders that 
disproportionately affect the growing elderly population in the United States, including delayed-
onset, selective neuronal death, and protein misfolding. Across these conditions, there are few 
treatments and no known cures; however, their shared features suggest common underlying 
mechanisms, and delayed-onset hints at possible prevention or reversal. CAG-expansion-number 
and age are related to diagnosis and can be used to estimate age-of-onset for prodromal (pre-
diagnosis) individuals, who possess the causal mutation but have not manifested diagnosis-
associated motor symptoms. Over a decade before diagnosis, prodromal individuals differ from 
controls in brain structure and connectivity, cognition, and motor functioning. Although age and 
CAG-number account for most observed variability in HD-onset, persons with identical CAG-
numbers often develop symptoms at different ages, indicating that additional genetic and 
environmental factors also mediate decline. Little is known about detrimental and protective 
genetic factors in HD. Studying prodromal progression can inform interventions by 
highlighting early prevention targets. 
This research leverages advanced multivariate techniques applied to legacy PREDICT-
HD data to characterize brain structure, cognition, and motor functioning across prodromal HD 
and investigate genetic factors accounting for variability in these domains. Regarding brain 
structure, these experiments provide evidence for: regional co-occurrence in prodromal decline, 
early fronto-striatal degradation, dorso-ventral reduction gradients, and delayed atrophy in 
certain movement-related and subcortical regions. The genetic findings suggest a protective role 
of NTRK2 and identify NCOR1 and ADORA2B variants with early, CAG-independent 
detrimental effects on gray matter. Previously identified onset-delaying variants are also 
confirmed as CAG-independent modulators of brain structure and clinical functioning. Clinical 
findings highlight motor functioning as the best indicator of brain-structural integrity until the 
late prodrome and demonstrate that distinct regions coincide with cognitive compared to motor 
functioning; furthermore, regions that most align with clinical functioning vary at different 
prodromal stages. 
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1 INTRODUCTION 
1.1 Background 
Huntington’s disease (HD) is a progressive, heritable, delayed-onset condition 
predominantly associated with involuntary movements, known as chorea (1). Other HD-
associated symptoms include impaired executive functioning (e.g., working memory, response 
inhibition) (1-3), emotional processing (e.g., reward and punishment processing, impulsivity, 
recognition of negative facial expressions) (4, 5), and odorant recognition (6). 
HD has variable global prominence and affects around 1 in 10,000 individuals in the 
United States (7). Like Alzheimer's (AD) and Parkinson's (PD) diseases, HD is a proteinopathy, 
marked by protein misfolding and accumulation and regionally-selective neuronal death (8). HD 
is also the most common PolyQ disease, distinguished by pathological cytosine-adenine-guanine 
(CAG) expansion (9). Thus, despite its infrequent occurrence, it shares key features with several 
disorders that typically manifest delayed onset, suggesting similarities in underlying 
mechanisms. Because onset is often delayed until middle or late life, treatments that postpone 
onset could effectively eliminate the disease for many individuals.  
Although there is no known cure for HD, its cause has been known since 1993, when an 
abnormally-expanded CAG repeat at an exon 1 locus of the HTT gene was identified as causal 
for HD (10). The normal range of CAG-repeats at this locus is 17-20, and individuals with fewer 
than 36 repeats are not at risk of HD (11). At CAG-numbers greater than 36 there is highly 
elevated risk of developing HD, although the range of 36-39 is considered not fully penetrant (1). 
Higher CAG-numbers are associated with younger age-of-onset (12-14) and more rapid and 
severe symptom progression (15), although variability in onset and progression is observed, 
especially at lower CAG-numbers (16-18). Because of the relationship between CAG and onset, 
2 
age of or time to HD diagnosis can be estimated for prodromal individuals (those with 36 or 
more CAG-repeats) (19); this estimation is most accurate at >44 repeats. 
 The relationship between age (duration of exposure) and CAG is aptly captured by CAG 
age product (CAP), calculated as age × (CAG-number − constant) (19). This empirically-
validated metric has been used to index disease burden and the prodromal period. Prodromal 
individuals possess the causal mutation for HD but have not yet exhibited diagnosis-associated 
motor symptoms. A decade or more before HD diagnosis, prodromal individuals already differ 
from controls in brain structure as well as cognitive and motor functioning (2, 18, 20). 
Characterizing these early changes is a promising tactic for identifying treatment targets for the 
earliest possible disease interventions (21). 
 One of the most extensive studies tackling characterization of the prodrome is PREDICT-
HD, a multisite research group whose primary objective is to describe early prodromal changes 
and identify promising therapeutic targets (14, 21, 22). The PREDICT-HD dataset includes 
genomic, brain imaging, clinical (cognitive and motor), and demographic data collected from 
over 1,400 control and prodromal participants. Through these efforts, PREDICT-HD has 
identified several early prodromal changes occurring a decade or more before HD diagnosis, 
including alterations in widespread gray matter concentration (23), cortical and sub-cortical brain 
volumes (14, 21, 22), white matter tracts (24), and resting-state functional connectivity (25); 
many of these domains were associated with differences in motor and cognitive functioning (2, 
20, 26). 
Although CAG-number and age explain most of the variance in HD progression and 
onset, much of this variability remains unaccounted for (16-18). Within PREDICT-HD, one 
participant with 44 repeats remained undiagnosed at age 71 and an additional 13 participants 
3 
with fewer than 41 repeats were undiagnosed at age 70. These examples illustrate the observed 
variability in HD; in other words, prodromal persons with identical CAG-numbers may develop 
diagnoses-associated motor symptoms at different ages. Highlighting this, a recent HD pedigree 
study demonstrated that about 40% of symptom and onset variability was attributable to non-
HTT genetic factors (27). However, little is known about genetic and environmental factors that 
account for these differences, and these factors are likely reflected by intermediate phenotypes 
(such as measures of brain structure and function, as well clinical functioning variables) 
throughout the prodrome (28-30). 
 
1.2 Prodromal Brain Structure and Clinical Functioning 
The most intense structural abnormalities in HD and prodrome are consistently reported in 
the striatum, and progressive striatal degeneration, particularly in the caudate and putamen, is a 
landmark feature of HD pathogenesis. However, far from being restricted to striatal regions, 
atrophy in both gray matter (31) and white matter (20, 32-37) is reportedly widespread, although 
findings are hardly uniform across studies. Consensus regions for prodromal effects include the 
left putamen and right inferior frontal gyrus (IFG), identified in a meta-analysis of both 
prodromal and diagnosed HD Voxel-based Morphometry (VBM) gray matter concentration 
(GMC) studies (31). Somewhat surprisingly, the meta-analysis did not report consistent 
differences from controls in caudate GMC until diagnosed HD. HD patients, but not prodromal 
participants, also reliably differed from controls in left IFG and right middle frontal gyrus 
(MFG).  
In WM, differences (generally diffusivity increases and anisotropy reductions) have been 
measured within tracts in and adjacent to the striatum (24, 32, 38-40), thalamus (32, 39-42), and 
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corpus callosum (32, 40, 41, 43), as well parietal, occipital, and frontal regions (24, 32, 43, 44). 
Longitudinally, prodromal WM reductions have been detected in superior fronto-occipital 
fasciculus (41), frontal cortex (45), and tracts connecting the striatum (especially the putamen) 
with premotor, primary motor and sensory cortices (24). GM-adjacent-WM may account for 
most of these WM differences, as evidenced by a study reporting more significant atrophy in 
GM-adjacent-WM compared to whole WM (32). 
Many studies of prodromal brain structure have not staged the prodrome; those that did 
have noted marked differences in brain structure depending on the degree of prodromal 
progression. In a study of cortical thinning across the prodrome, the earliest changes were 
detected in cortical areas including primary auditory cortex (46); this thinning extended into 
adjacent regions later in the prodrome, in conjunction with occipital and frontal cortical regions 
(such as premotor and supplementary motor cortices) and parietal areas (including precuneus). 
By the late prodrome, thinning was evident in most of the cortex, although anterior frontal and 
inferior temporal areas were comparatively spared.   
Studies linking brain structure to motor and cognitive functioning in prodromal HD 
consistently highlight the sensitivity of particular clinical assessments to prodromal changes in 
brain structure, including: the Unified Huntington’s Disease Rating Scale Total Motor Score 
(UHDRS-TMS) (20), the Symbol Digit Modalities Test (SDMT) (20), Trail-Making Tests A and 
B (TMTA, TMTB) (47, 48), and Stroop tasks (48). In one of the few longitudinal brain-structural 
and clinical functioning studies, UHDRS-TMS was the only independent predictor of WM 
decline in HD and the prodrome (47). Associations with prodromal clinical functioning have 
been reported in widespread brain regions, including the putamen, thalamus, corpus callosum, 
and regions in every lobe of the brain (20).  
5 
 
1.3 Genetic Modifiers of Prodromal Symptoms 
HTT, the site of the causal locus for HD, encodes the ubiquitously expressed huntingtin 
protein. Mutant huntingtin (mHTT) interferes with important cellular functions spanning 
endocytosis (49), secretion (49), calcium homeostasis (50), glutamatergic synaptic signaling 
(51), vesicular transport (52), mitochondrial functioning, p53 signaling (53), apoptosis (54), and 
transcription (52), among others; genes that contribute to these processes, particularly via 
interactions with HTT, are especially promising candidate modifiers of HD progression and 
onset.  
Some candidates are particularly relevant to prodromal HD, including brain-derived 
neurotrophic factor (BDNF), a neurogenesis promotor that colocalizes with the majority of 
pyramidal motor cortical (99%) and striatal (75%) neurons and is necessary for the survival and 
signaling of medium spiny striatal neurons (MSNs), by far the most afflicted neuronal population 
in HD (55). In mice, prodromal BDNF reductions that are more severe at higher CAG-numbers 
have been reported and associated with worsening motor symptoms and structural changes in the 
brain (56), and the effects of reduced BDNF on MSN survival increases with age in a manner 
that is consistent with delayed-onset. Because mHTT disrupts the transcription and vesicular 
transport of BDNF, it is likely that the effects of BDNF and BDNF-signaling-genes are 
modulated at least in part by CAG. While several other genes have been identified as potential 
modifiers of HD progression and onset (29, 30, 57-60), including ADORA2A (61, 62) and 
GRIN2B (63), few studies have examined genetic effects on brain-based phenotypes and clinical 
functioning. Genetic effects independent from CAG are also relatively unexplored. 
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Several methods are available to probe for genetic modifiers of disease states, with 
genome-wide association studies (GWAS) being among the most popular. Although these 
methods have led to valuable insights into many healthy and clinical phenotypes alike, the tens 
of thousands of participants required to isolate effects with statistical confidence can be an 
infeasible data collection feat for researchers dealing with rare clinical populations like HD. 
Furthermore, disease phenotypes are often the consequence of multiple gene interactions rather 
than a single variant (64). Due to stringent statistical thresholds, univariate methods such as 
GWAS often isolate only one or two of the most influential variants, missing important 
covariation and obscuring detection of underlying pathways (64, 65).  
Fortunately, several multivariate approaches are now available that permit the assessment 
of interrelated patterns rather than point-by-point comparisons, enabling detection of weaker 
effects in complex, high-dimensional datasets (64, 65). Many of these methods are based on a 
source localization technique known as Independent Component Analysis (ICA) that has many 
applications involving the extraction of independent sources from a mixed signal (66). One such 
technique, Source-based Morphometry (SBM), is an ICA-based method optimized for brain 
imaging data that extracts maximally independent imaging patterns (each comprised of multiple 
co-occurring brain regions) from a population (67). SBM is not limited to regions of interest and 
has demonstrated enhanced sensitivity to widespread and early clinical differences compared to 
similar univariate methods such as VBM (67, 68). Another ICA-based method, parallel ICA 
(pICA), permits simultaneous assessment of multimodal data (such as genomic and imaging 
data), such that the cumulative influences of multiple genetic variants on brain imaging pattern 
phenotypes can be investigated (64, 65). PICA is both an exploratory and hypothesis-driven 
technique that is ideal for investigating interactions among multiple genes. 
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1.4 Purpose of the Study  
The present study encompasses four overarching experiments that leverage powerful 
multivariate methods and one of the largest, most comprehensive prodromal HD datasets to 
clarify prodromal patterns in clinical and brain-structural decline (in both gray matter and white 
matter) across the HD prodrome. Furthermore, these experiments test for genetic mediators that 
confer susceptibility or resilience to prodromal decline. The exploration of detrimental and 
protective genetic factors in HD and the prodrome is still in its infancy, and elucidating these 
mediators is an important step toward identifying targets for early therapeutic interventions. In 
addition to testing specific hypotheses (e.g., BDNF) and providing exploratory framework for 
future research, these experiments provide a means for re-establishing or refuting previous 
findings from smaller prodromal HD studies, as well as provide insight regarding changes across 
the prodrome that is missing from many HD studies. 
 
1.4.1 Experiment 1 
 In the first study, gray matter concentration (GMC) patterns at various stages of 
prodromal HD are cross-sectionally characterized in the largest VBM (univariate) and the first 
SBM (multivariate) study in this population. This work also provides a methodological 
comparison of VBM and SBM for use in prodromal HD studies, as the same imaging 
segmentations are used as input files in both analyses.    
Expected Results: differences between control and prodromal participants, as well as 
different prodromal groups, are expected. The most substantial GM reductions are anticipated in 
the caudate. GM components (i.e., profiles) are expected to include groupings of functional and 
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structural neighbors (e.g., the caudate is expected to co-occur with the putamen, thalamus, and 
connected cortical areas). Methodologically, the multivariate SBM method is predicted to 
uncover a greater number of affected regions than univariate VBM, particularly in the early 
prodrome; however, substantial overlap between VBM and SBM results is also expected, 
particularly in consensus regions such as the striatum. 
 
1.4.2 Experiment 2 
 In this experiment, cross-sectional and longitudinal co-occurring changes in gray-matter-
adjacent white matter (WM) are delineated and compared to cognitive and motor functioning 
variables by leveraging linear mixed model (LMM) analyses.  
Expected Results: cross-sectionally and longitudinally, the prodromal groups closest to 
and furthest from estimated diagnosis are expected to differ most and least drastically from 
controls, respectively, across measures of WM and clinical functioning. Across groups, frontal 
WM changes are anticipated to align most with changes in cognitive functioning. Across groups, 
changes in the striatum, thalamus, and cortical areas important for movement (such as primary 
motor, premotor, and supplementary motor cortices) are expected to be most similar to changes 
in motor functioning. 
 
1.4.3 Experiment 3 
 Using pICA with references, the hypothesis that BDNF-signaling-related genes influence 
prodromal brain structure and clinical functioning is tested in a prodromal cohort (N =715).  
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Expected Results: SNP profiles encompassing multiple genes are anticipated to correlate 
with GMC profiles that relate to clinical functioning. Maximum effects are expected in genetic 
profiles highlighting BDNF-signaling-related genes. 
 
1.4.4 Experiment 4 
This study assesses CAG-independent genetic effects on prodromal brain structure and 
clinical functioning: (1) in a full genomic dataset; (2) within a pre-established pathway of genes 
implicated in HD pathology; (3) within a candidate region of ch15q13.3 previously associated 
with delayed HD-onset. 
Expected Results: at least one genetic profile extracted from the HD pathway gene 
dataset is anticipated to correlate with a GM profile, after accounting for CAG effects. Variants 
in the ch15q13.3 candidate region are expected to correlate with GM and clinical functioning 
variables.  
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2  PATTERNS OF CO-OCCURRING GRAY MATTER CONCENTRATION LOSS 
ACROSS THE HUNTINGTON’S DISEASE PRODROME 
This chapter has been previously published as Ciarochi JA, Calhoun VD, Lourens S, Long JD, Johnson 
HJ, Bockholt HJ, Liu J, Plis SM, Paulsen JS, Turner JA; PREDICT-HD Investigators and Coordinators of the  
Huntington Study Group. Patterns of Co-Occurring Gray Matter Concentration Loss across the Huntington Disease 
Prodrome. Front Neurol. 2016 Sep 21;7:147. 
2.1 Abstract 
Huntington disease (HD) is caused by an abnormally expanded cytosine–adenine–
guanine (CAG) trinucleotide repeat in the HTT gene. Age and CAG-expansion number are 
related to age at diagnosis and can be used to index disease progression. However, observed 
onset-age variability suggests that other factors also modulate progression. Indexing prodromal 
(pre-diagnosis) progression may highlight therapeutic targets by isolating the earliest-affected 
factors. We present the largest prodromal HD application of the univariate method voxel-based 
morphometry (VBM) and the first application of the multivariate method source-based 
morphometry (SBM) to, respectively, compare gray matter concentration (GMC) and capture co-
occurring GMC patterns in control and prodromal participants. Using structural MRI data from 
1050 (831 prodromal, 219 control) participants, we characterize control-prodromal, whole-brain 
GMC differences at various prodromal stages. Our results provide evidence for (1) regional co-
occurrence and differential patterns of decline across the prodrome, with parietal and occipital 
differences commonly co-occurring, and frontal and temporal differences being relatively 
independent from one another, (2) fronto-striatal circuits being among the earliest and most 
consistently affected in the prodrome, (3) delayed degradation in some movement-related 
regions, with increasing subcortical and occipital differences with later progression, (4) an 
overall superior-to-inferior gradient of GMC reduction in frontal, parietal, and temporal lobes, 
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and (5) the appropriateness of SBM for studying the prodromal HD population and its enhanced 
sensitivity to early prodromal and regionally concurrent differences. 
 
2.2 Introduction 
Huntington disease (HD) is a progressive, heritable condition most frequently associated 
with involuntary movements, and also characterized by impairments in executive functioning (1-
3), recognition of negative facial expressions (4), and odorants (6), reward and punishment 
processing, and impulsivity (5). It is caused by an abnormally large cytosine–adenine–guanine 
(CAG) repeat expansion on the HTT gene. Age at motor diagnosis (12-14) and rate of disease 
development (15) are related to CAG-expansion and can be used to index the prodromal (pre-
diagnosis) period; greater expansion numbers are associated with earlier onset and more rapid 
progression. Persons with fewer than 36 CAG-repeats are not at risk of HD; the range of 36–39 
is not fully penetrant, as individuals can die of other natural causes. CAG-expansion is fully 
penetrant for 40 or more repeats, as individuals in this range will develop diagnosable symptoms 
if they reach a sufficient age (1). Despite progress in elucidating the mechanisms of HD, there is 
currently no cure. Identifying brain regions and functions impacted at the earliest pre-diagnosis 
stages is crucial for developing therapies to halt or reverse this tragic condition. 
The current analyses use the PREDICT-HD dataset (21) to examine patterns of gray 
matter concentration (GMC) reduction in prodromal HD. PREDICT-HD is a multisite study 
containing possibly the largest collection of imaging data from individuals at various prodromal 
progression stages (14). We present the first application of multivariate source-based 
morphometry (SBM) and the largest application of univariate voxel-based morphometry (VBM), 
to a prodromal HD population, using a subset of 1050 PREDICT-HD participants to characterize 
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GMC across the prodrome. VBM allows whole-brain, voxel-by-voxel concentration or volume 
comparisons (69) and has previously been applied to smaller prodromal HD populations [see 
Lambrecq et al. (31) meta-analysis for GMC and Dogan et al. (70) meta-analysis for GM 
volume]. Most of these studies did not stage the prodrome or included symptomatic HD patients, 
precluding identification of the earliest-affected factors. 
Source-based morphometry, by contrast, is a multivariate approach that performs 
independent component analysis (ICA) on the same segmented structural images used for VBM, 
to examine co-occurring GMC patterns (67). Like VBM, SBM is beneficial for examining 
changes across the whole brain, rather than being limited to regions of interest. Unlike VBM, 
SBM is capable of determining the co-occurrence of gray matter differences in various areas of 
the brain. It is also more robust at localizing these changes (67, 68). SBM has been successfully 
applied to other clinical populations, including movement disorders such as multiple sclerosis 
(71) and Parkinson’s disease (72). It has also been used to study schizophrenia (68, 73-79) and 
Alzheimer’s disease (80), which share key features with HD, such as delayed onset, regional and 
cellular selectivity of atrophy, and cognitive abnormalities. Additionally, SBM may be more 
sensitive than previous methods to earlier and more widespread structural differences (67, 68, 75, 
81). It also ameliorates the multiple comparisons problem by decreasing the number of maps 
being tested for group differences and can capture noise in the data as separate components that 
can be easily removed (68, 79). The ability to capture patterns of covariation enables exploration 
of the diffusivity or specificity of anatomical changes (71), extending interpretation beyond what 
regions are affected to identification of regions that are affected together. 
We predict an overlap between significant regions in SBM and VBM results, with SBM 
revealing a greater number of affected regions, particularly in the early prodrome. We anticipate 
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differences in these components not only between cases and controls but also among different 
prodromal levels. We expect the caudate to be among the most significantly affected regions, 
grouped in a component with functional and spatial neighbors, such as the putamen, thalamus, 
and cortex. Other significant components are expected to also include functionally related 
regions. 
2.3 Materials and Methods 
2.3.1 Participants  
A total of N = 1292 (1016 prodromal and 276 control) participants were analyzed. Of 
these, 242 were excluded because of conversion to HD diagnosis (N = 82) or relatedness to 
another participant (N = 160). The remaining dataset included 1050 individuals (Table 2.3—1): 
831 prodromal (521 females, mean age = 40.94, SD = 10.86, range 18.84–71.27; 310 males, 
mean age = 42.23, SD = 10.82, range 20.06–82.53) and 219 controls (137 females, mean 
age = 46.27, SD = 10.86, range 20.38–68.61; 82 males, mean age = 45.90, SD = 13.59, range 
19.15–85.74). 
 
Table 2.3—1. Participant Demographics 
CAP group N 
(male/female) 
Mean age ± SD in 
years 
Mean years of 
education ± SD 
Mean CAG-repeat 
number ± SD 
Control 219 
(82/137) 
46.1 ± 11.9a 14.8 ± 3.0d 20.1 ± 3.5 
Low 216 
(72/144) 
34.6 ± 9.0a–c 14.1 ± 3.7 41.0 ± 1.9 
Medium 284 
(108/176) 
41.5 ± 9.9a–c 14.6 + 2.9 42.1 ± 2.2 
High 331 
(130/201) 
45.9 ± 10.5b 14.0 ± 3.5d 43.6 ± 9.4 
Participant CAP groups with mean age, years of education, and CAG-repeat number ± the SD. 
aThe mean age of the control group was significantly greater than that of the medium and low 
groups. bThe high group mean age was significantly greater than that of the medium and low 
groups. cThe medium group was significantly older than the low group. dThe control group had 
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significantly more years of education than the high group. Significant differences are not 
displayed for CAG-repeat number, as CAP group is based on CAG-repeat number, and is thus 
expected to significantly differ among prodromal groups. 
 
All PREDICT-HD participants provided written, informed consent and were treated in 
accordance with protocols approved by each participating institution’s internal review board. All 
participants underwent genotyping prior to study enrollment. Healthy controls had fewer than 36 
HTT CAG-repeats, while prodromal individuals had more than 35. Exclusion criteria included 
manifestation of any other central nervous system condition or unstable medical or psychiatric 
disorders (1). 
Prodromal progression level (low, medium, or high) for this study was indexed by a CAP 
score for each participant’s scanning session. CAP is a widely used measure for staging the 
prodrome and was developed based on an accelerated failure time model analysis with the entire 
PREDICT-HD database. CAP score factors age at first session and number of HTT CAG-repeats 
to assess prodromal disease burden [CAP = (age at first measurement) × (CAG − 33.6)]. For the 
present study, participants were classified into low, medium, and high CAP groups based on the 
algorithm described by Zhang et al. (19). 
 
2.3.2 Imaging Parameters 
High resolution anatomical MR images were collected at 32 collection sites (53 unique 
scanners) using General Electric, Phillips, and Siemens scanners with field strengths of 1.5 T 
(Tesla) or 3 T, using a variety of acquisition parameters. T1 images at each site were obtained 
using three-dimensional (3D) T1-weighted inversion recovery turboflash (MP-RAGE) 
sequences. Also, 1.5 T scans were collected using General Electric and Siemens scanners. The 
Siemens protocol was constructed to be similar to the General Electric scan parameters: 
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GRAPPA factor, 900 ms TI (inversion time), 2530 ms TR (relaxation time), 3.09 ms TE 
(excitation time), 256 mm × 256 mm field of view (FoV), 10° flip angle, 240 coronal slices with 
1 mm slice thickness, 256 × 128 matrix with 1/4 phase FoV, 220 Hz/pixel receiver bandwidth. 
Protocol for 3 T scanners commonly involved a sagittal localizing series followed by acquisition 
of an axial 3D volumetric spoiled gradient recalled acquisition in steady state (GRASS) 
sequence, using the following scan parameters: ~1 mm × 1 mm× 1.5 mm voxel size, 18 ms TR, 
3 ms TE, 24 cm FoV, 20° flip angle, 124 slices with 1.5 mm slice thickness, 0 mm gap, 256 × 192 
matrix with 3/4 phase FoV, number of excitations (NEX) of two. 
 
2.3.3 Preprocessing 
For each participant, the highest-quality T1 images from the earliest available scanning 
session were used for analyses. Images were aligned with the anterior commissure–posterior 
commissure (AC–PC) plane, resampled with 1 mm isotropic voxels to correct for inhomogeneity 
(82), and preprocessed using the SPM8 software package1. All images were segmented into gray 
matter, white matter, and cerebrospinal fluid, unmodulated (to isolate GM concentration) and 
normalized to the same SPM8 Montreal Neurological Institute (MNI) template. Voxel intensities 
of normalized, segmented images represent relative voxel GMC. Image voxels were re-sliced to 
2 mm × 2 mm × 2 mm. Gray matter images were smoothed to a full-width-half-maximum 
(FWHM) Gaussian kernel of 10 mm, based on recommendations for using high cluster-forming 
thresholds to reduce false positive rates in VBM studies (83). Processed images were 
90 × 109 × 91 voxels in size. 
 
                                                 
1 http://www.fil.ion.ucl.ac.uk/spm/software/spm8 
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2.3.4 Source-based Morphometry 
Source-based morphometry, using the GIFT Matlab toolbox2, was used to apply ICA to 
preprocessed (segmented, normalized, unmodulated, and smoothed) GMC images. The number 
of components from the 1050 images was estimated to be 23 using a minimum description length 
(MDL) criterion modified to account for correlated voxels (84). Each image was converted to a 
one-dimensional vector, yielding one participant-by-voxel data matrix. Using the infomax 
algorithm for spatial ICA, this matrix was decomposed into a mixing matrix, representing the 
relationship between 1050 participants and 23 components, and a source matrix, representing the 
relationship between the 23 components and the brain voxels. For the mixing matrix, rows are 
scores signifying how much each of the 23 components contributes to one participant’s data, 
while columns signify how one component contributes to each of the 1050 participants. The 
source matrix rows denote the degree to which one component contributes to brain voxels, while 
the columns are scores representing how a single voxel contributes to each of the 23 components 
(67). For each participant, the decomposition yields a loading coefficient for each component, 
with each component as a spatial map. ICASSO (85) was used to confirm component stability 
(20 iterations), and components were visually inspected to ensure that they primarily represented 
gray matter, rather than white matter or ventricles. As all 23 components were stable (with a 
minimum stability of above 0.90 and 21 components above 0.95), each participant had 23 
loading coefficients. 
MRI scanner site (53 sites total), gender, and CAP group were included as fixed factors, 
and years of education, age, and age2 were included as covariates. To examine the effects of 
CAP group on each SBM structural imaging component, a multivariate analysis of covariance 
                                                 
2 http://mialab.mrn.org/software/gift 
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(MANCOVA) using the General Linear Model (GLM) framework (with 23 dependent variables 
consisting of loading coefficients for each of the components) was executed in SPSS (86), 
followed by a Sidak post hoc test (34), thresholded at p ≤ 0.05, to examine specific CAP-group 
pairwise contrasts. The primary contrasts of interest were comparisons of the control group with 
each CAP group (low, medium, and high), as these contrasts represent differences between 
unaffected controls and different prodromal progression levels. Other pairwise contrasts (GMC 
in low > medium and medium > high) are included in Appendix A.1. 
 
2.3.5 Voxel-based Morphometry 
Voxel-based morphometry was carried out using SPM83 to compare local average GMC 
voxel-by-voxel across the entire brain. Input files were the same segmented, unmodulated, 
smoothed gray matter images used for SBM. To confirm proper registration of participant 
images to the SPM template, a correlation test was run to compare each image to the template. 
All resulting correlations were between 0.82 (only 5 images) and 0.96 (34 images). This is within 
the normal correlation range for SPM8, with 87% of images yielding correlations of 0.9 or 
higher. As an additional check, images with the lowest correlations were inspected using SBM’s 
checkreg. Analyses of CAP-group main effects and all pairwise group contrasts were carried out 
within the GLM framework, using the same covariates used for SBM (age, age2, gender, years of 
education, and scanning site). The main effects of group were determined with an F-test, and 
two-sided t-tests were used to compare pairwise group differences. Results were thresholded at a 
family-wise error (FWE) rate of p ≤ 0.05. Both positive and negative contrasts were investigated. 
 
                                                 
3 http://www.fil.ion.ucl.ac.uk/spm/software/spm8 
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2.3.6 Statistical Analysis 
For the SBM analysis, variance equality was confirmed through Levene’s test for 
equality of variance for each SBM component, to address the assumption of homogeneity of 
variance among CAP groups. Potential outliers were examined via scatter plots of component 
loading coefficients versus CAP group. Each scanner site was investigated for the presence of 
outliers or unbalanced participant demographics, and no such biases were found (see Appendix 
A.4 for each site’s participant data). Effects of gender and age (independent of disease burden) 
on GMC were accounted for via their inclusion as a fixed factor and covariate, respectively, in 
all analyses. To control for the influence of age (independent of disease burden) on GMC, age 
and age2 were also included as covariates in all analyses. 
 
2.4 Results 
Participant demographics at baseline scan are presented in Table 2.3.1—1. ANOVA t-
contrasts revealed that the control group was significantly older than the medium [t501 = 4.79, 
p < 0.0001] and low [t433 = 11.39, p < 0.0001] groups. The high group was also significantly older 
than the medium [t613 = 5.30, p < 0.0001] and low groups [t498 = 8.04, p < 0.0001], and the 
medium group was older than the low group [t501 = 4.79, p < 0.001]. The control group also had 
significantly more years of education than the high group [t535 = 2.61, p = 0.0092]. 
 
2.4.1 Main Effect of CAP Group 
There was a statistically significant omnibus effect of the mean weighted composite of 
SBM component loading coefficients for CAP group (F69,1990.51 = 3.92, p < 0.0001; Wilk’s 
Λ = 0.68, 
2
p
 = 0.12). The MANCOVA revealed significant effects of CAP group on SBM 
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loading coefficients from 12 of the 23 extracted components; the spatial maps are shown in 
Figures 2.4.1—1 and 2.4.1—2 and the primary brain regions involved in Tables 2.4—1 and 
2.4—2. Each component’s loading coefficients displayed a progression gradient with means in 
the order of control > low > medium > high (Figure 2.4.1—3). The five components with the 
highest CAP-group significance [p < 0.0001; components A (
2
p
 = 0.04), B (
2
p
 = 0.092), C (
2
p

= 0.04), E (
2
p
 = 0.04), and M (
2
p
 = 0.04)] contained neural sources spanning each lobe of the 
brain, in addition to the striatum, with the greatest contributions from frontal and temporal in 
addition to striatal areas. A complete list of components and encompassing regions is available in 
Appendix A.3. 
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Figure 2.4-1. Components with strongest CAP-group significance (p ≤ 0.0001).  
Multiview topography of Table 2.4.1—1 components, thresholded between Z = 4.0 and the 
component’s maximum Z-score (presented in column 3) to optimize display of regions with 
highest Z-scores. 
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Figure 2.4-2. Additional components with CAP-group significance of p ≤ 0.004 
Coronal, sagittal, and axial views of Table 2.4.1—2 components, thresholded to optimally 
view regions with maximum Z-scores. Regions displayed in each component have Z-scores 
between 4.0 and the component’s maximum Z-score, displayed in column 3. 
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Table 2.4—1. SBM components with strongest CAP-group effects (p ≤ 0.0001) 
Component CAP effect 
statistic (F3,688) 
Most significant 
regions 
Left/right 
volume (cc) 
Left/right maximum Z 
coordinates (x, y, z) 
A 12.1915 Superior temporal 
pole 
2.4/2.3 7.4 (−38, 13, −24)/7.2 
(44, 16, −25) 
Superior temporal 2.8/2.2 5.8 (−49, −3, −3)/5.9 (51, 
1, −8) 
Anterior 
cingulate/medial 
1.7/2.2 5.1 (1, 44, 11)/5.7 (3, 50, 
−4) 
Frontal, 
parahippocampal 
0.3/0.2 3.9 (−14, −4, −23)/4.0 
(18, 1, −24) 
B 37.733 Caudate 3.8/3.9 12.5 (0.10, 17, 5)/11.6 
(14, 20, 4) 
Thalamus 1.8/2.1 8.7 (−5, −13, 16)/8.3 (10, 
−15, 16) 
C 11.948 Precentral/mid frontal 6.9/5.3 5.2 (−37, −6, 62)/4.9 (43, 
−4, 60) 
Precentral/superior 
frontal 
4.2/2.7 4.6 (−34, −1, 55)/4.6 (30, 
−2, 63) 
Supplementary motor 1.1/1.0 4.2 (−5, −7, 66)/4.1 (13, 
−0, 66) 
E 11.873 Supplementary motor 2.9/5.4 7.7 (2, 15, 49)/6.2 (6, 15, 
47) 
Frontal superior 0.3/0.1 5.5 (0, 31, 33)/2.8 (2, 
−72, 31) 
Medial/cuneus 4.6/3.4 7.1 (2, −33, 60)/6.4 (6, 
−31, 58) 
Paracentral lobule 3.6/3.2 7.0 (2, −33, 60)/5.8 (6, 
11, 46) 
Mid 
cingulate/precuneus 
4.0/5.1 5.6 (2, −42, 56)/5.5 (6, 
−44, 62) 
M 9.220 Calcarine 0.6/7.2 4.7 (−25, −60, 7)/10.6 
(27, −50, 13) 
Left precuneus 1.9 6.9 (−25, −51, 14) 
Left mid temporal 1.0 4.5 (−46, −51, 12) 
Left superior occipital 0.5 4.1 (−20, −68, 20) 
Regions within components A, B, C, E, and M, including CAP-group effect F statistic derived from 
the Sidak post hoc, bilateral maximum Z scores with corresponding Montreal Neurological 
Institute (MNI) coordinates, and volumes in cubic centimeters (cc). 
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Table 2.4—2. Additional SBM components with CAP significance of p ≤ 0.004. 
Component CAP effect 
statistic (F3,688) 
 Most significant 
regions 
Left/right 
volume (cc) 
Left/right maximum Z 
coordinates (x, y, z) 
G 5.650  Superior parietal 4.0/3.8 5.8 (−26, −71, 52)/5.0 
(28, −70, 53) 
 Angular gyrus 2.8/2.9 5.0 (−43, −65, 50)/4.6 
(45, −59, 53) 
 Left mid occipital 1.4 4.8 (−31, −80, 41) 
 Left inferior parietal 0.4 4.3 (−35, −78, 41) 
J 6.805  Right angular 1.2 5.2 (53, −48, 25) 
 Superior temporal 7.7/7.1 4.9 (−58, −12, 1)/4.8 (51, 
−47, 21) 
 Right precuneus 4.0 4.6 (14, −65, 24) 
 Right superior 
temporal 
2.9 4.6 (14, −65, 24) 
 Right cuneus 1.2 4.4 (21, −65, 26) 
O 9.418  Superior occipital 6.5/6.5 8.1 (−7, −101, 9)/7.6 (17, 
−98, 3) 
 Occipital/calcarine 0.9/1.1 6.5 (−12, −97, −3)/5.4 
(32, −95, −0) 
 Calcarine/inferior 
occipital 
1.0/1.9 6.3 (−5, −97, 21)/6.0 (10, 
−95, 23) 
 Occipital/calcarine 0.3/0.3 4.7 (−25, −96, 3)/5.9 (27, 
−93, 2) 
D 3.88  Middle frontal 5.0/7.2 5.1 (−30, 57, 12)/6.0 (30, 
54, 21) 
 Superior frontal 8.3/11.3 5.1 (−30, 50, 25)/5.9 (30, 
55, 17) 
 Medial frontal 0.4/1.2 4.9 (−10, 65, 12)/5.1 (10, 
65, 12) 
Regions within components G, J, O, and D (CAP-group significance of p ≤ 0.004), with CAP effect 
F statistics from the Sidak post hoc, bilateral maximum Z scores, and corresponding MNI 
coordinates and volumes. 
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Figure 2.4-3. CAP-group differences in SBM loading coefficients 
Significant pairwise group contrasts in CAP-group-significant components, derived from 
the Sidak post hoc test. Comparisons labeled with a single asterisk (*) denote significance 
of p ≤ 0.05; comparisons labeled with two asterisks (**) denote significance of p ≤ 0.0001. 
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All VBM results were thresholded at a FWE rate of p ≤ 0.05. Similar to the SBM results, 
the voxel-based F-test within the GLM framework revealed widespread gray matter degradation 
throughout disease progression, with the strongest effects in the caudate [F3,992 = 124.18, 
p < 0.0001, z = Inf (left); F3,992 = 131.13, p < 0.0001, z = Inf (right)]. Other regions exhibiting 
overall group differences included inferior frontal orbital [F3,992 = 12.14, p = 0.001, z = 5.23 
(left); F3,992 = 10.80, p = 0.008, z = 4.87 (right)], inferior occipital [F3,992 = 9.83, p = 0.028, 
z = 4.60 (left); F3,992 = 9.45, p = 0.044, z = 4.48 (right)], right inferior temporal (F3,992 = 9.36, 
p = 0.050, z = 4.45), hippocampus [F3,992 = 9.36, p = 0.049, z = 4.46 (left); F3,992 = 11.97, 
p = 0.002, z = 5.19 (right)], left lingual gyrus (F3,992 = 14.97, p < 0.0001, z = 5.93), and thalamus 
[F3,992 = 16, p < 0.0001, z = 6.16 (left); F3,992 = 13.71, p < 0.0001, z = 5.63 (right)] (Figure 2.4.1—
4). 
 
Figure 2.4-4. Group main effects (ANCOVA F contrast) 
Main effects of CAP group on VBM, showing regions that vary throughout the prodrome 
(p ≤ 0.05). Global maximum: x = 10.00, y = 12.00, z = 6.00; F3,992 = 131.13. The colored 
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bar legend codes the F statistic at each voxel, with white areas denoting voxels with the 
highest significance levels. 
 
2.4.2 Pairwise Group Contrasts 
The Sidak post hoc test yielded at least one significant pairwise CAP-group contrast for 
13 of the 23 SBM components (Figures 2.4.1—3 and 2.4.2—1). In addition to capturing 
differences between control and prodromal groups, some components demonstrated differences 
between prodromal groups (such as low and medium groups). These components may most 
sensitively capture differences within the prodromal period (see Appendix A.1 for all 
supplemental contrasts). VBM pairwise group contrasts (Figure 2.4.2—1) revealed the greatest 
group differences in contrasts with the high group. VBM pairwise contrast images are available 
in Appendix A.2. 
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Figure 2.4-5. SBM components and pairwise contrasts 
SBM regions significant in control > low, control > medium, and control > high contrasts. 
Pairwise contrasts are provided in Appendix A.1. Regions are grouped into boxes, with 
each box representing a component that was significant in the contrast. Components are 
ordered by descending Sidak significance for the contrast (p-value). Regions within 
components are listed in descending order of their contribution to the component (Z-score). 
Dark gray boxes denote components/regions that were significant in all three contrasts, 
light gray boxes are components/regions that were significant in two contrasts, and white 
boxes (present only in the control > high contrast) contain components/regions that were 
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significant in only the one contrast. Bolded regions within white boxes signify regions that 
did not appear in any other significant component/contrast. 
 
Table 2.4—3. T statistics and coordinates for significant VBM regions. 
Region Brodmann 
area 
Cluster 
size 
Peak p Peak 
T 
Talairach 
coordinates 
Control > medium contrast 
Right caudate 25 268 <0.0001 5.83 (8, 10, 4) 
Left putamen 48         0.005 4.98 (−6, 10, 2) 
Right putamen 48 23 0.006 4.93 (22, 14, 4) 
Control > high contrast 
Right caudate 25 26,289 <0.0001 15.51 (10, 12, 6) 
Left caudate 25 
 
<0.0001 14.51 (−8, 10, 4) 
Left olfactory – 
 
<0.0001 11.86 (0, 8, 8) 
Right cerebellum 6 – 303 <0.0001 5.8 (8, −74, 16) 
Right mid temporal 21, 37 504 <0.0001 5.55 (56, −4, −18) 
Right superior 
temporal 
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0.001 5.26 (−32, 36, −20) 
Right inferior temporal 37 139 0.002 5.13 (48, −48, −24) 
Right mid frontal 10, 46, 8 56 0.006 4.93 (−30, 56, 8) 
Left inferior temporal 20 22 0.012 4.76 (−64, −44, −14) 
Left mid temporal 22, 37 15 0.029 4.56 (−64, −26, −4) 
Significant regions in VBM pairwise contrasts. Significant regions with corresponding Brodmann 
areas, cluster sizes (in voxels), peak p-values, peak T-values, and Talairach coordinates are 
provided for VBM control > high-prodromal (near onset) and control > medium-prodromal 
contrasts. Values in front of parentheses are T992 scores; numbers inside parentheses are MNI 
coordinates (x, y, z). 
 
2.4.3 Low-Prodromal Group 
The Sidak test revealed significant differences between the control and low groups in 
seven SBM components (O: p < 0.001, Cohen’s d = 6.2; C: p < 0.001, Cohen’s d = 7.1; J: 
p = 0.009, Cohen’s d = 4.6; G: p = 0.016, Cohen’s d = 4.3; F: p = 0.011, Cohen’s d = 4.5; D: 
p = 0.032, Cohen’s d = 4.1; H: p = 0.046, Cohen’s d = 3.9). These components contained 
contributions from middle and superior frontal gyrus (D and C), precentral gyrus and 
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supplementary motor (C), occipital (O; G in mid/superior only; F in inferior only), calcarine (O 
and F), cuneus and precuneus (J), fusiform (H), superior (J) and inferior temporal (H and F), 
superior parietal (G), angular gyrus (G and J), and cerebellum crus 1 (F). By contrast, no 
substantial VBM differences were evident between control and low groups. 
 
2.4.4 Medium-Prodromal Group 
Four SBM components were significantly different between the control and medium 
groups (C: p = 0.005, Cohen’s d = 4.8; A: p = 0.010, Cohen’s d = 4.5; B: p = 0.020, Cohen’s 
d = 4.2; D: p = 0.039, Cohen’s d = 3.9). These contained caudate and thalamus (B), frontal gyrus 
[superior (C and D), middle (A, C, D)], supplementary motor (C), precentral (C), superior 
temporal (A), anterior cingulate (A), and parahippocampal (A). For VBM, the medium group 
had significant reductions relative to controls, but only in right caudate (T992 = 5.83, p < 0.0001, 
Cohen’s d = 0.3) and putamen [T992 = 4.98, p = 0.005, Cohen’s d = 0.3 (left); T992 = 4.93, 
p = 0.006, Cohen’s d = 0.4 (right)]. 
 
2.4.5 High-Prodromal Group 
Thirteen SBM components were significantly different between the control and high 
groups [p < 0.0001: components A (Cohen’s d = 8.4), B (Cohen’s d = 13.1), C (Cohen’s d = 5.7), 
E (Cohen’s d = 7.8), J (Cohen’s d = 6.0), M (Cohen’s d = 7.2); p = 0.001: G (Cohen’s d = 5.5); 
p = 0.005: K (Cohen’s d = 4.7); p = 0.013: D (Cohen’s d = 4.3); p = 0.033: H (Cohen’s d = 3.9); 
p = 0.035: N (Cohen’s d = 3.9); p = 0.037: I (Cohen’s d = 3.8); p = 0.041: F (Cohen’s d = 3.8)]. 
Eight of these were significant in earlier control-prodromal contrasts (C > L, C > M). The 
remaining five components (E, I, K, M, and N) were not significant in earlier contrasts but 
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contained regions within components that were significant in these contrasts, including putamen 
and thalamus (Q), mid- and superior-frontal (N), precuneus and calcarine (M), and inferior 
temporal (N, I). These components also contained regions not present in other contrasts, 
including paracentral (E), mid cingulum (E), mid temporal (M and I), inferior frontal (M), 
cerebellum 9 (K), right lingual (K), vermis 4, 5, 9 (K), cerebellum 9 (K), cerebellum crus 2 (K). 
For VBM, the high group exhibited differences relative to controls in caudate 
[T992 = 14.51, p < 0.0001, Cohen’s d = 0.9 (left); T992 = 15.51, p < 0.0001, Cohen’s d = 1.0 
(right)], right mid frontal (T992 = 4.93, p = 0.006, Cohen’s d = 0.3), right superior temporal 
(T992 = 5.24, p = 0.001, Cohen’s d = 0.3), right and left middle temporal [T992 = 5.55, p < 0.0001, 
Cohen’s d = 0.4 (right); T992 = 4.56, p = 0.029, Cohen’s d = 0.3 (left)], right and left inferior 
temporal [T992 = 5.13, p = 0.002, Cohen’s d = 0.3 (right); T992 = 4.76, p = 0.012, Cohen’s d = 0.3 
(left)], right cerebellum (T992 = 5.80, p < 0.0001, Cohen’s d = 0.4), and left olfactory 
(T992 = 11.86, p < 0.0001, Cohen’s d = 0.8). 
 
2.4.6 Differences Across the Prodrome 
Components C (precentral gyrus, mid and superior frontal, supplementary motor) and D 
(middle and superior frontal gyrus) exhibited significant differences between the control group 
and each progression group (low, medium, high). Components G (superior parietal, angular, mid 
and superior occipital), H (inferior temporal, fusiform), J (angular gyrus, superior temporal, 
cuneus, precuneus), and F (calcarine, inferior temporal, inferior occipital, cerebellum crus 1) 
were similar but lacked significant differences between control and medium groups. 
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2.5 Discussion 
2.5.1 Voxel-based Morphometry 
Our VBM GMC results coalesce well with existing literature. While many VBM studies 
have examined gray matter volume (GMV), one meta-analysis (31) compiled GMC VBM 
findings in prodromal and diagnosed HD. The GMC meta-analysis condensed 11 studies (297 
patients and 205 controls) and reported a prodromal consensus on reductions in the left putamen 
and right inferior frontal gyrus (IFG) relative to controls. We replicated these findings in our 
PREDICT-HD sample and also found bilateral differences in caudate, thalamus, inferior frontal, 
hippocampus, and inferior occipital. Left lingual and right inferior temporal were also 
significantly affected. 
According to the meta-analysis, symptomatic (but not prodromal) HD patients differed 
from controls in the left caudate body, left IFG, and right middle frontal gyrus, all of which were 
significant in our prodromal-control and prodromal level comparisons. This regional overlap is 
unsurprising; Although PREDICT-HD does not include HD cases, its incorporation of over twice 
as many participants as the meta-analysis lends increased statistical power. This explanation is 
bolstered by the particular prominence of these regional differences in our medium > high 
contrast, which suggests that these regions may be among the most dramatically affected in the 
late prodrome. Notably, the meta-analysis reported that HD (but not prodromal) patients 
consistently had reduced caudate GMC compared to control (and prodromal) subjects. The meta-
analysis did not stage the prodrome, and the few studies it included that did index the prodrome 
had far fewer participants than the present study. In our large sample, we did not detect any 
VBM differences between the earliest prodromal group and the control group, and this may 
highlight the heterogeneity of the prodromal population. If a study considers the prodrome as a 
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whole, yet has a disproportionate representation of early or late prodromal cases, certain 
differences may fail to replicate in many studies. This may be further compounded by 
methodological and parameter differences among studies, as well as individual participant trait 
differences across sites. 
Our results align with those reported in the meta-analysis; however, its authors conclude 
that the data support a left-hemispheric degradation bias that extends bilaterally at the 
symptomatic stage. For their data, this is evident in the striatum, as the putamen and caudate 
demonstrated only left-hemispheric consensus significance. However, it is less supported by 
their results in other regions; right IFG was significant for the prodromal < control contrast, 
while left IFG was significant only in the HD < control condition. This would appear to suggest 
initial right-hemispheric changes in certain regions, which is supported by our findings. We 
observed stronger left-hemisphere effects in earlier prodromal contrasts in inferior frontal, 
putamen, thalamus, and inferior occipital, and significant findings in olfactory and lingual were 
limited to the left hemisphere. However, we also observed differences that were restricted to the 
right hemisphere in mid frontal, superior temporal, and cerebellum, as well as right-hemispheric 
differences preceding those in left-hemispheric mid/inferior temporal, hippocampus, and caudate 
(although caudate effects were overall bilateral). These results appear to support a hemispheric 
effect with regional variability. 
 
2.5.2 Source-based Morphometry 
Our SBM analysis revealed patterns both complementary to and distinct from those 
reported in previous VBM studies. Many imaging phenotypes were most reduced in the high 
CAP group (closest to diagnosis) and least perturbed in the low group, consistent with a low-to-
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high prodromal disease gradient. Both SBM and VBM identified strong GMC reductions in the 
high-prodromal progression group. Differences between control and low groups were present in 
several SBM components but were absent from VBM results, consistent with previous VBM–
SBM comparison studies in which results were comparable, but SBM yielded additional regions 
that were not uncovered with the univariate method (68, 75, 79). This could indicate, as others 
have suggested (67, 68, 75), that multivariate SBM is more sensitive to early clinical differences 
in certain populations than similar univariate methods, such as VBM. 
As the first application of SBM to prodromal HD, our results constitute novel evidence 
for SBM’s enhanced sensitivity to early prodromal HD differences. This benefit may be afforded 
by the inter-subject-variability present in heterogeneous clinical populations, such as prodromal 
HD, where differential CAG-expansion number and age confer a range of phenotypic severity in 
the population. A similar explanation was offered by the authors of a first-episode schizophrenia 
study in which SBM, but not VBM, yielded significant differences from controls (75); this was 
attributed to the heterogeneity of first-episode schizophrenia patients and the noise-dependency 
of the VBM method, both of which could be exacerbated by methodological problems or 
preprocessing differences. 
In addition to early sensitivity, SBM may detect more widespread concentration 
differences throughout the prodrome. The SBM results captured each region present in the VBM 
results, as well as several other regions that were not detected with VBM (including thalamus, 
superior frontal, frontal inferior trigeminal, precentral, superior/inferior parietal, 
parahippocampal, hippocampus, precuneus, occipital, calcarine, lingual, fusiform, cuneus, 
anterior/mid cingulate, supplementary motor, paracentral lobule, fusiform, and areas in the 
vermis and cerebellar lobule VI). Furthermore, each region within the SBM components that 
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yielded the greatest control-low differences (such as frontal regions) was only significant in 
VBM contrasts involving more advanced progression groups. This may be explained by SBM’s 
ability to integrate covarying brain regions and capture network-level differences, which 
contrasts with VBM’s focus on individual voxels that more robustly captures differences in small 
regions with few voxels. 
The SBM results also provide insight regarding regions that are changing together, 
covariation that is captured by SBM’s grouping of regions into the same component. In many 
cases, regions within components were spatial or functional neighbors, exemplified by the 
presence of both the caudate and thalamus in component B; these regions work in concert with 
the subthalamic nucleus and substantia nigra to subserve coordinated voluntary movement (87). 
Frontal regions, in particular, tended to be grouped within the same components. Temporal 
regions were also more likely to dominate components than parietal and occipital regions, which 
were frequently grouped together. This may suggest that frontal and temporal regions change 
more independently from each other, while parietal changes may more frequently impact 
occipital areas and vice versa. While the components do not represent networks per se, the 
concurrence of these regional differences may highlight network-level changes by pinpointing 
areas where differences tend to coincide in participants. In light of the comparability, overlap, 
and extension of the VBM results present in the SBM results, the remainder of the discussion 
will focus on SBM component pairwise comparisons. 
 
2.5.3 Differences Across the Prodrome 
Two components (C and D) were sensitive to differences from controls at all three 
prodromal stages. Interestingly, both of these were dominated by frontal regions (superior 
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frontal, mid/medial frontal, precentral, and supplementary motor). These areas may begin to 
change early in prodromal development and continue to be affected throughout its course, 
potentially making them appealing targets for early and ongoing interventions. 
 
2.5.4 Early Prodromal Differences (Control > Low) 
Many SBM components exhibited differences between the control and low-prodromal 
groups, indicating widespread GMC loss even at early prodromal stages. The most commonly 
significant regions in this contrast were superior frontal, mid frontal, angular gyrus, and inferior 
temporal (each in two components). Overall, the strongest early effects were frontal (Component 
C: superior/mid/medial frontal, precentral, supplementary motor; Component D: superior/medial 
frontal). These areas are functionally relevant to HD, with supplementary motor cortex being 
integral to movement planning and coordination, and the precentral gyrus containing primary 
motor cortex (M1). A recent study examining prodromal functional connectivity of M1 reported 
that increased CAG-expansion was associated with reduced M1 connectivity with postcentral 
gyrus (primary somatosensory cortex) and visual centers in the cuneus (88). This could be 
accompanied by or related to gray matter degradation in these regions, aligning with their 
presence in group-significant SBM components. Component O, which contained widespread 
occipital and calcarine, was also highly affected in the early prodrome, consistent with reports of 
complex visual integration deficits being particularly discriminatory between symptomatic and 
prodromal individuals (89). The next most strongly affected component (J) contained cuneus, 
precuneus, superior temporal, and angular gyrus, possibly reflecting an early disruption of the 
default-mode network (which includes precuneus, angular gyrus, and temporal areas) (90). This 
component also implicates striatal pathways; the cuneus is connected to the angular gyrus, which 
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associates with superior frontal regions and the caudate via the occipitofrontal fasciculus (91, 
92). 
 
2.5.5 Later Prodromal Differences 
Source-based morphometry first detected significant caudate and thalamus differences in 
the control > medium contrast (component B). Aside from the caudate, dorsomedial and 
anteroventral thalamic regions were the strongest contributors to this component. These 
subdivisions project to prefrontal and temporal cortices, respectively (93), both of which were 
also significant in this contrast (Components A, C, D). This thalamo-cortical projection is 
important for motor control, sensory relay (94), and many aspects of executive functioning (95), 
congruent with reported executive functioning impairments that worsen with increased 
prodromal progression. 
The control > high-prodromal contrast captured each component that was significant in 
earlier prodromal contrasts. Within the five components that were not significant until the 
control > high contrast, many represented brain regions were also present in significant 
components from earlier prodromal contrasts, including precentral, calcarine, mid/superior 
frontal, and inferior/mid temporal. By contrast, late prodromal differences in the absence of 
earlier differences occurred in paracentral, mid cingulum, mid temporal, inferior frontal, lingual, 
vermis (4, 5, 9), and cerebellum crus 2. This suggests that, while many areas are affected early in 
the prodrome and continue to change throughout it, other (notably subcortical) regions may be 
substantially affected only at later prodromal stages. Several of these regions are important for 
motor performance, which is subtly affected in the early prodrome but declines steeply close to 
diagnosis-onset (1). The paracentral lobule, for example, interacts with supplementary motor 
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cortex and distal limbs for somatosensation and is among regions that demonstrate reduced 
activation during processing of emotional faces in HD patients. The cingulum presents another 
example; the anterior cingulate (Component A) demonstrated intermediate and late prodromal 
differences, while the mid cingulate (Component E) only showed late differences. Anterior 
cingulate is involved in emotional regulation and has been implicated in depression and apathy 
(96), which co-occur in HD (1, 97, 98). Mid cingulate, by contrast, innervates premotor and 
motor cortical areas (99) and may contribute to increasing motor deficits with later prodromal 
progression. 
 
2.5.6 Summary 
Frontal components were sensitive to early, intermediate, and late prodromal stages, with 
differences beginning earliest and remaining strongest in superior and mid frontal areas. Frontal 
differences were first observed (control > low contrast) in precentral, supplementary motor, and 
mid and superior frontal regions that tended to be grouped in the same components. These may 
be among the most continuously affected regions in prodromal HD. 
Inferior frontal trigeminal was the only affected inferior frontal region and exhibited 
differences only in the late prodromal contrast. A similar pattern was observed in inferior 
temporal, which was much more typical and significant in the late compared to early prodromal 
contrast. Superior temporal and angular gyrus also displayed robust early prodromal differences 
that continued into the mid and late prodrome, while inferior parietal was absent from the results 
entirely. Overall, this suggests a superior-to-inferior gradient of GM degradation across the 
prodrome, with the exception of the occipital lobe (both superior and inferior occipital were 
significant in early and late contrasts). 
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Many occipital and subcortical regions did not exhibit concentration differences until the 
late prodromal stage, including cerebellum crus 2, vermis 4, 5, 9, right lingual gyrus, and mid 
cingulum. Significant inferior frontal trigeminal, mid temporal, and paracentral lobule effects 
were also limited to this contrast. This delayed contribution of regions important for movement 
is in accordance with motor impairment as the primary instigator of diagnosis, as well as the 
observed non-linear prodromal pattern of motor functioning that culminates with sudden 
deterioration in the late prodrome (1). 
The overlap between results from SBM and VBM (the latter of which has been applied in 
other prodromal HD studies) suggests that SBM is suitable for studying this population. 
Consistent with previous findings in other clinical populations (67, 68, 75), SBM appeared to 
detect concentration differences at earlier progression stages and in more regions than VBM. 
Furthermore, the grouping of regions into SBM components highlights covarying areas that may 
be good targets for investigating network-level changes. 
 
2.6 Limitations 
There are a number of important factors to consider while interpreting these results. In 
any study involving a large number of participants with a rare condition, multiple scanning sites 
are typical, and thus a certain degree of inhomogeneity in data collection is inevitable. This study 
used data from several unique 1.5 or 3 T scanners. Every effort was made to control for possible 
confounds relating to multiple collection sites. Uniform protocols were established to ensure 
maximal homogeneity of data collection, and field strength was included as a fixed factor in all 
analyses. As described in the Section “Statistical Analysis,” collection sites were examined for 
outliers and unbalanced participant demographics (site demographics are provided in Appendix 
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A.4). It is also worth noting that a study investigating scan parameter effects on SBM 
components from a multisite schizophrenia study found that site effects were successfully 
eradicated with both GLM (VBM) and SBM correction (100). 
Given the dramatic striatal role in HD, the lack of significant differences between the 
control- and low-prodromal groups in the caudate/thalamus component was surprising. This 
component was strongly significant in every other pairwise contrast (including supplemental 
contrasts low > medium and medium > high), indicating that SBM robustly captured prodromal 
progression in these regions. Additionally, as exemplified by the VBM GMC meta-analysis, 
caudate differences are not always found in the earliest prodromal contrasts (although this does 
not seem to be the case in volumetric analyses). Concentration measures may capture subtler 
changes in underlying cellular mechanisms that are not yet reflected by structural volumes, 
which may also underlie other dissimilarities between GMV and GMC results. Nonetheless, we 
investigated possible explanations for this finding. Although the SBM components were 
examined for and did not appear to contain artifacts, prodromal individuals may have smaller 
intracranial volumes (ICV) than controls (101), and it is important to investigate the possibility 
that ventricular artifacts in some components could mask GMC reduction. Unsurprisingly, ICV 
was significantly correlated with 19 of the 23 SBM components. However, when ICV was 
included as an additional covariate in the SPSS MANCOVA analysis, it did not substantially 
change either the MANCOVA results or the Sidak post hoc results (7 components were still 
significant for control > low, 4 for control > medium, and 11 for control > high). ICV also did not 
alter the caudate component effects, which was of particular concern given the unexpected lack 
of control > low significance. It may also be possible for subtle head motions that are 
undetectable during data collection to influence results (102), an inevitable possibility in any 
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study investigating movement disorders using motion-sensitive equipment. While it was not 
possible to address this with the current dataset (beyond behavioral data and motion-correcting 
preprocessing steps), we aim to investigate possible motion effects using measures of framewise 
displacement from resting state data, available for some participants. 
Source-based morphometry components generally followed an expected pattern of 
control > low > medium > high. However, the finding that seven components were significant for 
the control > low contrast compared to four for the control > medium contrast was an unexpected, 
but not totally unprecedented finding. Cognitive and clinical findings in the medium-prodromal 
group have also been less consistent than in the other groups (14). Explanations for these 
differences have varied; some have suggested potential protective effects in the early prodrome, 
aligning with observations of compensatory increased task-based connectivity and activity 
during performance of certain tasks (103). Even pathological nuclear protein aggregation is 
suspected of having a protective role, as it does not correlate well with disease symptoms or 
onset (104). Inconsistent group results could also reflect an imperfect parsing of prodromal 
groups, highlighting an underlying goal of this study (pinpointing additional sources of variation 
beyond CAG-expansion and age). We attempted to control for important group differences (like 
age) that could skew results. Additionally, our group and others are working to develop “risk 
scores” that encapsulate other factors in onset variability. However, the present heterogeneity in 
the medium group may account for some unexpected findings. 
 
2.7 Conclusion and Future Directions 
Our findings support the utility of SBM for investigating prodromal HD. The results 
reinforce the acknowledged widespread nature of neural degradation in HD, with reduced GMC 
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being evident across the entire brain rather than isolated to the striatum. They also provide 
insight into patterns of atrophy and concurrently affected regions; frontal and temporal areas 
differed relatively independently compared to (often co-occurring) parietal and occipital 
differences. Additional evidence was uncovered for differential patterns of decline across the 
prodrome, with the earliest differences affecting more superior areas, intermediate differences 
increasing in middle regions, and later differences in more inferior, occipital, and subcortical 
structures. 
Future research would benefit from exploiting the increased sensitivity of morphometric 
techniques like SBM to address questions regarding how subtle structural differences relate to 
cognitive, motor, and psychiatric functioning. The parsing technique inherent in SBM can also 
be used to investigate differences between prodromal white and gray matter changes. 
Furthermore, it is possible that differences in HTT and other genes in the HD signaling pathway 
(105) underlie some observed structural differences. Investigation of genotypes associated with 
structural phenotypes may elucidate markers of disease progression that are present earlier than 
detectable deficits on clinical batteries. 
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3.1 ABSTRACT 
Huntington’s disease (HD) is a neurodegenerative disorder caused by an expansion 
mutation of the cytosine–adenine–guanine (CAG) trinucleotide in the HTT gene. Decline in 
cognitive and motor functioning during the prodromal phase has been reported, and 
understanding genetic influences on prodromal disease progression beyond CAG will benefit 
intervention therapies. From a prodromal HD cohort (N = 715), we extracted gray matter (GM) 
components through independent component analysis and tested them for associations with 
cognitive and motor functioning that cannot be accounted for by CAG-induced disease burden 
(cumulative effects of CAG expansion and age). Furthermore, we examined genetic associations 
(at the genomic, HD pathway, and candidate region levels) with the GM components that were 
related to functional decline. After accounting for disease burden, GM in a component 
containing cuneus, lingual, and middle occipital regions was positively associated with attention 
and working memory performance, and the effect size was about a tenth of that of disease 
burden. Prodromal participants with at least one dystonia sign also had significantly lower GM 
volume in a bilateral inferior parietal component than participants without dystonia, after 
controlling for the disease burden. Two single-nucleotide polymorphisms (SNPs: rs71358386 in 
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NCOR1 and rs71358386 in ADORA2B) in the HD pathway were significantly associated with 
GM volume in the cuneus component, with minor alleles being linked to reduced GM volume. 
Additionally, homozygous minor allele carriers of SNPs in a candidate region of ch15q13.3 had 
significantly higher GM volume in the inferior parietal component, and one minor allele copy 
was associated with a total motor score decrease of 0.14 U. Our findings depict an early genetical 
GM reduction in prodromal HD that occurs irrespective of disease burden and affects regions 
important for cognitive and motor functioning. 
 
3.2 Introduction 
Huntington’s disease (HD) is a neurodegenerative disorder characterized by deterioration 
of motor, cognitive, and psychiatric functioning. Abnormal cytosine–adenine–guanine (CAG) 
repeat expansion (>35 repeats) in the huntingtin gene (HTT) causes this progressive disorder, and 
age of clinical diagnosis is inversely correlated with CAG expansion length (i.e., greater 
expansion is associated with more rapid progression) (16). Although CAG repeat number is the 
primary determinant of the rate of pathogenesis (explaining about 56% of the variation in onset 
age), overall onset time is highly variable, especially in patients with lower CAG repeat numbers 
(16-18). Other genetic and environmental factors likely account for additional onset variation 
(28-30), as illustrated by an HD pedigree study showing that approximately 40% of the variation 
in onset age (after accounting for CAG effects) was due to non-HTT genetic factors (27). 
Up to a decade prior to clinical diagnosis, individuals with the abnormal CAG expansion 
already differ from healthy controls in brain structure as well as cognitive and motor functioning 
(2, 18, 20). Investigating early prodromal changes may be necessary for identifying optimal 
targets for disease prevention or delay (21). This is a major goal of PREDICT-HD, a multisite 
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prodromal HD study that has characterized many features of the HD prodrome (14, 21, 22), 
including widespread gray matter (GM) concentration reductions [even at the earliest prodromal 
stage (23)], robust annual changes in putamen, caudate, and nucleus accumbens volumes, as well 
as metrics of motor and cognitive functioning (18), resting state functional connectivity changes 
(25), and subcortical brain volume variations associated with motor symptom severity, cognitive 
control, and verbal learning (2, 20, 26). The extensiveness of brain structural and functional 
changes in this population supports the suitability of brain-based phenotypes for probing early 
genetic effects on prodromal disease progression. 
To date, several promising non-HTT genetic modulators, including ADORA2A (61, 62) 
and GRIN2A-2B (63), among others (29, 30, 57-60), have been highlighted as potential modifiers 
of disease onset or progression. The GeM-HD (genetic modifiers of HD) consortium conducted 
the largest such study, compiling genetic data from multiple projects and investigating genetic 
factors associated with residual variance in onset time (after controlling for CAG influence). This 
study identified two genomic significant loci in chromosome 15 that accelerated or delayed onset 
by 6.1 and 1.4 years, respectively (58). Another new study of disease progression in both 
prodromal and diagnosed HD patients reported an association between single-nucleotide 
polymorphisms (SNPs) in chromosome 5 and a reduced rate of change in motor and functional 
capacity scores (106). However, no study has examined genetic modulation of brain-based 
phenotypes during the HD prodrome. 
The CAG age product (CAP), computed as age × (CAG repeat − constant), captures the 
cumulative effect of CAG expansion on the duration of exposure, and is a validated index of 
disease burden in HD (19, 107). During the prodromal phase, CAP significantly and reliably 
associated with brain volumetric changes and cognitive and motor decline (19), yet it cannot 
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explain all the variation in these measures (or in clinical onset age) (18). Thus, to pinpoint non-
HTT genetic factors that influence prodromal brain-based phenotypes, we intentionally removed 
CAP influence on GM variation through regression; this is analogous to the residual variance in 
onset time implemented in the GeM-HD study. We then identified GM networks associated with 
cognitive or motor decline in prodromal individuals and tested these for genetic effects. 
 
3.3 Materials and Methods 
3.3.1 Participants 
715 (447 female and 268 male) PREDICT-HD prodromal individuals from 33 sites were 
analyzed. These participants were gene positive (with >36 CAG repeats) independent samples, 
and did not convert to HD during the study. All participants provided written, informed consent 
and were treated in accordance with protocols approved by each participating institution’s 
internal review board. Detailed enrollment and exclusion criteria can be found in previous 
publications (22). Participant demographic information is provided in Table 3.3.1—1. There 
were no differences in age, CAG repeats, or education years between males and females. 54 
participants had fewer than 40 CAG repeats; even though these participants may or may not 
develop HD in their lifetimes, the large variability in their prodromal disease progression (which 
partially contributes to the uncertainty of onset) makes it more appealing to include them in the 
prodromal analysis. 
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Table 3.3—1. Demographic information of participants 
 
715 prodromal HD Female (N = 447, 
62.5%) 
Male (N = 268, 
37.5%) 
Age 42.55 ± 10.53 (19–
83) 
42.6 ± 10.5 43.5 ± 10.7 
Cytosine adenine guanine 
repeats 
42.47 ± 2.54 (37–
61) 
42.43 ± 2.57 42.53 ± 2.50 
Education years 14.50 ± 2.61 (8–20) 14.36 ± 2.55 14.73 ± 2.69 
Race (self-reported) 694 (97.06%) White 96.64% White 97.76% White 
1 American Indian 1 American Indian 1 Asians 
3 Asians 2 Asians 3 intermixed 
14 intermixed 11 intermixed 2 unknown 
7 unknown 5 unknown 
Race (genetic estimated) 97.34% Caucasian 97.09% Caucasian 97.76% Caucasian 
1 Asian 1 Asian 2 intermixed 
2 intermixed 12 Mexican/Indians 5 Mexican/Indians 
17 Mexican/Indians 
 
3.3.2 Cognitive and Motor Functioning Assessments 
Motor variables included total motor score (TMS) from the Unified Huntington’s Disease 
Rating Scale and the chorea, bradykinesia, oculomotor, and dystonia subdomains from the 15-
item standardized motor assessment (1, 108). Many participants had low or 0 scores on the motor 
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variables, skewing the data toward a negative exponential distribution. Cognitive variables 
included the Symbol Digit Modalities Test (SDMT) (1, 109), Stroop Color, Stroop Word, and 
Stroop Interference tests (1, 110), and Trail Making Tests A (TMTA) and B (TMTB) (1, 111, 
112). Cognitive variables had approximately normal distributions. More details for each variable 
are available in Appendix B.1. 
Total motor score, oculomotor, bradykinesia, and chorea were highly correlated (e.g., 
TMS correlated with oculomotor, bradykinesia and chorea at r = 0.79, 0.83, and 0.70, 
respectively; Appendix B.6). Thus, we used principal component analysis (PCA) to extract the 
first PC (89% of the total variance) as the representative variable for overall motor function; 
higher scores indicate more abnormal motor control, and the most weighted variable is TMS. 
Similarly, SDMT and Stroop scores were highly correlated (r = 0.53–0.78), and we obtained the 
first PC (76% of the total variance) as the representative variable for attention and working 
memory; higher scores indicate better performance, and the most weighted variable is Stroop 
Word. TMTA and TMTB were grouped and the first PC (95% of the total variance) was 
obtained as the representative variable for problem solving; higher scores indicate slower 
processing, and the most weighted variable is TMTB. For dystonia, which was not highly 
correlated with the other motor variables, 639 participants had scores of 0, 37 had scores of 1, 24 
had scores of 2, and 5 had scores higher than 2. The low scores on dystonia are in line with the 
prodromal status of the participants, as dystonia is usually a sign of disease manifestation. We 
converted dystonia score into a binary variable representing presence or absence of dystonia 
signs. 
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3.3.3 Genetic Data Preprocessing 
Genomic SNP data were downloaded from dbGAP (Study Accession: phs000222.v4.p2). 
We removed problematic loci in accordance with PREDICT-HD quality control 
recommendations, and filtered SNPs for a missingness rate of 5% per sample and 5% per SNP 
and a minor allele frequency of 5%. Family relatedness was determined using PLINK identity-
by-descent analysis, and only one member per family was included. The top 10 multidimensional 
scaling (MDS) factors from PLINK were used to correct for population structure. A total of 
1,160,231 SNPs across the genome were investigated. In parallel, we also investigated an HD 
pathway derived from the Ingenuity Pathway Analysis knowledgebase and the KEGG database. 
The HD pathway from the two combined databases included 310 genes and 3,404 SNPs after 
pruning with r2 > 0.5. 
 
3.3.4 Candidate Selection 
Since only prodromal patients were investigated and prodromal functional decline is 
more relevant to symptom onset than to disease progression [which accelerates significantly 
faster after onset compared to during the prodrome (106)], we selected candidate SNPs for 
modifying onset time; these were from the GeM-HD study, and included two regions 
(chr15q13.2-3: rs146353869, rs2140734; chr8: rs1037699) with significant influences on age of 
motor diagnosis and nominal associations with cognitive and psychiatric symptom onset (58). 
We tested SNPs within these regions for effects on prodromal progression. Although our data did 
not include these exact three SNPs, we identified seven nearby SNPs in high linkage 
disequilibrium (LD) with rs2140734 (r > 0.98 based on NIH LDlink web4): rs11293, 
                                                 
4 https://analysistools.nci.nih.gov/LDlink/ 
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rs11629793, rs8034856, rs7176569, rs35784593, rs1474380, and rs61997138. These SNPs were 
highly correlated in our data (r > 0.99), exhibiting almost identical genotype patterns. There were 
also three SNPs in our data with identical genotype patterns that were in high LD with rs1037699 
(r > 0.85): rs16869295, rs11777942, and rs11778107. 
 
3.3.5 Imaging Data Processing 
T1-weighted images from the earliest available MRI scans were segmented into GM, 
modulated, normalized to MNI space, and smoothed with an 8 mm × 8 mm × 8 mm Gaussian 
kernel using the statistical parametric mapping 8 software package5. Images less than 80% 
correlated with the averaged GM were removed, and a >0.2 GM volume mask was generated to 
include only GM relevant voxels. Since these imaging data were collected from 50 site and 
scanner field strength (1.5 or 3 T) combinations, known influences of site scanner, age, sex, and 
disease burden on GM were removed by applying a linear regression model to each GM voxel. 
Site scanners were coded as 49 dummy variables, and disease burden was calculated using the 
formula suggested by PREDICT-HD: CAP = age × (CAG − 33.66) (19). 
 
3.3.6 Source-based Morphometry 
We then applied independent component analysis (ICA) to whole-brain GM voxels using 
the source-based morphometry toolbox within the GIFT software package 
(http://mialab.mrn.org/software/gift). ICA decomposes the brain imaging data into maximally 
independent GM components, often comprised of multiple brain regions, with each 
component/network grouping voxels that covary among subjects (67). The model can be 
                                                 
5 http://www.fil.ion.ucl.ac.uk/spm/software/spm8/ 
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described simply as X = A × S, where X is the measured data, S contains the extracted 
components, and A is the loading matrix. A participant’s loading coefficient for a given 
component indicates how strongly that component manifests in the participant’s imaging data 
[see Ref. (67, 113-115) for details]. Fifteen GM components were estimated, as determined by 
the minimum description length criteria (116). 
 
3.3.7 Statistical Analyses 
We first tested whether the cognitive and motor variables were significantly associated 
with disease burden in our prodromal sample. PCA-derived representative variables and original 
variables were tested one by one, separately. A regression model (cognitive or motor 
variable = age + sex + CAP) was used for each variable. Due to different distributions for motor 
versus cognitive variables, a linear regression model was used for cognitive variables, a logistic 
regression model was used for the converted binary dystonia variable, and a Poisson regression 
model was applied to the other motor variables. 
Next, we tested for associations between the extracted GM components and cognitive and 
motor functioning variables using a regression model in which the cognitive or motor 
functioning variable = age + sex + GM loadings + CAP. Similarly, linear, Poisson, and logistic 
models were used accordingly. The GM components significantly contributing to motor or 
cognitive functioning after adjusting for CAP were our primary components of interest for 
genetic associations. For any GM component of interest, a regression model (GM 
loading = SNP + top 10 MDS scores) was used to test for SNP associations at the genomic, 
pathway and candidate levels. We also tested for associations between clinical (motor or 
cognitive) variables and SNPs using the following regression model: motor or cognitive 
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variable = age + sex + CAP + SNP + top 10 MDS scores. All tests, genomic level and pathway 
level, were false discovery rate (FDR) corrected at p < 0.05 for the number of tested SNPs. 
 
 
3.4 Results 
3.4.1 Disease Burden and Clinical Functioning 
Individual motor and cognitive variables and derived representative variables were all 
associated with CAP after controlling for age and sex (p = 0.04 for the converted binary dystonia 
score, p = 0.01 for the original dystonia score, and p < 1 × 10−11 for all other variables). Due to 
highly consistent results among representative variables and original individual variables, 
hereafter we report the results from representative measures. Results from individual variables 
are provided in Appendix B.4. The total variance explained by the regression model was 19% for 
overall motor function (9–18% for individual variables), 18% for working memory/attention 
(12–21% for individual variables), and 15% for problem solving (13 and 15% for TMTA and 
TMTB, respectively). The pseudo R2 for dystonia was 1.3% (2% for the original dystonia score). 
 
3.4.2 GM and Clinical Functioning 
Fifteen GM components were extracted (see Appendix B.8), one of which was a typical 
artifact forming a ring around brain [as demonstrated by Chen et al. (100)]. This component was 
thus removed from further analyses. As expected, none of the GM components were related to 
CAP. The association tests with cognitive and motor functioning revealed a GM component 
(Figure 1A), mainly in cuneus, lingual gyrus, and middle occipital gyrus, that was significantly 
related to working memory and attention (p = 1.39 × 10−4 uncorrected, passing FDR correction). 
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Higher GM volume in this component was related to better attention and working memory 
performance, explaining 1.7% of the variance after controlling for age, sex and CAP, as shown 
in Figure 3.4.2—1A (CAP explained 15.7%). Another GM component, mainly in bilateral 
inferior parietal and superior/middle temporal regions, was significantly related to dystonia 
(Figure 3.4.2—1B; logistic regression p = 2.34 × 10−4 uncorrected); prodromal participants with 
at least one dystonia sign had significantly lower GM volume in this network (Cohen’s d = 0.47, 
p = 2.37 × 10−4). 
 
Figure 3.4-1. Gray matter (GM) components associated with working memory/attention 
and dystonia after controlling for disease burden 
Gray matter (GM) components associated with working memory/attention and dystonia 
after controlling for disease burden. (A) GM component containing cuneus, lingual gyrus, 
and middle occipital gyrus, and its association with working memory/attention. (B) GM 
component highlighting bilateral inferior parietal and superior/middle temporal gyri, and 
its association with dystonia. The GM loadings are relative values without unit. 
 
3.4.3 GM and SNPs (Full Genomic Data and HD Pathway) 
Over one million SNPs were tested for associations with GM variation in the 
aforementioned two components, and none exhibited a genomic significant association passing 
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FDR correction. Similarly, no significant genomic associations with cognitive or motor 
functioning variables were observed. In our separate analysis of SNPs in 310 HD pathway genes, 
only one SNP (rs71358386 in NCOR1) was significantly associated with GM in the cuneus 
component (p = 2.38 × 10−5, passing FDR), with minor allele G being negatively linked to GM 
volume. For this SNP, 636 participants were homozygous major allele (A) carriers, 77 were 
heterozygous, and 2 were homozygous minor allele (G) carriers. We pooled the heterozygous 
and homozygous minor allele carriers together and computed the difference between minor allele 
carriers and homozygous major allele carriers. The difference was significant (p < 1.56 × 10−5 for 
the two-sample t-test and p < 6.42 × 10−6 for the Wilcoxon rank test), with a Cohen’s d of 0.53 
(Figure 3.4.3—1). Interestingly, another SNP (rs78804732 in ADORA2B) was in strong LD with 
rs71358386 (r = 0.91). This SNP was also significantly associated with GM in the cuneus 
component (p = 1.51 × 10−5), with minor allele A being linked to lower GM volume and A 
carriers having significantly lower GM volume than major allele C carriers (Cohen’s d = 0.59; 
p < 8.0 × 10−6 for the two-samples t-test; p < 3.48 × 10−6 for the Wilcoxon rank test; Figure 
3.4.3—1). These two SNPs were also nominally associated with GM in the inferior parietal 
component (p = 0.02 and p = 0.04, respectively), with minor alleles being linked to lower GM 
volume. An extended analysis on these two SNPs provided some promising but not strictly 
significant results, and we reported them in Appendix B.5 for the interest of readers. At the 
pathway level, no SNPs were significantly associated with motor or cognitive functioning, 
though these two SNPs were marginally associated with overall motor functioning (p = 0.05, not 
passing FDR correction), with more minor alleles being linked to greater motor dysfunction. To 
obtain an intuitive effect size, we assessed these SNPs’ effects on TMS and found that one minor 
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allele copy was associated with an increase of 0.20 U in TMS score after controlling for age, sex, 
CAP, and MDS. 
 
Figure 3.4-2. Association of rs71358386 and rs78804732 with a cuneus GM component 
Association of two single-nucleotide polymorphisms, rs71358386 and rs78804732, with a 
cuneus gray matter (GM) component. GM loadings are relative values without unit. In the 
box plots, the middle line is the median value, the top and bottom of each box are the 25th 
and 75th percentile values, the whiskers extend from the ends of the interquartile to the 
further values within 1.5 times the interquartile, and plus (+) signs show values that are 
more than 1.5 times the interquartile range away from the top or bottom of the box. The 
plot of medium and 25/75th percentile presents a similar overall pattern as the mean and 
standard deviation in these data. 
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3.4.4 Candidate SNP Analyses 
Seven SNPs in LD with rs2140734 in chromosome 15 showed a marginal connection to 
GM in the inferior parietal network in the regression model (p = 0.06–0.09, not significant); 
greater minor allele number was linked to increased GM in the network. Further ANOVA tests 
revealed that the main driver of the association was the homozygous minor allele carrier group. 
As shown in Figure 3.4.4—1 using the example of rs11293, there was no difference between 
homozygous major allele G carriers and heterozygous carriers (p = 0.75), but homozygous minor 
allele A carriers had significantly higher GM than the other groups (p = 0.01, no multiple 
comparison correction was applied due to near identical patterns among the seven SNPs). This 
SNP was also negatively related to overall motor function (p = 0.01), indicating an association 
with better motor performance. To obtain an intuitive effect size, we assessed its effect on TMS, 
and found that one minor allele copy was associated with a TMS score decrease of 0.14 U after 
controlling for age, sex, CAP, and MDS. No connections with GM, cognition or motor 
functioning were observed for SNPs in LD with rs1037699 on chromosome 8. 
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Figure 3.4-3. rs11293’s association with an inferior parietal GM component 
Single-nucleotide polymorphism rs11293’s association with an inferior parietal gray 
matter (GM) component. GM loadings are relative values without unit. In the box plots, 
the middle line is the median value, the top and bottom of each box are the 25th and 75th 
percentile values, the whiskers extend from the ends of the interquartile to the further 
values within 1.5 times the interquartile, and plus (+) signs show values that are more than 
1.5 times the interquartile range away from the top or bottom of the box. The plot of 
medium and 25/75th percentile presents a similar overall pattern as the mean and standard 
deviation in these data. 
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3.5 Discussion 
Gray matter and motor and cognitive functioning show significant prodromal decline in 
HD (14, 23, 24, 26, 34, 41, 107, 117). Our results first confirmed that variation in these domains 
relates significantly to CAP, a metric reflecting disease burden and based on CAG mutation and 
exposure time (age) (19). Individuals with more CAG repeats are likely to develop symptoms 
more rapidly and be diagnosed at younger ages. However, our results agree with previous work 
showing that a considerable amount of variance in prodromal functional decline is beyond this 
disease burden (18, 58). After regressing out CAP effects, two GM components yielded 
significant associations with working memory/attention and dystonia, respectively, though the 
variance accounted for was relatively small compared to CAP influence (about one tenth). 
Nonetheless, this is an exciting finding; the HTT CAG expansion is a causal mutation associated 
with HD, and age has widely known effects on GM variation and clinical functioning in both 
prodromal/HD patients and healthy individuals. Thus, modest residual effects are to be expected. 
As modifiers of disease progression, symptoms, and onset continue to be discovered, the 
potential for promising gene therapies increases as well. Such therapies could eventually target 
multiple modifiers with modest individual effects but substantial combined influence on 
progression. These findings reinforce evidence that the disease burden from CAG mutation and 
age does not explain all observed variance in prodromal disease progression and clinical onset 
(18, 58), and further suggest that GM variability may be a useful phenotype for examining 
genetic factors that account for unexplained variability in HD progression and onset. 
Better performance on working memory and attention tasks was associated with higher 
GM volume in a component that included cuneus, lingual gyrus, and middle occipital gyrus. 
Structural changes in occipital regions have been consistently documented in prodromal and 
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diagnosed HD, albeit overshadowed by caudate and putamen effects (2, 41, 46, 70, 118, 119). 
Our findings are mirrored by a study staging cortical thinning across the prodrome, in which 
visual cortical regions were among the earliest and most severely affected regions, and cortical 
thinning in these regions was associated with lower scores on Stroop Color, Stroop Word, and 
SDMT (46). Similarly, a PREDICT-HD study investigating neuroanatomical correlates of five 
cognitive functions also reported that occipital cortical thickness was associated with letter-
number sequencing working memory, as well as SDMT performance (2). In prodromal and 
diagnosed patients (relative to controls), TRACK-HD also reported reduced occipital cortical 
thickness, which was associated with poorer performance on the SDMT, Stroop Word test, and 
TMTA (118). Taken together, these findings highlight cuneus, lingual, and occipital 
abnormalities in prodromal and diagnosed patients, and indicate that these aberrations may 
influence cognitive performance. Our findings support these previous associations, and further 
suggest that they may be partially modulated by factors outside of HTT CAG repeat number and 
age. 
Dystonia is a common symptom of HD manifesting at varying degrees of severity (120). 
In our cohort, dystonia signs were associated with reduced GM in a component containing 
inferior parietal and middle and superior temporal regions, after controlling for CAP. Inferior 
parietal areas interface with other sensorimotor regions to promote motor planning and initiation 
(121), and show increased activation before self-initiated movements (122). Inferior parietal GM 
loss has been reported in prodromal patients and is consistently observed in diagnosed HD (46, 
70, 123), and has been further linked to abnormal eye movement (123). A meta-analysis of HD 
voxel-based morphometry studies identified brain clusters associated with motor symptoms, 
grouping inferior parietal together with precentral gyrus, primary motor, postcentral gyrus, and 
59 
somatosensory cortex; these regions were more strongly related to motor functioning than the 
caudate (70). As for superior temporal gyrus, a smaller prodromal study (N = 325) associated 
bilateral superior temporal cortex with motor timing precision, and found that it was the greatest 
structural contributor to performance outside of the striatum and middle frontal cortex (2). These 
studies emphasize the importance of temporal and parietal regions in movement-related tasks in 
both healthy controls and prodromal and diagnosed HD patients. Our results reinforce these 
findings, and the removal of CAP effects in our analyses further suggests that a portion of these 
effects relates to factors outside of the disease-determining HTT mutation. 
Frontal and striatal abnormalities are the most robust and commonly reported effects in 
HD, and these regions are heavily involved in cognitive and motor functioning. Our findings 
reflect brain structural influences on cognition and movement that are not accounted for by 
disease burden. It is thus unsurprising that the striatum and frontal lobe were not key contributors 
to the effects we report. Alternatively, our results pinpoint occipital, parietal, and temporal 
regions of the brain that comprise networks important for attention, working memory, and 
planned movement. These areas often work in concert with the frontal lobe and striatum to 
promote cognitive and motor functioning. In this large prodromal cohort, these regions appear to 
contribute to prodromal clinical functioning in a manner that is independent of HTT CAG 
influence. 
The genome-wide association test did not produce significant results, which is not 
particularly surprising since HD is a rare disorder and genomic tests require very large sample 
sizes to balance multiple comparison corrections and small effect sizes. Similar to studies of 
genetic modifiers of motor onset time (29, 58), some true genetic effects may be missed due to 
strict genome-wide significance thresholds. The HD pathway-based genetic association analysis 
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leveraged prior knowledge of gene functions and their involvement in HD. Therefore, these 
findings fit into the double-hit phenomena in which gene functions are known to contribute to 
disease pathogenesis, and changes in these genes are also related to GM variation that 
contributes to prodromal symptoms and cognitive decline. Thus, these genetic variants have an 
increased likelihood of affecting disease progression. 
We observed two SNPs in strong LD but located in two different genes (NCOR1 and 
ADORA2B, 54k base pairs apart) that were associated with GM variations. In fact, SNP 
rs71358386 in NCOR1 regulates expression of ADORA2B in various tissues based on the GTEx 
database6 (124). In our cohort, minor allele carriers of the two SNPs showed significant occipital 
GM reduction and some level of reduction in inferior parietal regions, as well as marginally 
higher motor dysfunction. NCOR1 is part of the HD pathway and encodes the protein nuclear 
receptor corepressor 1, which mediates transcriptional repression of thyroid-hormone and 
retinoic acid receptors. This protein reportedly interacts with mutant HTT (125, 126) to alter 
nuclear receptor function and is also differentially located in patient brain tissue (125, 127). 
ADORA2B encodes adenosine receptor subtype A2B, a protein that interacts with netrin-1, which 
is involved in axon elongation. Currently, ADORA2B is not part of the HD pathway, although 
ADORA2A is (128-130). ADORA2A and ADORA2B are two of four human genes that encode 
adenosine receptors that increase cyclic adenosine monophosphate (131), which is important for 
signal transduction and other biochemical processes (132). We cannot currently establish these 
SNPs as true causal mutations, and further investigation of the molecular, cellular, and functional 
impact of these genes is warranted. 
                                                 
6 https://gtexportal.org 
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In addition, within two candidate regions selected based on their significant effects on 
clinical onset time (58), our results revealed that SNPs in ch15q13.3 (MTMR10 and FAN1 genes) 
affected GM in prodromal participants; homozygous minor allele carriers had higher GM 
densities in the inferior parietal component. Given the negative link between GM volume in this 
component and dystonia symptoms and overall motor functioning, this minor allele has a 
protective effect on prodromal dystonia and motor dysfunction, with one minor allele copy being 
associated with a TMS score decrease of 0.14. Excitingly, this finding is in total agreement with 
the reported clinical onset delay attributed to these SNPs [the minor allele was associated with a 
1.4-year onset delay (58)]. The possible mechanisms through which these genes influence 
disease progression have been elaborated upon by the GeM-HD study. Our results suggest that 
genetic variations outside of HTT are already altering GM in the prodromal phase, before the 
emergence of diagnosis-associated motor symptoms. 
This investigation of extra-HTT genetic modifiers before clinical diagnosis represents a 
new direction for the development of treatments to prevent or delay this devastating disorder. 
Leveraging brain structural variation, which is likely more precise and subtle than clinical 
outcome changes, enhances power for identifying genetic modifiers. The findings of this study 
demonstrate that: (1) GM variation beyond CAG influence is associated with disease progression 
and manifests as early as the prodrome; (2) genetic modifiers of biologically measured GM 
volume are already exerting their effects during the prodromal phase; and (3) the accumulation 
of these effects across disease progression ultimately alters clinical onset time. Replication using 
an independent sample and follow-up studies manipulating cell lines or animal strains should be 
carried out to fully illuminate the mechanisms of these genetic modifiers. As a proof of concept, 
our findings suggest that studying brain structural variation beyond disease burden can be a very 
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promising method for identifying genetic modifiers of HD progression. The limitations of this 
study include the following: (1) inclusion of some gene positive participants who may never be 
diagnosed with HD and thus may be healthy participants; (2) only linear relationships between 
GM, cognition, motor functioning, and genetic variations were tested; and (3) a longitudinal 
study on changes in GM, cognition, and motor functioning, as well as a carefully designed 
comparison with healthy controls, would help confirm the genetic effects reported here. 
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4 HIGH AND LOW LEVELS OF AN NTRK2-DRIVEN GENETIC PROFILE AFFECT 
MOTOR- AND COGNITION-ASSOCIATED FRONTAL GRAY MATTER IN 
PRODROMAL HUNTINGTON’S DISEASE 
This chapter has been previously published in Brain Sciences special issue, "New Insights in Huntington's 
Disease", as Ciarochi JA, Liu J, Calhoun VD, Johnson H, Misiura M, Bockholt HJ, Espinoza FA, Caprihan A, Plis 
S, Turner JA, Paulsen JS; the PREDICT-HD Investigators and Coordinators of the Huntington Study Group. High 
and Low Levels of an NTRK2-driven Genetic Profile Affect Motor- and Cognition- associated Frontal Gray Matter 
in Prodromal Huntington’s Disease. Brain Sci. 2018 June 8(7), 166. 
 
4.1 ABSTRACT 
This study assessed how BDNF (brain-derived neurotrophic factor) and other genes 
involved in its signaling influence brain structure and clinical functioning in pre-diagnosis 
Huntington’s disease (HD).  
Parallel independent component analysis (pICA), a multivariate method for identifying 
correlated patterns in multimodal datasets, was applied to gray matter concentration (GMC) and 
genomic data from a sizeable PREDICT-HD prodromal cohort (N = 715).  
PICA identified a genetic component highlighting NTRK2, which encodes BDNF’s TrkB 
receptor, that correlated with a GMC component including supplementary motor, 
precentral/premotor cortex, and other frontal areas (p < 0.001); this association appeared to be 
driven by participants with high or low levels of the genetic profile.  
The frontal GMC profile correlated with cognitive and motor variables [Trail Making 
Test A (p = 0.03); Stroop Color (p = 0.017); Stroop Interference (p = 0.04); Symbol Digit 
Modalities Test (p = 0.031); Total Motor Score (p = 0.01)]. A top-weighted NTRK2 variant 
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(rs2277193) was protectively associated with Trail Making Test B (p = 0.007); greater minor 
allele numbers were linked to better performance.  
These results support a protective role of NTRK2 in prodromal HD, particularly in 
individuals with certain genotypes, and suggest that this gene may influence the preservation of 
frontal gray matter that is important for clinical functioning. 
 
4.2 Introduction 
4.2.1 Huntington’s Disease 
HD is a progressive, heritable condition characterized by chorea (involuntary motion) as 
well as cognitive alterations spanning executive functioning, working memory, olfactory and 
facial recognition, and emotional processing (1). HD, along with Alzheimer's (AD) and 
Parkinson's Disease (PD), is a proteinopathy distinguished by regionally-selective neuronal death 
and protein misfolding that manifests as expanded huntingtin in HD, Lewy bodies in PD, and β-
amyloid plaques in AD (8). Unfortunately, across these conditions limited treatment options and 
no known cures are available. However, their shared features have sparked speculation about 
common underlying mechanisms, and the delayed-onset of these disorders raises the appealing 
possibility of developing treatments that postpone onset indefinitely, effectively eradicating the 
disease.  
A promising way to identify treatment targets is to characterize the earliest changes 
before HD-onset. Motor impairments associated with HD, such as dystonia and chorea, often 
lead to diagnosis because their disruptiveness prompts affected individuals to seek medical 
attention. However, cognitive symptoms and alterations in brain volume and morphology are 
already present more than a decade before diagnosis, during a period known as the prodrome 
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(14). In keeping with this, PREDICT-HD is a multi-site research study aiming to identify the 
earliest changes in the HD prodrome, with the hopes of identifying targets for the earliest 
possible interventions (14). PREDICT-HD has amassed a comprehensive dataset of genomic, 
structural MRI, DTI, fMRI, cognitive and motor assays, CAG-repeat information, and 
demographic variables from 1,449 prodromal HD and control participants, including longitudinal 
data from over 900 participants. 
Although there is no cure for HD, its cause is known. An abnormally large cytosine-
adenine-guanine (CAG) expansion (≥36 repeats) at an HTT exon 1 locus determines future HD 
development. The HTT gene encodes huntingtin protein, which is widely expressed in the brain 
and central nervous system (133). Abnormally-expanded HTT encodes mutant huntingtin 
(mHTT), which compromises numerous cellular processes including endocytosis and secretion, 
calcium homeostasis (50), glutamatergic synaptic functioning (51), vesicular transport (52), 
mitochondrial functioning (134), p53 signaling (52), apoptosis and transcription (55). 
 
4.2.2 Effects of Multiple Genes and Variants 
Both within and outside the realm of huntingtin’s interactions, several lines of evidence 
implicate non-HTT factors as modulators of prodromal progression and HD onset; the reduced 
genetic complexity of HD makes it tractable to disentangle onset-protection and susceptibility 
factors. HTT CAG-expansion length considerably influences age at diagnosis and can be used to 
estimate the age of, or time to, HD-onset. Despite strong prediction accuracy for many 
prodromal individuals, some outcomes deviate from expectations. For example, one PREDICT-
HD participant with 44 CAG-repeats lacked positive diagnosis at age 71, and 13 participants 
with <41 repeats reached age 70 with no diagnosis. HD-onset prediction (based on age and 
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CAG-repeat number) is most accurate in individuals with >44 repeats and increasingly variable 
as repeat-number decreases, and different disease progression rates are often observed in persons 
with the same number of CAG-repeats. These examples highlight onset variability and suggest 
that additional genetic factors may promote or suppress HD conversion (especially at lower 
CAG-repeat numbers), yet little is known about non-HTT genetic factors that account for 
variability in the rapidity and severity of HD symptoms and onset.  
The influence of such factors is likely also reflected by differences in brain structure and 
clinical functioning throughout the prodrome. Known polygenetic neural effects suggest that 
multiple genes may modulate decline; this is in keeping with the prevailing common disease-
common variant model, which posits that the combined effects of multiple common nucleotide 
variants, or single nucleotide polymorphisms (SNPs), with weak individual effects may confer 
disease susceptibility or resistance (64). At an individual level, these polymorphisms may occur 
in several, sometimes interacting genes, bestowing weak enough effects to fall below statistical 
thresholds and avoid elimination via natural selection (64). We observe similar covariance in the 
brain; even in disorders with regionally concentrated damage, multiple brain regions and cell 
types are usually affected. 
 
4.2.3 Benefits of Multivariate Methods 
Interactions among multiple genes can have complex effects on disease phenotypes (64). 
Univariate methods such as genome-wide association studies (GWAS) have dominated large-
scale human genetic studies, despite an inability to capture this important covariation (64, 65). 
Univariate tests require tens of thousands of participants, which can be impossible to achieve in 
rare clinical populations, and must correct for many statistical tests. These stringent statistical 
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standards can result in an overshadowing of small-to-moderate genetic effects and obscure 
interpretation of impacted biological pathways, as results generally consist of a few of the most 
significant genes, each of which is involved in multiple cellular processes and pathways. For 
these reasons, multivariate methods may be more suitable for extensive genetic studies, 
especially in rare clinical populations with fewer available study participants. Rather than 
assessing related points, multivariate tests find interrelated patterns and can detect weak effects 
in high-dimensional data. 
 
4.2.4 Parallel Independent Component Analysis (pICA) 
Combined effects of nucleotide-level differences (or SNPs) on gray matter concentration 
(GMC) across the brain can be assessed across the genome and in candidate genes using the 
multivariate method parallel ICA (pICA) (64, 65). Through simultaneous analysis of multimodal 
data, pICA can isolate groups of correlated SNPs into novel, maximally-independent networks 
that affect patterns of GMC in a population. In other words, a person whose genome aligns with 
a pICA SNP profile that is correlated with a GMC profile will also likely display brain structure 
consistent with that GMC profile. PICA has been successfully applied to other clinical 
populations, including schizophrenia and Alzheimer's disease (74, 135), which share key features 
with HD such as delayed onset, regional and cellular selectivity of atrophy, and cognitive 
abnormalities.   
Like other multivariate methods, pICA is optimal for examining multi-gene interactions 
because it considers cumulative effects of changes at multiple loci, likely accounting for more 
variation than the strongest changes in single genes (64). Consequently, it requires fewer 
statistical tests than univariate Genome-Wide Scanning (GWS) analyses (< 30 compared to 
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hundreds of thousands). An additional advantage of pICA is that it permits both hypothesis-
driven testing (via inclusion of reference SNPs) and exploration of new and unexpected patterns 
(disease-related or otherwise) that connect genes and their expression to brain structure and 
function. These advantages allow affected pathways and gene networks to be more thoroughly 
defined. 
4.2.5 BDNF-Signaling Genes (a Candidate Pathway) 
Genes that interact with mHTT and are involved in mHTT-compromised processes are 
strong candidate HD-progression mediators. One such target is brain-derived neurotrophic factor 
(BDNF). BDNF mediates neurogenesis, and accumulating evidence suggests its importance in 
HD development and onset (55, 56). BDNF co-localizes with huntingtin in 99% of pyramidal 
motor cortical neurons and 75% of striatal neurons, and is necessary for healthy cortico-striatal 
synaptic activity and striatal GABA-ergic medium spiny neuron (MSN) survival (55).  
mHTT interferes with BDNF transcription and vesicular transport (Figure 4.2.5—1). (a) 
Huntingtin enhances BDNF microtubule transport by binding to HAP1, which engages vesicle 
transport proteins. mHTT binds too tightly to HAP1, inhibiting transport. (b) Huntingtin 
stimulates transcription from the BDNF exon II promoter, which is 60% less active in cells over-
expressing mHTT (55). Like many neuronal-gene promoters, BDNF is regulated by Repressor 
element 1/neuron-restrictive silencer element (RE1/NRSE), which is modulated by RE1 
silencing transcription factor/neuron-restrictive silencer factor (REST/NRSF) (52). REST is a 
neuron-specific, master gene repressor that binds to BDNF promoter II RE1 sites and recruits a 
co-repressor complex that includes Sin3A and REST co-repressor (coREST). Huntingtin 
indirectly sequesters REST in the cytoplasm by interacting with HAP1 and REST-interacting 
LIM domain protein (RILP), which directly binds REST/NRSF to mediate translocation to the 
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nucleus. mHTT disrupts this complex by failing to isolate REST in the cytoplasm, leading to its 
increase in the nucleus and consequent recruitment of transcriptional repressors 
 
Figure 4.2-1. Effects of Mutant Huntingtin 
Mutant huntingtin (mHTT) affects (a) BDNF vesicular transport across microtubules and 
(b) BDNF transcription. (a) Huntingtin binds to HAP1 to recruit vesicular transport 
proteins. The dynein complex is shown in yellow and the dynactin complex in purple. 
Together, these proteins enable retrograde vesicular transport, which is disrupted by 
mHTT binding too tightly to HAP1. (b) Huntingtin sequesters REST in the cytoplasm, 
inhibiting its accumulation in the nucleus. mHTT fails to sequester REST, leading to its 
nuclear buildup and consequent reduced BDNF transcription 
 
BDNF is particularly relevant to prodromal HD. Compared to controls, asymptomatic 
HD transgenic mice have reduced striatal BDNF that is lower at higher CAG-repeat numbers, 
indicating a prodromal BDNF deficit (56). Further BDNF reduction in these mice lowers onset-
age and worsens motor symptoms, correlating with brain morphology changes. Furthermore, 
BDNF deficiency only modestly contributes to early-life MSN survival, yet significantly reduces 
MSNs (by 35%) in later life, consistent with delayed HD-onset. Interestingly, the striatum does 
not produce its own BDNF, but receives ~95% from the cortex and the remainder from the 
substantia nigra pars compacta, amygdala, and thalamus (56). Thus, prodromal BDNF suggests 
possible early deficits in regions that supply striatal BDNF. Given that BDNF mRNA and 
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protein reductions are present in prodromal and diagnosed HD and are causally related to 
symptom severity and HD-onset, factors that interact with BDNF likely confer additional 
symptom and onset variability. 
 
4.2.6 The Present Study 
Using pICAr, this study leveraged legacy imaging, genomic and clinical data from 
PREDICT-HD to investigate how SNPs in BDNF-signaling genes impact clinical functioning 
and patterns of brain morphology in prodromal HD. As an expansion of the pICA results, we 
assessed the effects of four individual SNPs in NTRK2 (which encodes BDNF’s TrkB receptor) 
on frontal gray matter and clinical functioning. Profiles including SNPs from multiple genes 
were anticipated to correlate with gray matter concentration profiles and clinical functioning, 
with maximum effects in BDNF-related, HD-compromised pathways. 
 
4.3 Materials and Methods 
4.3.1 Participants 
A cohort of 715 expansion-positive (≥36 CAG-repeats) prodromal PREDICT-HD 
participants were included in the study [448 females and 267 males: ages 18-82, mean CAG-
repeat number = 42.5 (SD = 2.5)]. Participant data included genotyping, T1-weighted structural 
MR images, cognitive and motor variables, and demographics (including age, sex, years of 
education, and CAG-repeat number) from PREDICT-HD (22). Exclusion criteria included poor 
genomic or imaging data quality, relatedness to another participant, or presence of any other 
CNS disorder or unstable medical or psychiatric condition. All PREDICT-HD participants 
provided written, informed consent and were treated in accordance with protocols approved by 
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each participating institution’s internal review board. Participants underwent genotyping before 
study enrollment, and those with more than 35 CAG-repeats who did not meet criteria for HD 
diagnosis were designated as prodromal. 
 
4.3.2 Data Availability 
SNP data included in this study are publicly available from dbGAP (Study Accession: 
phs000222.v4.p2). Other PREDICT-HD data, including baseline T1-weighted MR images (used 
as input files in this study), subcortical and cortical segmentations, and longitudinal clinical 
measurements, are available on the public download site 
(ftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs000222). Release of the specific genetic and 
imaging component data generated in this study is forthcoming, however similar ICA-generated 
gray matter imaging components from a different PREDICT-HD study by the lead author have 
been made available in the latest study version (Study Accession: phs000222.v5.p2; Dataset 
Name: SBM_sMRI; Dataset Accession: pht006857.v1.p2). Access to the specific component 
data from the study may be requested from the corresponding author. 
 
4.3.3 Cognitive and Motor Variables 
Seven clinical variables were selected and tested for brain structural and genetic 
associations (outlined below), based on their established clinical reliability and sensitivity to 
prodromal HD progression (18). Because we were interested in genetic and brain-structural 
effects on cognitive and motor functioning, we analyzed the portions of the Unified Huntington 
Disease Rating Scale (UHDRS) relevant to these domains. The UHDRS includes four sections 
measuring movement, cognition, behavior, and functional capacity. We assessed the Total Motor 
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Score (UHDRS-TMS), which comprises the movement portion of the UHDRS and is a sum of 
the scores on the individual motor variables (oculo-motor function, dysarthria, chorea, dystonia, 
gait, and postural stability). We also analyzed the Symbol Digit Modalities Test (SDMT) and the 
Stroop test (Color, Word, and Interference conditions), which are two of the three parts of the 
UHDRS cognition section (we did not assess verbal fluency). In addition to the UHDRS-TMS, 
SDMT, and Stroop Interference, we also analyzed Trail-Making Tests A and B (TMTA and 
TMTB), which are not part of the UHDRS. We chose these tests because of our specific interest 
in cognition and motor functioning, and because previous work by the PREDICT-HD group has 
demonstrated that these measures are particularly sensitive to prodromal changes in brain 
structure (18). 
Briefly, the SDMT measures working memory, complex scanning, and processing speed, 
and is an adaptation of the Wechsler Digit Symbol subtest (136, 137). Participants are provided 
with a key of symbols paired with numbers at the top of the test page. On the same test sheet, a 
series of numbers are presented in a horizontal row, and the task is to fill in the symbol matching 
each number in the sequence as quickly and accurately as possible. Raw scores represent the 
number of correctly completed items within 90 seconds; thus, higher scores indicate better 
performance (109).  
The Stroop Color and Word Test consists of three 45-second conditions that measure 
basic attention and inhibition of an overlearned response (110, 138). For the color condition, the 
task is to identify colors presented on stimulus cards. For the word condition, the task is to read 
color names presented in black ink. Both the color and word conditions measure basic attention. 
For the interference condition, participants identify the ink color in which color-names are 
printed, rather than reading the color name itself. For example, for the word “blue” printed in 
73 
green ink, the correct response is “green.” The interference condition measures the ability to 
inhibit the dominant (or automatic processing) response, which is to read the word. For each of 
the three conditions, raw scores reflect the number of correct trial responses, and higher scores 
thus reflect better performance.  
TMTA and TMTB measure visual attention and task switching (111, 112). For TMTA, 
the task is to sequentially connect a series of numbered circles (e.g., 1-2-3-4, etc.) as quickly as 
possible. For TMTB, participants consecutively connect numbers and letters in 
ascending/alphabetical order, alternating between numbers and letters (e.g., 1-A-2-B-3-C, etc.). 
For both TMTA and TMTB, raw scores reflect time (in seconds) taken to complete the task. 
Thus, higher scores reflect poorer performance.  
The UHDRS TMS assesses several indicators of motor performance spanning 
oculomotor function, bradykinesia, chorea, dystonia, gait, and postural stability (1, 58). Higher 
scores indicate poorer motor functioning. 
 
4.3.4 Genomic Data Preprocessing 
Data for 1,160,231 SNPs assayed with the Illumina Human 1M platform were 
downloaded from dbGAP (Study Accession: phs000222.v4.p2). Data were filtered at a 5% 
missingness rate per sample and per SNP, and SNPs with a minor allele frequency (MAF) of 
>0.05 were selected. After linkage disequilibrium (LD) pruning (r2 > 0.5), the full genomic 
dataset consisted of 305,271 SNPs that were included in further analyses. Only one participant 
per family was included in the study; the family structure was determined using PLINK identity-
by-descent analysis, where p̂ > 0.18 indicates relatedness 
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(http://zzz.bwh.harvard.edu/plink/ibdibs.shtml). The top 10 multi-dimensional scaling (MDS) 
factors were used to correct for population structure. 
 
4.3.5 Imaging Data Collection 
High-resolution anatomical MR images were collected at 33 sites using General Electric, 
Phillips, and Siemens scanners with field strengths of 1.5 T (Tesla) or 3 T. The study used a 
standardized acquisition protocol that was modified for each site by our MR physicist. Secondary 
to upgrades and acquisition changes over the twelve-year study, additional variation occurred. A 
total of 50 site/scanner field strength combinations were analyzed, with at least three participants 
from each different MRI scanner. Images at each site were obtained using three-dimensional 
(3D) T1-weighted inversion recovery turboflash (MP-RAGE) sequences. 1.5 T scans were 
collected using General Electric and Siemens scanners. The Siemens protocol was constructed to 
be similar to the General Electric scan parameters: GRAPPA factor, 900 ms TI (inversion time), 
2530 ms TR (relaxation time), 3.09 ms TE (excitation time), 256 mm × 256 mm field of view 
(FoV), 10° flip angle, 240 coronal slices with 1 mm slice thickness, 256 × 128 matrix with 1/4 
phase FoV, 220 Hz/pixel receiver bandwidth. Protocol for 3 T scanners commonly involved a 
sagittal localizing series followed by acquisition of an axial 3D volumetric spoiled gradient 
recalled acquisition in steady state (GRASS) sequence, using the following scan parameters: 
~1 mm × 1 mm× 1.5 mm voxel size, 18 ms TR, 3 ms TE, 24 cm FoV, 20° flip angle, 124 slices 
with 1.5 mm slice thickness, 0 mm gap, 256 × 192 matrix with 3/4 phase FoV, number of 
excitations (NEX) = 2. 
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4.3.6 Imaging Data Preprocessing 
Images were aligned with the anterior commissure-posterior commissure (AC–PC) plane, 
resampled with 1 mm isotropic voxels to correct for inhomogeneity (82), and preprocessed using 
SPM8 (http://www.fil.ion.ucl.ac.uk/spm/software/spm8/). Images were segmented into gray 
matter, unmodulated (to isolate GM concentration), and normalized to the same SPM8 Montreal 
Neurological Institute (MNI) template. Voxels were re-sliced to 2×2×2 mm3, and images were 
smoothed by a 10x10x10 mm3 full-width-half-maximum (FWHM) Gaussian kernel. Processed 
images were 90 × 109 × 91 voxels in size. A linear regression model was applied to each GM 
voxel to account for effects of age, sex, and site (inclusive of field strength); the site variable was 
coded as 49 dummy variables. 
 
4.3.7 Parallel ICA with References (pICAr) 
Prodromal GMC and SNP patterns were identified and tested for correlations by applying 
pICAr to the GMC imaging and the genomic data. SNPs within nine genes implicated in BDNF-
signaling were included as references: BDNF, NGFR, NTRK2, RCOR1, SIN3A, SORT1, HAP1, 
REST, and RILP (see Table 4.3—1). SNPs within 20 kbp of these genes were also included to 
capture regulatory elements in intronic and intergenic regions. 
Table 4.3—1. Genes from which available SNPs were included as references for parallel 
independent component analysis with reference (pICAr) 
Factor Gene(s) pICA 
referenc
e SNPs 
(#) 
Full Name Function 
REST/ 
NRSF 
REST, 
RCOR1
, 
RCOR3
† 
4 RE1 silencing transcription 
factor/neuron-restrictive 
silencer factor 
Transcriptional repression 
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Sin3A SIN3A 2 SIN3 transcription 
regulator family member A 
Part of co-repressor complex 
with REST and coREST 
CoRES
T 
RCOR1 9 REST co-repressor Part of co-repressor complex 
with REST and Sin3A 
HAP1 HAP1 7 Huntingtin-associated 
protein 1 
Binds to huntingtin, 
facilitates BDNF 
transcription and transport 
TrkB NTRK2 52 Tropomyosin receptor 
kinase B 
BDNF high-affinity receptor 
P75 NGFR 26 Low-affinity nerve growth 
factor receptor 
BDNF low-affinity receptor 
RILP RILP 5 REST-interacting LIM 
domain protein 
REST nuclear receptor 
Sortilin SORT1 12 Sortilin 1 Suggested apoptotic function 
with p75 and pro-BDNF 
BDNF BDNF 6 Brain-derived neurotrophic 
factor 
Neuronal growth, survival, 
differentiation 
†SNPs from this gene were not available 
PICA is an extension of ICA, a robust and popular method for isolating maximally 
independent sources from a mixed signal [10,11,26]. (1) In a general ICA model, X = AS: X is 
an observation (i.e. subject-by-variable matrix); S is a statistically independent component 
matrix (component-by-variables); A is the loading coefficient or mixing matrix, the 
representation of each component in the subject or sample (subject-by-component). PICA 
performs this extraction simultaneously on two modalities, X1 and X2. For this experiment, X1 
was a participants-by-voxels matrix of the masked GMC images, and X2 was a participants-by-
loci matrix of the 305,271 SNPs. PICAr decomposes the observation into maximally independent 
sources (component matrices S1 and S2) by updating W1 and W2 (unmixing matrices) to 
optimize (2) F1 (Infomax algorithm that maximizes independence of modality-1 components), 
(3) F2 (modified Infomax that optimizes modality-2 component independence AND similarity to 
the reference matrix), and (4) F3 (maximizes correlations between the two modalities' loading 
coefficient matrices, A1 and A2) (64, 65). Each reference is a vector containing alleles of a gene 
likely to be in linkage disequilibrium, meaning they co-occur more or less frequently than 
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expected for independent loci. A reference vector for each gene listed in Table 4.3.7—1 
comprised reference matrix r. PICA outputs a loading coefficient for each participant for each 
SNP and imaging profile, representing how much the participant's genome and brain structure 
matches each profile detected in the sample. 
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4.3.8 SNP and GMC Correlations with Clinical Variables 
We then queried SNPs of interest (i.e., SNPs within Table 4.3.7—1 BDNF-signaling 
genes that were also highlighted in the pICA results) for correlations with the cognitive and 
motor variables. Five SNPs in NTRK2 were tested in separate multivariate general linear model 
(GLM) tests using SPSS (86); the clinical measures were dependent variables, and the SNP value 
(a continuous variable between 0 and 2) was a covariate. We similarly examined associations 
between the clinical variables and a pICA SNP and GMC component that were significantly 
correlated with each other. Here, the clinical measures were the dependent variables and the SNP 
or GMC loading coefficient was a covariate. 
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4.3.9 Associations of Top Weighted Component SNPs with Clinical Variables 
To test whether observed effects were explained by the entire component cumulatively or 
were largely an effect of heavily-weighted SNPs, restricted genetic coefficients based on the 
most important SNPs in the component were calculated. First, the distribution of the weights for 
the 305,271 SNPs in the SNP component was fitted to a logistic distribution. Based on this, 
SNPs with weights more than 4.25 standard deviations (SDs) from the mean were selected as top 
contributing SNPs (N = 61). Weights for these 61 SNPs within the component (61 x 1 matrix) 
were multiplied by participant genotypes for these SNPs (715 x 61 matrix) to yield new 
participant loadings for the top 61 contributing SNPs. These new loadings were correlated with 
loadings for the full component at r(713) = 0.77 (two-tailed significance of p < 0.001). A list of 
the top 61 SNPs, associated genes, and weights in the component is available in Appendix C.2.  
 
4.3.10 Confirmation of Significant Results 
Permutation testing and leave-N-subjects-out (10-fold, 10% of total sample) cross-
validation were used to verify significant pICA component correlations (64, 139). Permutation 
testing involves a random shuffling/mismatching of participant SNP and GMC data, which are 
then subjected to pICA and correlation testing. The permutation testing is performed multiple (in 
this case, 1,000) times, allowing a null distribution to be formed that reveals the likelihood of 
obtaining the significant GMC-SNP correlation by chance. Leave-N-out (or 10-fold-validation) 
is achieved by running pICA on ten separate datasets, each containing 90% of the full data, to 
determine if the results from the original analysis are replicable. 
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4.3.11 Regression Influence Plot 
An influence matrix was generated using the regression influence plot function in R (140, 
141), to pinpoint any individuals disproportionately driving the outcome of the significant GMC-
SNP component correlation; this function outputs a plot of studentized residuals by hat values as 
well as a data frame containing hat values, studentized residuals and Cook's distances. The 
approach efficiently describes the influence each dependent variable value has on each fitted or 
predicted value. 
 
4.4 Results 
4.4.1 PICAr 
In our PREDICT-HD prodromal cohort, pICAr detected a significantly correlated GMC-
SNP component pair [r(713) =  0.17, p < 0.001]. This association remained significant after 
Bonferroni correction for multiple testing. The GMC component most strongly represented 
supplementary motor, superior, mid, and medial frontal, and precentral/primary motor regions 
(Figure 4.4.4—1). The correlated SNP component had strong contributions from the NTRK2 
gene, which encodes BDNF’s high-affinity receptor type (TrkB) (Figure 4.4.1—2). Four intronic 
NTRK2 SNPs (rs11140810, rs4877289, rs10868241, rs2277193) were among the top 10 SNPs 
contributing to the component. Other top genes included CDK14, FAM114A1 and HEATR4 
(Table 4.4.1—1). 
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Figure 4.4-1. Frontal GMC component significantly paired with NTRK2 SNP component 
in pICAr 
(a) maximum effects in right premotor and supplementary motor. Crosshairs are 
positioned at the global maximum [T(1) = 30.75] and thresholded at p = 0.05; (b) 
multislice axial topography (threshold: Z = 2.5), showing a mostly positive component with 
strong representation from superior frontal gray matter and Brodmann area 6 
(supplementary and premotor cortex). Images are displayed using xjView (a; 
http://www.alivelearn.net/xjview) and Fusion ICA Toolbox (b; 
http://mialab.mrn.org/software/fit) 
 
Figure 4.4-2. Manhattan plot of top weighted SNPs 
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Manhattan plot showing top weighted SNPs within the SNP component that correlated with 
a frontal/supplementary motor gray matter profile in parallel ICA. The top 10 SNPs 
contributing to the component are highlighted in green, and the four top NTRK2 SNPs are 
circled in red. The Y axis indicates each SNP’s weight, or contribution, to the SNP 
component. The plot was generated using the qqman package in R version 3.4.1 
 
 
Table 4.4—1. The 10 SNPs most heavily weighted in the SNP component 
SNP Weight 
(||) 
+/
- 
Ranki
ng 
Gene Minor Allele Frequency Class 
rs7801922 1.29 + 1 CDK14 T=0.34/1704 (1000 
Genomes) T=0.38/11000 
(TOPMED)  
SNV 
rs11140810 1.20 + 2 NTRK2 G=0.42/2104 (1000 
Genomes) G=0.42/12329 
(TOPMED) 
SNV 
rs4877289 1.08 + 3 NTRK2 G=0.38/1926 (1000 
Genomes) G=0.38/11160 
(TOPMED) 
SNV 
rs548321 1.03 + 4 70kb 5' of LRRC55 G=0.41/2055 (1000 
Genomes) G=0.38/11140 
(TOPMED) 
SNV 
 
rs11214051
9     
1.01 + 5 53kb 3' of NUS1 -=0.33/1652 (1000 
Genomes) 
DIV 
rs427790 1.00 + 6 MIR181A1, NR5A2 C=0.33/1658 (1000 
Genomes) C=0.38/10948 
(TOPMED) 
SNV 
rs10868241 1.0 + 7 NTRK2 A=0.32/1614 (1000 
Genomes) A=0.24/6986 
(TOPMED) 
SNV 
rs7655305 0.99 + 8 FAM114A1 G=0.43/2140 (1000 
Genomes) G=0.43/12519 
(TOPMED) 
SNV 
rs2277193 0.98 + 9 NTRK2 C=0.34/1679 (1000 
Genomes) C=0.41/11827 
(TOPMED) 
SNV 
rs8012614 0.98 + 10 HEATR4 C=0.29/1442 (1000 
Genomes) C=0.37/10860 
(TOPMED) 
SNV 
The 10 SNPs most heavily weighted in the SNP component, with rs IDs, weights in the 
component and their directions, associated genes, minor allele frequencies, and variant class. 
SNV = single nucleotide variation, DIV = deletion/insertion variation. 
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4.4.2 SNP and GMC Correlations with Clinical Variables 
The frontal GMC component highlighted by pICA (and associated with the NTRK2 SNP 
component) was significantly correlated with four of the seven queried clinical variables, 
including UHDRS total motor score [F(1,672) = 6.8, p = 0.009, surviving Bonferroni multiple 
testing correction], TMTA [F(1,672) = 6.3, p = 0.01, passing Bonferroni], Stroop Color 
[F(1,672) = 4.7, p = 0.03], and Stroop Interference [F(1,672) = 3.8, p = 0.05]. This component 
also approached a significant correlation with the other three clinical variables [SDMT: F(1,672) 
= 3.5, p = 0.06; Stroop Total: F(672) = 3.4, p = 0.07; TMTB: F(1,672) = 3.1, p = 0.08)]. In each 
case, higher GMC was linked to improved performance. 
The frontal-GMC-associated NTRK2 SNP component was not significantly related to the 
clinical measures. However, one of the top NTRK2 SNPs contributing to the component 
(rs2277193) was significantly associated with TMTB [F(1,672) = 6.7, p = 0.01], an effect that 
survived Bonferroni correction. Here, the minor allele was associated with better TMTB 
performance. This SNP also approached a significant correlation with Stroop Interference 
[F(1,672) = 3.6, p = 0.058], with the minor allele similarly being associated with better 
performance. NTRK2 SNP rs111408010 was also correlated with UHDRS TMS [F(1,672) = 3.7, 
p = 0.05], with a greater minor allele number being associated with better functioning (lower 
TMS score), but this effect did not withstand multiple testing correction. 
 
4.4.3 Confirmation of Significant Results 
The pICA results passed permutation testing; the ratio of correlation values above 
maximally linked components was 0.013, translating to about a 1% likelihood that results were 
obtained by chance. However, the results did not replicate in all the 10-fold validation runs, 
83 
likely because the GMC-SNP component correlation was driven by several individuals with high 
or low levels of the SNP component (Figure 4.4.3—1). The visual interpretation was confirmed 
by the regression influence analysis, which highlighted 25 participants that dominate the 
association (Appendix C.1). All these participants had SNP component values 2-4SDs above or 
below the mean. 
 
Figure 4.4-3. Correlation between pICA frontal GMC and NTRK2 SNP components 
(a) the full prodromal sample and (b) participants with SNP component values ≥2 SDs 
above or below the mean (N = 28). Mean SNP component value = 0.015 (full prodromal 
sample), SD = 0.005, X axis = SNP component weights, Y axis = GMC component weights, 
R2 = r2. Graphics generated with R version 3.4.1 
 
4.4.4 Associations of Top Weighted Component SNPs with Clinical Variables 
Similar to tests with the full SNP component, clinical associations with weights 
comprised of the top 61 component SNPs yielded no significant results. Derived p and r2 values 
were slightly weaker for the top 61 weights but were essentially comparable. 
 
4.5 Discussion 
4.5.1 High or Low Levels of the NTRK2 SNP Profile Affect Prodromal Frontal GMC 
Our results suggest that a strong or weak presence of the NTRK2-weighted genetic profile 
may be required to significantly affect the frontal gray matter profile. The genetic effect on 
frontal/supplementary motor GMC in individuals in the tail of the sample was still strong enough 
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to be significant and apparent within the larger sample. In keeping with this, all 25 individuals 
driving the significant SNP-GMC component relationship (according to the regression influence 
analysis) had SNP component scores 2-4 SDs above or below the mean; only three individuals 
with SNP component values in this range were not highlighted by the regression influence test. 
By contrast, only six of these participants also had GMC component values ≥2 SDs from the 
mean in either direction, suggesting that the effect is specific to the SNP component. These 
participants did not stand out in any other obvious way from the full prodromal sample, and 
represented both sexes and a variety of ages, sites, and CAG-repeat-numbers.  
Four NTRK2 SNPs were among the top 10 SNPs contributing to the GMC-related SNP 
component. NTRK2 (Neurotrophic Receptor Tyrosine Kinase 2) is a large (358,613 base) 
chromosome 9 gene located between SLC28A3 (solute carrier family 28, sodium-coupled 
nucleoside transporter member 3) and AGTPBP1 (ATP/GTP binding protein 1). NTRK2 is 
widely expressed in the brain (Figure 4.5.1—1) and encodes BDNF’s high-affinity TrkB 
(tropomyosin receptor kinase B) receptor. TrkB has important cellular functions that may 
underlie NTRK2’s prominence and protective role in this study. 
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Figure 4.5-1. Expression of NTRK2 in various tissue types, showing relatively strong 
expression in brain tissue 
TPM = transcripts per kilobase million. Expression threshold: > 0.1 TPM and ≥ 6 reads 
in 20% or more of samples. Box plots are 25th and 85th percentiles, with a black line at 
the median. Outliers are ±1.5 times the interquartile range. Data Source: GTEx Analysis 
Release V7 (dbGaP Accession phs000424.v7.p2) 
 
TrkB binds with BDNF, neurotrophin-4 (NTF4) and neurotrophin-3 (NTF3), and 
regulates neuronal differentiation, growth, and survival as well as synaptic plasticity and 
transcription of cell survival genes (142). Thus, it affects both long- and short-term learning and 
memory by mediating short-term synaptic function as well as long-term potentiation. TrkB has 
also been implicated in apoptosis-suppression and promotion of communication between neurons 
and glial cells. 
Regarding BDNF, TrkB is preferentially activated by mature BDNF and expressed in 
indirect pathway striatal MSNs (55), Following activity-dependent, anterograde transport by 
cortical afferents, BDNF can act post-synaptically on TrkB receptors to inhibit GABAergic or 
enhance glutamatergic synaptic transmission. By interacting with presynaptic TrkB receptors, 
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BDNF can also be retrogradely transported to the cell body, where it stimulates cortical 
glutamate release. TrkB also responds to neuronal damage; its mRNA increases following 
excitotoxic lesions, and reduced TrkB is associated with neurodegeneration in Alzheimer’s 
disease. In the context of HD, mHTT reduces TrkB expression in a CAG-dependent manner (in 
R6/1 mice), an effect that is rescued by mHTT inactivation (55).  
Like other neurotrophins, BDNF is synthesized in the endoplasmic reticulum (ER) as a 
large (32kDa) precursor protein (pro-BDNF) (55), then translocated to the Golgi complex and 
secretory vesicles, proteolytically cleaved, and released as mature BDNF (14 kDa). P75, 
BDNF's low-affinity receptor (encoded by NGFR), is preferentially activated by pro-BDNF 
and promotes apoptosis. There is evidence for a cortical pro-BDNF overabundance in HD, 
which is one explanation for the lack of consensus on cortical BDNF reductions in HD and the 
prodrome (55); pro-BDNF increases could mask BDNF reductions when probed with methods 
that do not differentiate between pro- and mature BDNF. In humans, a highly conserved and 
fairly common (20-30% heterozygotes, ~4% homozygotes) BDNF polymorphism (Val66Met) in 
the 5’ region that encodes pro-BDNF is associated with memory deficits and multiple disorders 
(56). Mature BDNF production is not affected by Val66Met, but pro-BDNF trafficking and 
packaging are substantially impacted. Interestingly, mHTT significantly blocks post-Golgi 
trafficking of Val66Val (but not Val66Met) BDNF, although neither allele is associated with 
disrupted transport from the ER to the Golgi. 
Considering the roles of BDNF’s high- and low-affinity receptor types in promoting cell 
survival and apoptosis, respectively, a pro- to mature-BDNF ratio imbalance could contribute to 
the abnormal apoptosis observed in HD (56). TrkB receptor underrepresentation could hinder 
BDNF's ability to increase its own expression. Similarly, p75 receptor or pro-BDNF 
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overabundance could amplify apoptosis and contribute to disease-related decline. The results of 
the present study suggest that NTRK2 variants could influence this balance protectively, 
promoting cell survival and preserving frontal gray matter and cognitive and motor 
performance. 
 
4.5.2 The SNP-GMC Component Correlation is Not an Aggregate Effect of the 
Entire SNP Component 
Weights comprised of the top 61 SNPs contributing to the component (rather than the full 
component with weights for all 305,271 SNPs) yielded comparable results when evaluated with 
the GMC profile and clinical variables. Derived p and r2 values were only slightly weaker in 
analyses using the top 61 SNP weights, indicating that the original results do not reflect 
aggregate effects of the entire SNP component but are rather primarily due to top contributing 
SNPs. 
 
4.5.3 The NTRK2-associated Frontal GM Profile is Related to Prodromal Cognitive 
and Motor Functioning 
The correlated GMC component, containing supplementary motor, superior, middle, and 
medial frontal, and precentral/primary motor cortex, was significantly related to both cognitive 
(TMTA, Stroop Color, Stroop Interference) and motor (TMS) performance in this cohort. 
Although the variance in individual clinical performance measures accounted for by the GMC 
component was small, such effects are typical when comparing single clinical variables to brain 
structural measures; the observed associations were consistent with literature reporting structural 
and functional changes in these regions that correlate with altered performance on these tasks in 
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independent samples (143-147). Although each of the cognitive tasks has a motor component 
(writing or verbalization is required for response), the stronger correlation for TMS compared to 
the cognitive measures likely reflects the strength of supplementary and primary motor cortex in 
the GMC component and the increased demand on these regions for motor relative to cognitive 
functioning (148). This may also explain why significant effects were not observed for SDMT 
and Stroop Word, as motor involvement in these tasks is relatively limited. 
 
4.5.4 Top Contributing NTRK2 SNPs 
Rs11140810, rs4877289, rs10868241, and rs2277193 were among the top 10 SNPs 
contributing to the frontally-related SNP component; no other gene was represented more than 
once in the top 10 SNPs. Interestingly, three of these four SNPs are between NTRK2 exons 19 
and 20 (the location of an alternative stop codon), with rs2277193 (the TMTB-related SNP) 
being the closest to exon 19. In fact, rs2277193 is only 799 base pairs from rs11140810, the 
strongest NTRK2 contributor to the component, and is 3577 base pairs from the other top SNP in 
this region (rs10868241). The placement of these SNPs (as well as the fourth NTRK2 SNP, 
located between exons 16 and 17) is fitting, as truncated NTRK2 isoforms that lack the catalytic 
tyrosine kinase domain (generated by alternate terminal exon 16 or exon 19) are considered the 
most clinically relevant (149).  
Of the NTRK2 SNPs, rs11140810 had the strongest weight in the component. The Lieber 
Institute for Brain Development’s (LIBD) expression quantitative trait loci (eQTL) browser, 
comprised of dorsolateral prefrontal cortex (DLPFC) expression data from 237 healthy controls 
and 175 schizophrenia patients, identifies this SNP as an eQTL for NTRK2 in the DLPFC at the 
expressed region level (150). According to Braineac (http://www.braineac.org), an eQTL 
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database from 134 healthy human brains (151), rs11140810’s regulatory effects on NTRK2 are 
strongest in the occipital lobe, thalamus, and frontal cortex. Other top affected genes include 
SLC28A3, HNRNPK, MIR7-1, and NAA35. Table 4.5—1 lists top component SNPs and their 
strongest reported regulatory effects on genes in the brain. HaploReg, a tool for visualizing 1000 
Genomes Project SNP LD information in conjunction with Roadmap Epigenomics and 
ENCODE chromatin state and protein binding annotation, shows an association of rs11140810 
with markers of H3K27 acetylation (linked to active transcription) in the brain (Table 4.5.4—3), 
as well as altered regulatory motifs including forkhead box (Foxa), glioma-associated oncogene 
(GLI), hypermethylated in cancer (Hic1), and zinc finger protein (Zec) (152). 
Table 4.5—1. Top SNPs’ effects on gene expression in the brain 
SNP (rs) Occ. Thal. Temp. WM Put. Hipp. Fron. Cereb. SNigra Med. DLPFC 
8012614 
HEATR4 
(I) 
 
NUMB; 
TMEM9
0A 
HEATR4   ACOT4 RBM25
; 
ACOT4 
 RBM25 RBM25  RBM25; 
ACOT4; 
HEATR
4; 
DNAL1 
7801922 
CDK14 
(I) 
 
STEAP1 C7orf63; 
STEAP2 
 
STEAP
2 
 
C7orf63 
 
STEAP2 DPY19
L2P4; 
CDK14 
 
C7orf63 
7655305 
FAM114
A1 (I) 
  
RPL6 PDS5A 
 
FAM11
4A1 
TLR6 PTTG2; 
FLJ13197
; UGDH 
FAM11
4A1 
FAM11
4A1 
TLR1 
548321 
LRRC55 
(IG) 
    UBE2L
6; 
ZDHHC
5 
 TIMM10     
427790 
MIR181A
1, NR5A2 
(IG) 
 
NEK7 NR5A2; 
PTPRC; 
ATP6V1
G3 
 
NR5A2; 
MIR181
A1 
 
MIR181
A1 
MIR181A
1 
NR5A2 
  
1114081
0 
NTRK2 
(I) 
NTRK2 NTRK2; 
HNRNPK
; MIR7-1 
 
NTRK2
; 
SLC28
A3 
NAA35 NTRK2 NTRK2 HNRNPK
; MIR7-1 
 
SLC28
A3 
NTRK2 
2277193 
NTRK2 
(I) 
 
SLC28A3; 
HNRNPK
; MIR7-1 
 
SLC28
A3 
 
NAA35 SLC28A
3; 
AGTPBP
1 
SLC28A3; 
HNRNPK
; MIR7-1; 
NAA35; 
AGTPBP
1 
NAA35 SLC28
A3 
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Top SNPs contributing to supplementary/frontal-related pICA SNP component and reported 
effects on gene expression in the brain. These SNPs are associated with gene expression changes 
most prominently in the frontal lobe (in agreement with the study results), thalamus, putamen, and 
cerebellum. The first column lists the SNP rs ID, associated or closest gene, and gene type (I = 
intronic, IG = intergenic). Occ. = occipital, Thal. = thalamus, Temp. = temporal, WM = white 
matter, Put = putamen, Hipp. = hippocampus, Fron. = frontal, Cereb. = cerebellum, SNigra = 
substantia nigra, Med. = medulla, DLPFC = dorsolateral prefrontal cortex. Genes associated 
with more than one SNP and more than tissue type are bolded and underlined. Genes associated 
with more than one tissue type are bolded. Expression data was obtained from Braineac [40] 
 
Table 4.5—2. Genes regulated by prominent NTRK2 SNPs 
4877289 
NTRK2 
(I) 
AGTPB
P1 
  
HNRN
PK; 
MIR7-1 
SLC28
A3 
 
RMI1; 
SLC28A
3; 
AGTPBP
1 
    
1086824
1 
NTRK2 
(I) 
 
HNRNPK
; MIR7-1 
 
SLC28
A3 
RMI1 SLC28
A3 
SLC28A
3; 
NTRK2 
  
HNRN
PK; 
MIR7-
1; 
AGTPB
P1 
NTRK2 
Gene 
name 
Full name Associated 
NTRK2 
SNP(s) 
Description Type Related pathways 
SLC28A
3 
Solute 
Carrier 
Family 28 
Member 3 
rs1114081, 
rs2277193, 
rs4877289, 
rs10868241 
 
Neurotransmission, vascular tone, 
adenosine concentration near cell 
surface receptors, 
transport/metabolism of nucleoside 
drugs 
Protein 
coding, 
Nucleoside 
transporter 
Vitamin and nucleoside 
transport, Thiopurine 
Pathway, 
Pharmacokinetics/ 
Pharmacodynamics 
AGTPBP
1 
ATP/GTP 
Binding 
Protein 1 
rs10868241 Contains nuclear localization signals 
and an ATP/GTP-binding motif, 
involved in deglutamylation of 
protein polyglutamate side chains, 
removal of gene-encoded 
polyglutamates from protein 
carboxy-terminus, shortening of 
long polyglutamate chains 
Protein 
coding, 
Zinc 
carboxypep
tidase, 
Metallocar
boxypeptid
ase 
Neuroscience 
HNRNP
K 
Heterogene
ous Nuclear 
Ribonucleo
protein K 
rs1114081, 
rs2277193, 
rs4877289, 
rs10868241 
 
major pre-mRNA-binding protein, 
binds to poly(C) sequences, involved 
in nuclear metabolism of hnRNAs, 
p53/TP53 response to DNA damage 
(transcriptional activation and 
repression) 
Protein 
coding, 
Heterogene
ous nuclear 
ribonucleo
protein 
(hnRNP) 
Translational Control 
and mRNA Splicing 
MIR7-1 MicroRNA 
7-1 
rs1114081, 
rs2277193, 
rs4877289, 
rs10868241 
Affiliated with an undefined RNA 
class 
RNA gene mRNA Splicing, 
SUMOylation 
NAA35 
 
N(Alpha)-
Acetyltrans
ferase 35, 
NatC 
rs1114081, 
rs2277193 
Involved in regulation of apoptosis, 
proliferation of smooth muscle cells 
Protein 
coding 
Golgi-to-ER, Trans-
Golgi-Network 
retrograde transport 
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Genes regulated by prominent NTRK2 SNPs in this study, along with their associated functions 
and pathways. Sources: GeneCards human gene database (142) and UniProt (153) 
 
The nearby rs2277193 had a protective effect on TMTB, in which the minor allele was 
associated with improved performance. In the brain, this SNP exhibits maximum regulatory 
effects on many of the same genes, albeit a less pronounced influence on NTRK2 (151). 
According to Haploreg, this SNP is associated with expression-enhancing chromatin states in the 
brain (Table 4.5—2), altered glucocorticoid receptor (GR) and paired-box protein (Pax-6) 
regulatory motifs, and AGTPBP1 expression in the PFC (152). 
Rs4877289 is correlated with H3K4me1 (enhancer activity associated) in anterior caudate 
and cingulate gyrus, and is in strong LD with other NTRK2 SNPs associated with histone 
enhancement and promotion, protein binding, altered regulatory motifs and eQTL hits. For 
example, rs11140785 (LD = 0.94) bound to STAT3 in ChIP-Seq and is associated with altered 
myocyte enhancer factor (Mef2) regulatory motif and expression-enhancing chromatin changes 
in the hippocampus, substantia nigra, caudate, inferior temporal, cingulate gyrus, angular gyrus, 
and DLPFC. In the brain, this variant most strongly affects RMI1, especially in frontal cortex 
(151). 
Like rs11140810, rs10868241 is an identified eQTL for NTRK2 in the DLPFC at the 
expressed region level in control and disease populations (150). It is also associated with 
enhancer and promoter-associated active histone modifications in several brain regions (Table 
4.5—2), and is in strong LD with SNPs linked to enhancer histone marks and altered regulatory 
motifs [for example, rs4457413 (LD r2 = 0.97) is associated with alteration of 12 regulatory 
motifs and with histone enhancers in the temporal lobe and PFC]. In the brain, rs10868241 most 
Auxiliary 
Subunit 
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strongly regulates many of the same genes as the other top NTRK2 SNPs (SLC28A3, HNRNPK, 
MIR7-1, NTRK2, AGTPBP1, RMI1) (151), especially in the frontal cortex and hippocampus. 
In summary, the four NTRK2 SNPs that contributed most to the SNP component were 
situated near alternative stop codons (rs4877289 between exons 16 and 17, and the others 
between exons 19 and 20); these SNPs act on NTRK2, its neighboring SLC28A3 and AGTPBP1 
genes, and other genes (HNRNPK, MIR7-1, NAA35, RM1) in and outside of brain tissue. These 
genes are implicated in apoptosis regulation, smooth muscle cell proliferation, mRNA splicing, 
neurotransmission, translational control, SUMOylation, Golgi and ER retrograde transport, and 
shortening of long polyglutamate chains, among other functions (Table 4.5—2). The effects of 
these NTRK2 SNPs on genes are most common and pronounced in the frontal cortex (in keeping 
with the SNP component’s connection to frontal gray matter), followed by thalamus, putamen, 
and cerebellum. Table 4.5—3 summarizes histone modifications and altered regulatory motifs 
associated with these SNPs. 
Table 4.5—3. Histone modifications contributing to chromatin states at top NTRK2 SNPs 
in the brain 
NTRK2 
SNP 
CG IT AG DLPFC Ant. Caud. MHipp SNigra Regulatory 
motifs 
altered 
rs11140
810 
H3K27a
c 
H3K27a
c 
H3K27ac H3K27a
c 
   Foxa, GLI, 
Hic1, Zec 
rs48772
89 
H3K4m
e1 
   H3K4me1    
rs10868
241 
H3K27a
c, 
H3K4m
e1 
H3K27a
c, 
H3K4m
e1 
H3K27ac H3K27a
c, 
H3K4m
e1 
H3K27ac H3K27
ac, 
H3K4m
e1 
H3K27a
c, 
H3K4m
e1 
 
rs22771
93 
H3K27a
c 
H3K27a
c 
H3K27ac H3K27a
c 
   GR, Pax-6 
Histone modifications contributing to chromatin states at top NTRK2 SNPs in the brain. Altered 
regulatory motifs associated with SNPs are also listed. H3K27ac = enhancer/promoter-
associated, H3K4me1 = enhancer-associated. CG = cingulate gyrus, IT = inferior temporal, AG 
= angular gyrus, DLPFC = dorsolateral prefrontal cortex, Ant. Caud. = anterior caudate, 
MHipp = middle hippocampus, SNigra = substantia nigra. Data from HaploReg v4.1 (152) 
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It is important to consider LD pruning when interpreting these results. Although two of 
these SNPs (rs1114081 and rs2277193) are not in high LD with other SNPs, rs4877289 is in high 
LD with three SNPs (rs10780691, rs10868235, rs10868230; r2: 0.92-0.98) and rs10868241 is in 
high LD with nine SNPs (rs7858707, rs10116596, rs10122796, rs7030319, rs4329345, 
rs11464614, rs10780693, rs11140813, rs4457413; r2: 0.97-1.0). Thus, the effects of the latter 
two SNPs in this study may be attributable to a SNP in high LD that was pruned from the 
dataset.   
 
4.5.5 Top Contributing SNPs Outside of NTRK2 
Although NTRK2 SNPs were disproportionally represented in the top component SNPs, 
other top SNPs included intronic CDK14, FAM114A1, and HEATR4 SNPs, as well as intergenic 
SNPs (rs548321 closest to LRRC55, rs427790 between MIR181A1 and NR5A2). Many of these 
genes are implicated in cancer regulation (Appendix C.3). Overall, compared to top component 
NTRK2 SNPs, top SNPs outside of NTRK2 were less commonly associated with histone 
modifications in the brain, but were more often reported to influence regulatory motifs and gene 
expression outside the brain. In Braineac data, the 10 strongest SNP influences on brain gene 
expression among our top 10 component SNPs were exhibited by three of the SNPs outside of 
NTRK2 (rs7655305, rs8012614, rs548321); rs7655305 accounted for half these effects. 
Appendix C.4, a complement to Table 4.5—3, summarizes brain histone modifications and 
altered regulatory motifs associated with these SNPs (the HEATR4 SNP is omitted due to the 
absence of relevant findings). Of these SNPs, the intergenic SNPs rs548321 (LRRC55-
associated) and rs427790 (MIR181A1 and NR5A2-associated) share perhaps the most overlap 
with the NTRK2 SNPs; rs2277193 (NTRK2) and rs548321 both alter GR (glucocorticoid 
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receptor) and Pax (paired box) regulatory motifs (Pax-4 for rs548321 and Pax-6 for rs2277193) 
and are associated with histone changes in the brain. Rs11140810 (NTRK2) and rs427790 alter 
the same Zec transcription factor and two distinct Fox regulatory motifs (Foxj1 for rs427790 and 
Foxa for rs11140810). Each of these SNPs are outlined in more detail below. 
The CDK14 variant (rs7801922) contributed to the SNP component more than any other 
SNP. This intronic SNP is 68,161bp upstream of CDK14 exon 1, and is an eQTL in the lungs 
(GTPBP10), tibial artery (CDK14), tibial nerve (GTPBP10), and thyroid (DPY19L2P4) (124). In 
the brain, rs7801922 is an eQTL for the DLPFC in psychiatric populations (150). In healthy 
populations, this variant most affects genes that exhibit reduced expression in white matter 
relative to other brain tissue types (e.g., STEAP2, DPY19L2P4, C7orf63) (151). Appendix C.5 
lists examples of gene regulation related to this SNP. Rs7801922 is associated with altered 
regulatory motifs [ecotropic virus integration site (Evi-1), GATA-binding factor (GATA), 
interferon regulatory factor (Irf), and suppressor of essential function (SEF-1)], and is in LD with 
three other CDK14 SNPs associated with other regulatory motif alterations (152). 
An intronic HEATR4 (HEAT Repeat Containing 4) variant was another top SNP. HEAT-
repeats are amino acid domains that often have roles in protein-protein interactions, and are 
considered important for intracellular transport, microtubule dynamics and chromosomal 
separation. Huntingtin is one of the first proteins HEAT-repeats were discovered in (HEAT 
stands for Huntingtin, Elongation factor 3, protein phosphatase 2A and TOR) [44]. The HEATR4 
SNP that was prominent in our genetic component (rs8012614) is an eQTL for ACOT4 (exon, 
expressed region, gene, and transcript levels), DNAL1 (expressed region level), and HEATR4 
(expressed region level) in the DLPFC (150); in controls, the SNP was an eQTL for ACOT4 only 
(exon, expressed region, and gene levels). Additionally, this SNP has more GTEx eQTL hits than 
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any other top contributing SNP, although these are mostly outside the brain in adipose, muscle, 
skin, heart, pancreas, and thyroid (124). The effect of this SNP on DNAL1 is particularly 
interesting, as this gene is not only part of the KEGG Huntington’s Disease gene pathway but is 
also directly involved in aberrant BDNF transport (154). DNAL1 is one of three genes associated 
with dynein axonemal light chain 4, part of the ATP-dependent outer dynein arms complex that 
acts as a molecular motor for cilia (142).  
The final intronic SNP, rs7655305, regulates expression of FAM114A1 (mostly in the 
medulla, substantia nigra, and hippocampus) (151) and other genes, especially in the cerebellum 
(Table 4.5.4—1). This variant is an eQTL for TLR1 in the DLPFC (transcript and exon levels in 
the disease population) (150) as well as other genes in many areas outside the brain, including 
skin (especially sun-exposed), tibial nerve, subcutaneous and visceral adipose, breast mammary 
tissue, testis, thyroid, and esophagus. Rs7655305 is associated with enhancer histone marks in 
four tissues outside of the brain, alteration of CCCTC-binding factor (CTCF) and telomere 
length regulation (Tel2) regulatory motifs (152), and active H3K36me3 (transcription-
associated) histone modification in the middle hippocampus (http://www.featSNP.org). This 
SNP is also in LD with several other intronic FAM114A1 SNPs with correlated enhancer histone 
marks, altered regulatory motifs, and eQTL hits (152).  
Rs112140519 is a deletion/insertion variation closest to NUS1 that is linked to H3K4me3 
promotion in adipose nuclei and duodenum smooth muscle as well as alteration of five 
regulatory motifs (Dbx1, Hoxb13, Ncx, ZNF263, Zfp105) [41]. Rs548321, an intergenic SNP 
70kbps from the 5’ end of LRRC55, most strongly affects expression of TIMM10, UBE2L6, and 
ZDHHC5 (especially in the putamen, although TIMM10 effects were most prominent in frontal 
cortex). Each of these genes exhibits the lowest expression in the cerebellum relative to other 
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brain tissue types (151). Haploreg data shows selective association with H3K4me1 and H3K27ac 
enhancements in anterior caudate, as well as alteration of GR and Pax-4 regulatory motifs (152).  
Rs427790, an intergenic SNP between MIR181A1 and NR5A2, is an eQTL hit in the testis and 
basal ganglia (124). Haploreg indicates associated alteration of double homeodomain (Dux1), 
Foxj1, and Zec regulatory motifs (152). 
 
4.5.6 Influence of HTT CAG-Repeats 
Including CAG-repeat number or CAG-age-product (CAP) score as a covariate did not 
affect the significance of the GMC-SNP component correlation. Similarly, inclusion of CAP did 
not nullify the significance of the NTRK2-SNP correlation with TMTB, although it did account 
for some of the variance. While we can currently only speculate on this finding, it may be 
attributable to the regression of age effects from the imaging data prior to pICA. CAP reflects the 
cumulative disease burden of age and CAG-repeat number. Because the GMC component had 
the effects of age subtracted from it, CAP and CAG would be expected to display a similar 
relationship to the GMC component, which is what we observed. The relationships between the 
GMC component and the clinical variables, however, could be accounted for by CAP, likely 
reflecting the sensitivity of these measures to CAG and age, both of which are highly related to 
the clinical variables assessed in this study. 
 
4.6 Conclusions 
The study results demonstrate the following: 
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1. In this PREDICT-HD prodromal cohort, high or low levels of a SNP profile with 
substantial contributions from NTRK2 were associated with a GMC profile representing 
supplementary and primary motor cortex, as well as other frontal regions (positive correlation) 
2. This frontal gray matter profile was associated with cognitive and motor 
performance in this population 
3. The SNP component was not significantly associated with clinical functioning, 
but one of its top NTRK2 SNPs had a protective association with performance on TMTB, a 
measure of task switching and visual attention, indicating some influence on cognition.  
4. Correlations between the SNP component and clinical/GMC variables were 
mainly due to top contributing SNPs, rather than being an aggregate effect of the entire SNP 
component 
5. Top component SNPs have been associated with active histone modifications in 
the brain (cingulate gyrus, inferior temporal, angular gyrus, DLPFC, caudate, hippocampus, and 
substantia nigra) and altered regulatory motifs [(especially glucocorticoid receptor (GR) and zinc 
finger protein (Zec)] 
6. Top NTRK2 SNPs in the component were close to alternative stop codons and 
reportedly regulate genes implicated in diverse functions (especially in the frontal cortex, 
thalamus, putamen, and cerebellum) 
Although further investigation is warranted, these results suggest that NTRK2 has 
protective potential in Huntington’s disease, especially in individuals with certain 
genotypes. Treatments that target BDNF receptors may help preserve frontal gray matter that is 
important for cognitive and motor functioning. 
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4.7 Limitations 
In any study involving many participants with a rare condition, multiple scanning sites 
are typical and a certain degree of inhomogeneity in data collection is thus inevitable. This study 
incorporates data from several unique 1.5 T and 3 T MRI scanners, and every effort was made to 
control for possible confounds related to this. Before data collection, uniform protocols were 
established to ensure maximal homogeneity of data collection. The effects of collection site and 
scanner field strength, as well as sex and age, were regressed from GMC images before pICA. 
Ideally, controls would be included in the analysis to permit comparisons with prodromal 
HD participants. PICA was carried out with a more extensive dataset (N = 903) that included 
controls (N = 189). However, the analysis did not extract a significantly correlated SNP-GMC 
component pair that withstood correction for multiple testing. The effects presented in this study 
may be unapparent in the combined sample with controls because they are related to other 
processes already aberrant in HD, such as BDNF transcription and nuclear translocation.  
Because the GMC-SNP component correlation was driven by a small percentage of 
participants, the results may not apply to the entire HD population, and treatments that target 
NTRK2 should consider the context of the patient’s genomic landscape. Nonetheless, for cancer 
and other diseases, emphasis is shifting away from blanket treatments toward more personalized 
gene therapies that consider individual genotypes. If clinical trials to reduce mHTT are 
ineffective or harmful for certain individuals in the long-run, therapies that instead target 
mediators of mHTT toxicity may provide a promising alternative. 
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4.8 Future Directions 
This study helped characterize the complex interactions of BDNF-signaling genes, brain 
structure and clinical functioning in prodromal HD. As genetic and epigenetic factors of 
prodromal HD progression continue to be identified, potential gene therapies (such as DNA-
methylating drugs and histone-deacetylase inhibitors) can be refined, tested and implemented 
more strategically (155). To aid the development of targeted treatments, future studies should 
test the validity of strong correlations observed in the most extensive available human datasets 
by establishing causal links in non-human animals. For example, many HD Drosophila (fruit fly) 
strains are available that permit rapid, efficient, and inexpensive querying of SNPs and genes of 
interest derived from human studies. The most promising candidates from these experiments can 
be flagged for continued research in mammals and eventual use in clinical trials. A promising 
direction is to examine how different ratios of BDNF TrkB and p75 receptors influence 
progression and onset in the context of HTT CAG-repeats. BDNF acts on TrkB receptors to 
increase its own continued expression; thus, an underrepresentation of these receptors may 
reduce BDNF. Similarly, p75 receptor overrepresentation or an overabundance of pro-BDNF 
may promote apoptosis and contribute to disease-related decline. Another important 
consideration is the impact of other BDNF exons. Huntingtin stimulates transcription from the 
BDNF exon II promoter, which is 60% less active in cells over-expressing mHTT (55). Although 
BDNF exon III and IV promoter actions are not linked to huntingtin, mHTT reduces their 
transcription through unknown mechanisms thought to involve CREB and CBP. Thus, promoter 
II transcriptional reduction may be linked to huntingtin reductions, while that of promoters III 
and IV may be related to mHTT toxicity. CREB and CBP are also linked to several altered 
functions in HD, and their investigation is a valuable avenue for future research. This study 
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examined BDNF-signaling genes in relation to GMC and clinical functioning. However, white 
matter is dramatically affected in HD and may also be influenced by these factors, a possibility 
that should be examined in future studies. Aside from genetic influences on HD progression, 
epigenetic marks (which can alter gene expression) also differ in patients compared to controls. 
This may be an especially promising therapeutic direction because, unlike the fixed DNA 
sequence, the epigenome changes across the lifespan and in response to environmental stimuli. 
Future studies should seek to characterize prodromal epigenetic differences in various tissues, as 
well as identify protective and detrimental variations in pathways with known clinical relevance 
to HD. An additional important future direction is to characterize these factors longitudinally. 
SNP and methylation patterns, for example, in BDNF/REST pathways may be associated with 
different rates of clinical decline or rapidity of HD-onset. Factors associated with disease 
resilience could then be incorporated into intervention strategies to slow or prevent HD 
conversion. 
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5 CONCURRENT CROSS-SECTIONAL AND LONGITUDINAL ANALYSES OF 
WHITE MATTER PROFILES AND CLINICAL FUNCTIONING IN PRE-
DIAGNOSIS HUNTINGTON’S DISEASE 
This chapter is being submitted to Journal of Huntington’s Disease as Ciarochi JA, Johnson H, Lourens S, 
Long JD, Calhoun VD, Bockholt HJ, Liu J, Misiura M, Espinoza FA, Caprihan A, Plis S, Turner JA, Paulsen JS; the 
PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Concurrent Cross-sectional and 
Longitudinal Analyses of White Matter Profiles and Clinical Functioning in Pre-diagnosis Huntington’s Disease. 
 
5.1 ABSTRACT 
We simultaneously assessed changes in gray-matter-adjacent white matter (WM) and 
cognitive and motor functioning variables at various stages of prodromal (pre-diagnosis) 
Huntington’s disease (HD). Imaging and clinical data from 1,336 (1,047 prodromal and 289 
control) PREDICT-HD participants who took part in at least two separate MRI sessions were 
analyzed (3,700 total sessions).  
MRI images were first segmented into gray matter, white matter (WM), and 
cerebrospinal fluid; using Source-Based Morphometry, Independent Component Analysis was 
applied to the WM segmentations to extract representative WM profiles from our population. 
The WM profiles were then analyzed in two sets of Linear Mixed Model (LMM) analyses: one 
to cross-sectionally and longitudinally compare the WM profiles among prodromal and control 
groups and an additional “stacked” LMM to concurrently compare WM profiles with cognitive 
and motor functioning variables at baseline and over time in each group. 
The results illustrated a widespread pattern of prodromal WM changes characterized by 
premotor, supplementary motor, middle frontal gyral and striatal changes early in the disease 
process that subsequently extend sub-gyrally with prodromal progression. Overall, the measure 
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of motor functioning agreed most with WM both cross-sectionally and longitudinally until the 
near-onset prodromal stage, when Stroop Interference was the best indicator. Across groups, 
TMTA outperformed the other cognitive variables in its similarity with WM, particularly at 
baseline.  
These findings suggest that distinct regions coincide with cognitive compared to motor 
functioning both at baseline and over time. Furthermore, at different prodromal progression 
stages, different regions appear to align best with clinical functioning, indicating that the 
informativeness of these measures varies according to the type of data available (cross-sectional 
or longitudinal) as well as the ages and CAG-numbers of prodromal participants. 
 
5.2 Introduction 
Huntington’s Disease (HD) is a progressive, delayed-onset disorder primarily associated 
with involuntary motion (chorea) and also characterized by cognitive alterations spanning 
executive functioning (including task-switching, response inhibition, and working memory) (1-
3), odorant recognition (6), and emotional processing (4, 5). HD-associated disturbances also 
extend beyond the central nervous system, affecting cardiac, respiratory, and sleep systems.  
HD is, fortunately, a rare condition, affecting around 1 in 7,300 individuals in the United 
States (global prominence is variable) (7). However, as both a proteinopathy and the most 
common PolyQ disease7, it shares key features with disorders that are more difficult to 
disentangle due to increased genetic complexity. Proteinopathies, including HD, Alzheimer's 
disease (AD) and Parkinson's disease (PD), are distinguished by regionally-selective neuronal 
                                                 
7Q is the symbol for glutamine, the amino acid encoded by the CAG codon. 
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death8 and protein misfolding9. These conditions typically demonstrate delayed onset and 
disproportionately affect the elderly. 
There is no known cure for HD, though its cause has been known since the nascence of 
human genome sequencing. In 1993, an abnormally expanded cytosine-adenine-guanine (CAG) 
repeat at an exon 1 locus of the chromosome 4 HTT gene was identified as causal for HD (10). 
The normal range of CAG-expansion at this locus is 17-20 (11); repeat-numbers of 36 and above 
confer highly elevated risk of HD, with higher CAG-numbers being associated with earlier onset 
and more rapid symptom progression (14). In individuals with abnormally-expanded CAG, brain 
structural and cognitive differences from non-expanded individuals are measurable a decade or 
more before HD diagnosis, during a period known as the prodrome. The relationship between 
CAG and onset makes it possible to index the prodrome using CAG-number and age (19); many 
researchers have leveraged this fact to identify the earliest prodromal changes as potential targets 
for HD intervention. Because HD typically manifests in mid-to-late life, treatments that further 
delay symptoms could eradicate the disease for many individuals.  
PREDICT-HD is among the most extensive research groups to undertake characterization 
of the prodrome; this multi-site study has collected genomic, brain imaging, and clinical (motor 
and cognitive) data from 33 sites in the United States, Canada, Australia, and Europe (156). 
PREDICT-HD has identified many early prodromal indicators, including early widespread gray 
matter concentration reductions (23), longitudinal motor, cognitive, and volumetric changes (in 
the putamen, caudate, and nucleus accumbens) (18) as well as clinically-associated subcortical 
brain volume differences (2, 20, 26), and resting state functional connectivity alterations (25).  
                                                 
8Brain structural alterations are widespread in HD but concentrated in medium spiny striatal neurons. 
9Protein misfolding manifests as expanded huntingtin in HD, Lewy bodies in PD, and β-amyloid plaques in AD. 
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5.2.1 Brain Structure in Prodromal HD 
Gray matter atrophy, particularly in the basal ganglia, is a long-established symptom of 
the HD prodrome. More recently, prodromal white matter (WM) deterioration around the 
striatum (24, 32, 34, 44, 157-159) and across the brain (20, 32-37) has also been reported. 
Cerebral WM can offer independent power for predicting diagnosis proximity in prodromal HD 
(35). Prodromal WM changes may also precede those observed in gray matter, although reports 
have differed.  
To date, most prodromal HD WM studies have examined diffusion tensor or diffusion-
weighted imaging (DTI/DWI) measures such as fractional anisotropy (FA), mean diffusivity 
(MD), radial diffusivity (RD), and axial diffusivity (AD) to compare WM integrity between 
prodromal and control participants as well as among prodromal groups with different estimated 
proximities to diagnosis. This work has generally demonstrated prodromal anisotropy reductions 
and diffusivity increases in WM adjacent to the striatum (24, 32, 38-40) as well as in the 
thalamus (32, 39-42), corpus callosum (32, 40, 41, 43), and parietal and occipital areas (24, 32, 
43, 44). Frontal regions are also common sites of reported prodromal diffusivity differences (24, 
32, 39, 42-44, 160). In one of the only studies probing gray-matter-adjacent WM, the effect sizes 
for atrophy increases were more significant than those seen in whole WM (32). 
Longitudinal findings have been more limited and conflicting. The largest longitudinal 
study to date reported cross-sectional and longitudinal differences in WM tracts connecting the 
striatum to premotor, primary motor, and sensory cortices, with the most prominent longitudinal 
effects observed in putamen-connected tracts (24). Another two-year longitudinal WM 
diffusivity study of 64 prodromal participants reported differences in longitudinal diffusivity that 
were restricted to the superior fronto-occipital fasciculus (41). An additional two-year study 
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including 211 prodromal individuals found increased rates of atrophy in cerebral WM that were 
most pronounced in the frontal lobe (45). Notably, no changes were observed in lobe-specific or 
cortical gray matter volumes, and disease-related WM atrophy exceeded striatal atrophy when 
age-related atrophy was taken into account. Other studies, however, did not report any DTI 
changes over a 12- or 30-month period (33, 47, 161). 
 
5.2.2 Prodromal WM and Clinical Functioning 
Most studies linking WM to prodromal motor and cognitive functioning have also been 
cross-sectional, associating volumetric and FA reductions as well as MD, RD, and AD increases 
with clinical impairment (20, 44, 47, 48, 160, 162) (Table 5.2—1). In the HD prodrome, 
correlations between WM and clinical measures have indicated widespread regional involvement 
in cognitive and motor functioning. Few studies have compared WM and clinical change 
trajectories concurrently. In one such study, motor symptom increases were associated with 
diffusivity changes in the superior fronto-occipital fasciculus as well as volumetric changes in 
the corpus callosum, cerebrospinal fluid, and lateral ventricle (41). In another longitudinal study, 
UHDRS-TMS was the only independent predictor of longitudinal FA decline in both prodromal 
and symptomatic HD (47). 
Table 5.2—1. Reported Prodromal Cross-sectional WM-Clinical Associations  
  SDMT SC SI SW TMTA TMTB UHDRS-
TMS 
Source(s) 
v
o
lu
m
es
 Frontal       ✓ (20) 
Parietal ✓       (20) 
Occipital ✓      ✓ (20) 
Temporal ✓      ✓ (20) 
tr
ac
ts
 
Putamen-
prefrontal 
RD RD RD RD    (44) 
Corpus 
callosum-
prefrontal 
FA, 
MD, 
RD 
   FA, 
MD, 
RD 
FA, 
MD, 
RD 
FA, MD, 
RD 
(47, 48) 
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Anterior 
thalamic 
radiations 
MD, 
RD 
MD, 
RD 
   MD, 
RD 
 (48) 
Inferior fronto-
occipital 
fasciculi 
MD, 
RD 
MD, 
RD 
MD, 
RD 
MD, 
RD 
MD, 
RD 
MD, 
RD 
 (48) 
Uncinate 
fasciculi 
    FA RD  (48) 
R medial 
orbitofrontal 
     FA  (160) 
R pars 
opercularis 
     FA, RD  (160) 
R pars 
triangularis 
     FA, RD  (160) 
Previously reported associations between prodromal WM volumes/tracts and cognitive and motor 
functioning variables. R = right. All reported FA differences are reductions and all other 
diffusivity differences reflect increases. 
 
5.2.3 The Present Study 
This work complements and extends the current literature regarding brain-structural and 
clinical changes in the HD prodrome by:  
(1) investigating co-occurring regional patterns in the brain 
(2) focusing primarily on GM-adjacent-WM rather than WM tracts, and in some cases 
examining WM patterns that co-occur with those in GM  
(3) examining cross-sectional and longitudinal WM changes 
(4) concurrently comparing trajectories of change in WM and clinical functioning 
variables  
(5) analyzing one of the most extensive prodromal HD datasets ever collected  
 
To accomplish these goals, we extracted brain imaging patterns primarily consisting of 
GM-adjacent-WM from our population using Source-Based Morphometry (SBM), an 
Independent Component Analysis (ICA)-based method optimized for brain imaging data. We 
then leveraged Linear Mixed Model (LMM) analyses to concurrently compare cross-sectional 
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differences and longitudinal trajectories of these WM profiles with those of clinical (cognitive 
and motor) functioning measures. 
Cross-sectionally, we predicted that the prodromal group closest to estimated diagnosis 
would most drastically differ from controls, whereas the group furthest from onset would present 
with the most modest differences. We also expected the most robust longitudinal changes in the 
near-onset group, particularly in motor functioning and in areas underlying diagnosis-associated 
motor symptoms, such as the striatum. Across groups, we anticipated that frontal changes would 
be the most similar to cognitive changes, whereas changes in the striatum, thalamus, and cortical 
areas important for movement (such as motor cortices) would align most with changes in motor 
functioning. These predictions reflect the broader underlying hypothesis that different brain 
structural changes accompany early prodromal cognitive changes compared to the delayed motor 
dysfunction that generally instigates diagnosis. 
 
5.3 Methods 
5.3.1 Participants 
1,336 PREDICT-HD participants (1,047 prodromal and 289 control) who underwent a 
total of 3,700 data collection sessions were analyzed. Participant demographics are presented in 
Table 5.3—1. Prodromal participants were stratified into Low, Medium, or High disease 
progression levels based on estimated time to diagnosis as indexed by CAG-age-product (CAP) 
score, a widely used metric for establishing clinical diagnosis likelihood that was developed 
based on an accelerated failure time model analysis with the entire PREDICT-HD dataset (19). 
CAP was calculated using the formula CAP = (age at first MRI scan session) × (CAG − 33.6). 
Based on this grouping, the participant pool (at baseline) included 288 Low (CAP scores < 
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287.16), 365 Medium (CAP: 287.16 - 367.12), and 394 High (CAP > 367.12) prodromal 
participants, with High group designation indicating the highest likelihood of a looming HD 
diagnosis. Because CAP-score encompasses age and CAG-repeat-number, age differences 
between CAP-groups were anticipated. The High group was older than the Medium and Low 
groups at their earliest scans, and the Medium group was older than the Low group. The Low 
and Medium groups were also younger than the Control group. The High group had fewer years 
of education than the Control and Medium groups, and the Low group had fewer years of 
education than the Control group. Significant CAP-group differences in gender were also 
observed (there were more female participants overall) but were driven by the High vs. Low 
contrast. These statistics are presented in Appendix D.1. 
Table 5.3—1. Participant Demographics 
Group Total 
Participants 
CAP Score 
Mean     SD       
Total 
Sessions 
Participant 
Sessions 
Mean   SD             
Baseline Age  
(years) 
Mean        SD 
Sex 
Male   
Female 
Education 
(years) 
Mean    SD 
Control 289 - - 875 3.22 1.82 44.44 11.93 100 189 15 2.44 
Low 
CAP 
288 235.75 40.17 768 2.81 2.05 33.83 8.72 92 196 14.49 2.46 
Medium 
CAP 
365 330.14 22.76 1,009 3.06 1.87 40.68 9.62 128 237 14.71 2.39 
High 
CAP 
394 429.03 54.12 1,048 2.86 1.54 44.89 10.40 166 228 14.41 2.61 
All 1,336 341.39 87.94 3,700 2.95 1.82 41.26 11.05 486 850 14.64 2.51 
Participant demographics, including baseline CAG-age-product (CAP), age, gender, years of 
education, and number of sessions. 
 
All PREDICT-HD participants provided written, informed consent and were treated in 
accordance with protocols approved by each participating institution’s internal review board. 
Participants underwent genotyping before study enrollment; those with fewer than 36 HTT CAG-
repeats were designated as controls and those with more than 35 as prodromal. Participants with 
any other central nervous system condition or an unstable medical or psychiatric disorder were 
excluded from the study. 
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5.3.2 Imaging Data Acquisition 
High-resolution anatomical MR images were collected at 33 sites using General Electric, 
Philips, and Siemens scanners with 1.5 T (Tesla) or 3 T field strengths and various acquisition 
parameters. Each site underwent a calibration process to minimize inherent differences between 
site and scanner manufacturer capabilities. The intent was to collect images with similar 
properties at each site under the constraints of each site’s scanner capabilities. T1 images were 
obtained using three-dimensional (3D) T1-weighted inversion recovery turboflash (MP-RAGE) 
sequences. The Siemens protocol was designed to be similar to the General Electric scan 
parameters: GRAPPA factor, 900 ms TI (inversion time), 2,530 ms TR (relaxation time), 3.09 ms 
TE (excitation time), 256 mm × 256 mm field of view (FoV), 10° flip angle, 240 coronal slices 
(1 mm thickness), 256 × 128 matrix with 1/4 phase FoV, and 220 Hz/pixel receiver bandwidth. 3 
T scanner protocol commonly included a sagittal localizing series followed by an axial 3D 
volumetric spoiled gradient recalled acquisition in steady state (GRASS) sequence acquisition 
and the following scan parameters: ~1 mm × 1 mm× 1.5 mm voxel size, 0 mm gap, 18 ms TR, 
3 ms TE, 24 cm FoV, 20° flip angle, 124 slices (1.5 mm thickness), 256 × 192 matrix with 3/4 
phase FoV, number of excitations (NEX) = two. 
 
5.3.3 Imaging Data Preprocessing 
T1-weighted images were processed using a Nipype pipeline optimized for efficient 
large-scale multicenter data processing (163) with BRAINSTools suite 
(http://github.com/BRAINSia/BRAINSTools.git) and the ANTs (Advanced Normalization 
Tools) package (164). Images were spatially normalized to an anterior commissure-posterior 
commissure (AC-PC) and interhemispheric fissure reference orientation (165, 166), then 
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segmented into tissue types (gray matter, white matter, and cerebrospinal fluid) using an 
Expectation Maximization (EM) and a fuzzy k-Nearest Neighbor (KNN) classification 
incorporating bias-field correction and image registration (165, 167). The extracted WM 
segmentations were used in further analyses. Whole brain segmentation/labeling was achieved 
using Multi-Atlas Label Fusion (168) applied to bias-field corrected T1 images, resulting in 180 
independent, FreeSurfer-compatible regional labels. 
 
5.3.4 Clinical Variables 
Seven clinical variables were selected for analyses based on their established clinical 
reliability and sensitivity to prodromal HD progression (1): Symbol Digit Modalities Test 
(SDMT), three conditions from the Stroop Color Word Test, Trail-Making Tests A (TMTA) and 
B (TMTB), and the Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS-
TMS). Table 5.3—2 includes examples of each clinical measure. The SDMT, an adaptation of 
the Wechsler Digit Symbol subtest, is an indicator of working memory, complex scanning, and 
processing speed capabilities (109, 136); participants are tasked with matching numbers to 
corresponding symbols using a provided key. The Stroop Color and Word Test includes the color 
(SC), word (SW), and interference (SI) conditions. The color and word conditions measure basic 
attention, whereas the interference condition also entails inhibition of a dominant (automatic 
processing) response (110). For the color condition, participants identify colors presented on 
stimulus cards. For the word condition, the task is to read color names that are presented in black 
ink. For the interference condition, participants identify the ink color in which a color-name is 
presented (e.g., for the word “blue” printed in green ink, the correct response is “green”). TMTA 
primarily measures visual attention, whereas its more complex counterpart, TMTB, also 
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measures task-switching (111, 112). TMTA entails sequentially connecting a series of numbered 
circles (e.g., 1-2-3-4). For TMTB, consecutive numbers and letters are alternately connected in 
ascending/alphabetical order (e.g., 1-A-2-B-3-C). The UHDRS-TMS encompasses several 
indicators of motor functioning, including oculomotor function, bradykinesia, chorea, dystonia, 
gait, and postural stability (1, 58). 
Table 5.3—2. Clinical Variables 
SDMT SC SW SI TMTA TMTB UHDRS-TMS 
    
  
 
Examples of each clinical variable analyzed in the present study. For SC, SW, SI, TMTA, and 
TMTB, correct responses are shown. For SDMT, an example key and uncompleted response sheet 
are displayed, and two sample questions from the UHDRS-TMS are presented. 
 
5.3.5 Source-based Morphometry 
ICA, a blind-source separation technique, was applied to processed white matter 
segmentations using SBM via the GIFT Matlab toolbox (http://mialab.mrn.org/software/gift). 
The number of components representing the 3,700 images was estimated to be 45 using a 
minimum description length (MDL) criterion modified to account for correlated voxels (84). The 
steps of SBM are concisely summarized below. 
Each image is first converted into a one-dimensional vector (a participant-by-voxel data 
matrix) (67). This matrix is then decomposed into a mixing matrix (participant-by-component, 
where components are the 45 white matter profiles) and a source matrix (component-by-voxel) 
using the infomax algorithm for spatial ICA. The goal of ICA is to determine the mixing matrix 
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(or rather, its inverse), which represents how much each participant’s brain structure resembles 
each statistically independent white matter profile extracted from the population. Rows of the 
mixing matrix are weights (or loading coefficients) representing how much each of the 45 
components/profiles contributes to one participant’s data, and columns represent how strongly a 
component is represented in each participant. For the source matrix, by contrast, rows indicate 
how robustly each voxel is represented in a component and columns denote how much a single 
voxel contributes to each of the 45 components. For each participant, this decomposition 
produces a loading coefficient for each component, and each component is a spatial map10.  
As quality control, component stability was confirmed using ICASSO (85). All 45 
components were stable, with 41 components having minimum stabilities above 0.95 and only 
two components with minimum stabilities below 0.90 (components 44 and 45 had stabilities of 
0.85 and 0.72, respectively). Following ICA, components were visually inspected to ensure that 
they maximally represented white matter.  
 
5.3.6 Linear Mixed Model Analyses 
To determine mean baseline (intercept) differences and rates of longitudinal change 
(slopes) in the SBM white matter profiles among CAP and Control groups, we employed Linear 
Mixed Models (LMMs) for longitudinal data (169). LMMs are particularly appropriate for large, 
complex datasets because they can furnish unbiased parameter estimates even when some data is 
missing, as long as the data is missing at random (MAR). 
                                                 
10For the present study, many participants underwent two or more scanning sessions. Thus, in this description, 
“participant” might be more accurately described as “session”, as a given participant may be represented more than 
once in the dataset in the form of multiple sessions or images. 
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For each WM profile/component (outcome variable), two models were fit and compared 
via a likelihood ratio test (LRT) to assess the omnibus null hypothesis of no intercept or slope 
group differences: (1) a full model, inclusive of CAP-group-specific intercepts and slopes; (2) a 
reduced model that lacked CAP-specific effects, in which each group shared the same slope and 
intercept. Any component for which the two models were not significantly different was 
excluded from further analyses and results. 
Both LMMs included a time variable representing years of study participation (with 0 
denoting study entry), as well as covariates for sex, education (years), and CAP-group. Because 
the study was longitudinal, random intercepts for each participant were included in the model to 
account for correlations due to repeated measurements. Because data from several collection 
sites and scanners were included in the study, random site intercepts were also added to account 
for correlations due to common scanner or site-specific features. For random effects and random 
error, maximum likelihood methods were used to estimate under assumptions of normality (169). 
General Linear Hypothesis testing was used to compare component intercepts and slopes among 
groups. 
 
5.3.7 Stacked Linear Mixed Model Analyses 
We then compared longitudinal trajectories of the SBM WM profiles to those of clinical 
(cognitive and motor) functioning measures using a “stacked” LMM regression analysis that 
simultaneously analyzed the brain structural and clinical data. Concurrent testing of these 
variables enabled us to address hypotheses involving direct comparisons of clinical functioning 
and brain structural integrity, both at baseline and over time across groups. For example, we 
tested the hypothesis that motor functioning in the prodromal group furthest from estimated HD-
114 
onset deteriorates at a rate (and in a direction) similar to that of WM in motor-implicated frontal 
regions (e.g., supplementary and premotor cortex), whereas motor functioning deterioration in 
the prodromal group closest to estimated onset is more comparable to striatal and subcortical 
changes.  
To allow meaningful comparisons across variables that are scaled differently, outcome 
vectors were standardized by subtracting the vector mean (across participants and times) and 
dividing by the standard deviation. A detailed description of the statistical approach is provided 
in the supplemental materials of Shaffer et al., 2017 (24). Following standardization of the 
outcome vectors, the repeated measures outcome variables and their respective covariate data 
were combined into a stacked format to enable concurrent analysis (170). For example, to test 
the hypothesis that a supplementary motor WM profile and motor performance are changing at 
similar rates, vectors containing each subject’s repeated measures from the supplementary motor 
profile were combined with vectors containing each participant’s repeated UHDRS-TMS scores; 
the covariate matrices were likewise concatenated, with the stacked analyses including the same 
covariates as the un-stacked analyses.  
Dummy variables were coded for each outcome variable and its covariates, enabling 
estimation of baseline and longitudinal covariances for outcome variables. The use of these 
dummy variables facilitates direct comparison of two outcome variables by generating a 
confidence interval representing the slope difference between two outcome variables. Random 
effects (including site and participant) were assumed to be joint-normally distributed and have a 
general covariance matrix. To permit accurate comparisons of outcome variable trajectories, 
component (WM profile) values were multiplied by -1 for comparisons with clinical variables 
for which higher scores indicate poorer performance (TMTB, TMTA, and UHDRS-TMS). 
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5.4 Results 
In the combined sample, 22/45 components (~49%) yielded Chi-square values with 
associated p-values of <0.001, representing the most robust CAP group effects observed in our 
cohort and a negligible probability of obtaining the observed Chi-square statistic under the null 
hypothesis that all regression coefficients in the model equal zero. Nine components exhibited no 
differences between the null and CAP models; these components were excluded from further 
analyses. 
 
5.4.1 Source-based Morphometry 
A summary of the 15 SBM components (WM profiles) that exhibited the most prominent 
effects in our results (based on the number and strength of significant contrasts) is presented in 
Table 5.4—1. An expanded table with all components is available in Appendix D.2. A glossary 
of regions within components, including Brodmann areas, is provided in Appendix D.3. 
Table 5.4—1. SBM Component Regions 
Comp. Regions Max. 
Stat. 
Coordinates 
(x, y, z) 
A Angular Gyrus/BA39, Middle Temporal Gyrus, Superior Temporal 
Gyrus, Middle Occipital  
-9.0 -41, -62, 27       
B Angular Gyrus/BA39, Inferior Parietal Lobule, Precuneus, Middle 
Occipital, Superior Parietal Lobule/BA7, Superior Occipital, BA19, 
Inferior Parietal, Supramarginal/BA40 
-18.2 32, -60, 39 
C Angular Gyrus/BA39, Supramarginal/BA40, Superior Temporal Gyrus, 
Inferior Parietal Lobule, Middle Temporal Gyrus 
16.5 39, -55, 31 
D Superior OccipitalL, Cuneus, BA19, Superior Parietal Lobule/BA7, 
BA18, Precuneus, BA31 
-4.6 -18, -85, 29 
E Corpus Callosum, Limbic Lobe, Lateral Ventricle, Cingulate 
Gyrus/BA23, Posterior Cingulate 
13.1 -1, -19, 24 
F Supplementary Motor Area/BA6, Medial Frontal Gyrus, Superior 
Frontal Gyrus, BA8 
-11.7 10, -7, 64        
G Cerebellum Anterior Lobe, Culmen, Vermis 4,5, Cerebellum 4,5, 
Cerebellum Posterior Lobe, Declive, Vermis 3, Cerebellar Lingual, 
Midbrain, BrainstemR, Cerebellum 3, Vermis 6 
-9.5 -1, -56, -14 
H Cuneus, Superior Occipital, Middle Occipital Gyrus, BA18, BA19, 
Temporal Lobe 
-10.3 -24, -86, 21         
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I Precuneus, Superior Parietal Lobule/BA7, Superior Parietal, Superior 
Occipital, Cuneus 
-15.8 17, -67, 46 
J 
 
Postcentral Gyrus, Inferior Parietal, Inferior Parietal Lobule, 
Supramarginal/BA40, Superior Parietal, Paracentral Lobule, Superior 
Parietal Lobule/BA7, BA5, Precuneus 
23.6 30, -39, 41 
K PrecentralL, Middle Frontal Gyrus, Inferior Frontal Gyrus, 
DLPFC/BA9, Premotor/Supplementary Motor/BA6, Frontal Inferior 
Operculum 
-25.3  -36, 7, 38 
L Postcentral Gyrus/BA2/BA3, Inferior Parietal, Inferior Parietal Lobule, 
Supramarginal/BA40 
17.7 -30, -36, 45 
M Middle Temporal/BA21, Inferior Temporal  9.5 -55, -18, -12 
N Superior Temporal Gyrus/BA22, Middle TemporalL, Angular 
Gyrus/BA39, Middle Occipital 
24.1 -42, -58, 19 
O Precuneus, Superior Parietal Lobule/BA7, Angular Gyrus, Superior 
Parietal, Inferior Parietal, Inferior Parietal Lobule, Superior Occipital 
23.9 
 
26, -56, 45 
Regions within SBM components displaying the most robust significant effects, including 
maximum z-scores (Max. Stat. column) and coordinates of the most strongly represented regions. 
Components were ordered alphabetically based on the number and strength of significant 
contrasts across all analyses (i.e., component A displayed the maximum observed number of 
significant results). Primary contributing regions corresponding to maximum z-scores appear in 
bold, and regions in each component are listed in order of largest-to-smallest voxel cluster size in 
the most prominent cluster in the component. In cases where regional representation is 
hemisphere-specific, this is denoted with a superscript L (left) or R (right). 
 
5.4.2 Baseline (Intercept) Differences in WM Profiles 
T- and p-values for components with three or more significant pairwise CAP-group 
comparisons are presented in Table 5.4—2, and an expanded version including all 36 analyzed 
components is provided in Appendix D.4.  
Table 5.4—2. Baseline (intercept) pairwise group comparisons for components with 3+ 
significant contrasts 
Component Low vs. 
Control 
Medium vs. 
Control 
High vs. 
Control 
Medium vs. 
Low 
High vs. Low High vs. 
Medium 
A 3.68/2e-04 0.56/0.57 -1.25/0.21 -3.36/8e-04 -5.24/<1e-4 -1.96/0.05 
B -0.63/0.53 1.81/0.07 2.08/0.04 2.52/0.01 2.80/0.01 0.28/0.78 
C -3.36/1e-3 -2.96/3e-3 -3.73/2e-4 0.57/0.57 -0.18/0.86 -0.80/0.42 
D 3.04/2e-3 -0.05/0.96 -1.40/0.16 -3.29/1e-3 -4.69/<1e-4 -1.46/0.14 
E 2.59/0.01 -1.15/0.25 -1.91/0.06 -3.93/1e-04 -4.73/<1e-4 -0.82/0.41 
I -3.19/1e-3 -0.04/0.97 1.72/0.09 3.36/8e-04 5.17/<1e-4 1.90/0.06 
K -0.06/0.95 -0.72/0.47 -2.74/0.01 -0.66/0.51 -2.72/0.01 -2.18/0.03 
N 3.96/1e-04 3.69/2e-04 7.56/<1e-4 -0.47/0.64 3.43/6e-04 4.16/<1e-4 
O 3.94/1e-04 2.59/0.01 5.42/<1e-4 -1.58/0.11 1.27/0.20 3.05/2e-3 
Q -2.34/0.02 1.57/0.12 9.20/<1e-4 4.09/<1e-4 11.89/<1e-4 8.23/<1e-4 
T -0.96/0.34 2.55/0.01 8.76/<1e-4 3.62/3e-04 9.95/<1e-4 6.70/<1e-04 
X -3.37/1e-3 -2.35/0.02 -1.96/0.05 1.21/0.23 1.65/0.10 0.45/0.65 
AA 1.14/0.25 3.87/1e-04 5.21/<1e-4 2.72/7e-3 4.07/<1e-4 1.42/0.16 
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AB 2.03/0.04 3.01/3e-3 4.80/<1e-4 0.90/0.37 2.71/7e-3 1.91/0.06 
AD -2.10/0.04 -0.02/0.10 1.20/0.23 2.22/0.03 3.50/1e-3 1.32/0.19 
AE -0.27/0.79 -0.52/0.60 -2.71/0.01 -0.25/0.81 -2.47/0.01 -2.36/0.02 
AG 1.27/0.20 2.14/0.03 7.26/<1e-4 0.82/0.41 6.01/<1e-4 5.52/<1e-4 
Baseline (intercept) pairwise group comparisons for components with three or more significant 
pairwise contrasts in the unstacked LMM analyses. Bold denotes significant contrasts, and the 
strongest effects (p < 1e-04) are also underlined. 
 
Components T (cerebellum posterior lobe, cerebellum crus 1, uvula, and other cerebellar 
regions), Q (inferior parietal), and N (superior and middle temporal) exhibited the most 
prominent cross-sectional group differences, with five out of six contrasts; no component was 
significant in all six significant group contrasts. The most common significant baseline 
differences were observed between the High and Low groups (16 significant components, four at 
p < 1e-04), the High and Control groups (16 significant components, seven at p < 1e-04), and the 
Low and Control groups (15 significant components, minimum p = 1e-04). Significant 
differences with the Medium group were slightly less common, observed in 11 components for 
the Medium vs. Control (minimum p = 1e-04) and Medium vs. Low contrasts (one component 
significant at p < 1e-04) and 12 components in the Medium vs. High contrast (p < 1e-04 for four 
components). 
 
5.4.3 Longitudinal (Slope) Differences in WM Profiles 
Component t- and p-values for pairwise CAP-group slope comparisons are presented in 
Table 5.4—3, and an expanded version is provided in Appendix D.6. The rate of change in 
parietal component Q was the most distinct among groups, exhibiting significant differences in 
every group contrast (Table 5.4—3). Component Q was also strongly significant, yielding p < 
1e-04 in every group contrast except Control > Low. Other components with the most robust 
differences in rate of change among groups were frontal and sub-cortical, including F (premotor, 
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supplementary motor, medial frontal), H (cuneus, middle occipital), T (cerebellum posterior 
lobe, cerebellum crus 1, uvula), AA (left middle frontal), and AF (thalamus, ventral anterior 
nucleus), which were each significant in all but one group contrast. 
Like the baseline comparisons, the most common significant slope differences were seen 
between the High and Low groups (22 significant components, four at p < 1e-04) and the High 
and Control groups (21 components, three at p < 1e-04). The next most frequently observed 
differences in rates of change were between the Low and Medium groups (17 significant 
components, four at p < 1e-04), Medium and Control groups (16 significant components, five at 
p < 1e-04), and Low and Control groups (11 significant components). 
Table 5.4—3. Longitudinal (slope) pairwise group comparisons for components with 3+ 
significant contrasts 
Component Low vs. 
Control 
Medium vs. 
Control 
High vs. 
Control 
Medium vs. 
Low 
High vs. Low High vs. 
Medium 
A -0.13/0.90 2.92/4e-3 3.73/2e-04 3.10/2e-3 3.89/1e-04 0.93/0.35 
B 0.65/0.52 0.35/0.73 2.96/3e-3 -0.36/0.72 2.29/0.02 2.87/4e-3 
C 2.96/3e-3 1.69/0.09 -0.36/0.72 -1.51/0.13 -3.52/4e-4 -2.23/0.03 
D -0.69/0.49 2.36/0.02 1.50/0.13 3.16/2e-3 2.26/0.02 -0.92/0.36 
F -1.82/0.07 2.04/ 0.04 3.99/1e-04 4.02/1e-04 5.93/<1e-4 2.17/0.03 
G 2.83/0.01 0.25/0.80 2.94/3e-3 -2.82/0.01 -0.07/0.95 2.95/3e-3 
H 0.40/0.69 -4.71/<1e-4 -1.92/0.05 -5.19/<1e-4 -2.35/0.02 2.99/3e-3 
I 2.97/3e-3 0.68/0.50 -0.67/0.50 -2.55/0.01 -3.87/1e-04 -1.48/0.14 
J 0.98/0.33 1.52/0.13 3.93/1e-4 0.46/0.64 2.89/4e-3 2.66/0.01 
K -2.69/0.01 -2.39/0.02 -2.36/0.02 0.50/0.62 0.49/0.63 -0.003/1.0 
L -1.17/0.24 -0.04/0.97 2.10/0.04 1.23/0.22 3.36/1e-3 2.35/0.02 
M -0.68/0.50 2.20/0.03 1.44/0.15 2.95/3e-3 2.17/0.03 -0.80/0.42 
O -0.36/0.72 1.97/0.05 -0.17/0.86 2.38/0.02 0.21/0.83 -2.32/0.02 
P -2.51/0.01 1.81/0.07 0.62/0.54 4.55/<1e-4 3.30/1e-3 -1.28/0.20 
Q 3.16/2e-3 8.86/<1e-4 13.43/<1e-4 5.50/<1e-4 10.11/<1e-4 5.14/<1e-4 
S -3.12/2e-3 -2.47/0.01 -2.78/0.01 0.89/0.37 0.53/0.60 -0.38/0.71 
T 2.77/0.01 3.83/1e-04 6.70/<1e-4 0.87/0.38 3.81/1e-04 3.21/1e-3 
W 0.18/0.86 -0.13/0.90 2.78/5e-3 -0.32/0.75 2.61/9e-3 3.19/1e-3 
X 0.58/0.57 0.76/0.45 -2.4/0.02 0.14/0.89 -3.03/2e-3 -3.46/1e-3 
Y 1.57/0.12 3.80/1e-4 2.61/0.01 2.17/0.03 0.96/0.34 -1.27/0.21 
AA -2.45/0.01 -5.53/<1e-4 -2.69/7e-3 -2.96/3e-3 -0.10/0.92 3.04/2e-3 
AC 3.91/1e-04 5.05/<1e-4 3.48/5e-04 0.85/0.40 -0.67/0.50 -1.65/0.10 
AF 1.35/0.18 3.86/1e-04 7.49/<1e-4 2.44/0.01 6.12/<1e-4 4.05/1e-04 
AG 0.97/0.33 5.38/<1e-4 3.97/1e-04 4.42/<1e-4 2.98/3e-3 -1.48/ 0.14 
AI -1.14/0.25 -1.07/0.29 3.04/2e-3 0.16/0.87 4.30/<1e-4 4.50/<1e-4 
AJ -2.08/0.04 -1.75/0.08 1.15/0.25 0.49/0.63 3.42/1e-3 3.17/2e-3 
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Longitudinal (slope) pairwise group comparisons for components with three or more significant 
contrasts (t-value/p-value) in the unstacked LMM analyses. Bold denotes significant contrasts, 
and the strongest effects (p < 1e-04) are also underlined. 
 
5.4.4 Baseline (Intercept) Differences between WM Profiles and Clinical Variables 
The unstacked analyses compared WM profiles at baseline and over time among groups; 
thus, we were most interested in significant group differences. The stacked analyses, by contrast, 
compared baseline values (intercept) and trajectories of change (slope) between clinical 
functioning variables and the WM profiles; consequently, here we were most interested in non-
significant differences, as they indicate the most similarity between clinical variables and WM 
profiles. Ergo, in Table 5.4—4 we list the most robust non-significant baseline differences 
between clinical measures and WM profiles. We then present the full results for each clinical test 
below. Baseline and longitudinal differences are visualized in Figures 5.4—1 and 5.4—2, and p-
values for every contrast and group are provided in Appendices D.7-D.13.  
Table 5.4—4. WM components most similar to clinical variables at baseline. 
Clinical 
variable 
Max. # of NS 
contrasts  
Control Low Medium High Top regions 
UHDRS-
TMS 
4 H, I H, I H, I H, I precuneus, cuneus, middle occipital 
SDMT 1 - A - - angular gyrus, middle temporal 
SC 1 C A - - angular gyrus, middle temporal, supramarginal 
gyrus 
SI 2 C A, C, 
D, E, 
H 
- - cuneus, middle occipital, angular gyrus, middle 
temporal, supramarginal gyrus, superior 
occipital, corpus callosum 
SW 1 - A - - angular gyrus, middle temporal 
TMTA 3 A, C, 
F, H, I 
A, B, 
C, D, 
E, F, 
G, H 
A, C, H - precuneus, cuneus, middle occipital, angular 
gyrus, middle temporal, supramarginal gyrus, 
superior occipital, corpus callosum, 
supplementary motor, premotor, medial frontal, 
cerebellum anterior lobe, culmen, vermis 4,5 
TMTB 1 C A - - angular gyrus, middle temporal, supramarginal 
gyrus 
The maximum number of non-significant (NS) contrasts (out of four) observed in at least one 
component is provided for each test along with corresponding component identities and the 
participant groups in which these associations were observed (e.g., components H and I were NS 
different from UHDRS-TMS at baseline in all four groups). Regions most contributing to these 
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effects are listed in the far-right column and color-coded according to location (frontal = green, 
temporal = blue, parietal = purple, occipital = red, sub-gyral/other = black).   
 
Unified Huntington’s Disease Rating Scale - Total Motor Score (UHDRS-TMS): baseline 
UHDRS-TMS aligned least (indicated by the most significant differences) with baseline WM in 
the High and Medium groups. For the Low and Control groups, by contrast, less than half the 
components were significantly different from UHDRS-TMS, indicating more similarity between 
WM and motor functioning in persons with relatively unaffected motor functioning. 18 
components were significantly different from UHDRS-TMS at baseline in the Control group 
(three at p < 1e-04), 14 in the Low group (two at p < 1e-04), 21 in the Medium group (six at p < 
1e-04), and 30 in the High group (21 at p < 1e-04).  
Symbol Digit Modalities Test (SDMT): although only one component yielded a single 
non-significant intercept contrast (angular gyrus/middle temporal component A for the Low 
group), baseline SDMT differed the most from WM in the High group and was most similar to 
WM in the Low group. In the Control, Medium, and High groups, all 36 analyzed components 
significantly differed from SDMT (with 32, 34, and 36 components significant at p < 1e-04, 
respectively). In the Low group, 35 components significantly differed from SDMT (26 at p < 1e-
04).  
Stroop Color (SC): baseline SC aligned least with WM in the High group followed by the 
Medium group, and matched best with WM in the Low and Control groups, particularly in 
angular gyrus components A and C. 35 components significantly differed from SC in the Control 
and Low groups (26 at p < 1e-04 in both groups). All components were significantly different 
from baseline SC in the Medium and High groups (36 and 31 components at p < 1e-04, 
respectively).  
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Stroop Interference (SI): baseline SI also aligned least with WM in the High group 
followed by the Medium group, and matched best with WM in the Low group and to a lesser 
extent the Control group. 35 components differed from baseline SI in the Control group (26 at p 
< 1e-04), 31 in the Low group (19 at p < 1e-04), and all 36 in the Medium and High groups (28 
and 36 at p < 1e-04, respectively).  
Stroop Word (SW): baseline SW scores were least similar to WM in the High group 
followed by the Medium group, and most similar to WM in the Low group. In the Control, 
Medium, and High groups, all components differed from SW (with 32, 34, and 36 components 
significant at p < 1e-04, respectively). In the Low group, all but one component exhibited 
significant differences from SW (30 were significant at p < 1e-04).  
Trail-making Test A (TMTA): baseline TMTA scores differed the most from WM in the 
High group and were most similar to WM in the Low group. 31 components were significantly 
different from baseline TMTA in the Control group (18 at p < 1e-04), 28 in the Low group (11 at 
p < 1e-04), and 33 in the Medium group (21 at p < 1e-04). All components were significantly 
different from TMTA in the High group (34 at p < 1e-04).  
Trail-making Test B (TMTB): baseline TMTB aligned least with WM in the High group 
followed by the Medium group, and was most similar to WM in the Low group. At baseline, 44 
components significantly differed from TMTB in the Control and Low groups (28 and 26 at p < 
1e-04, respectively), and all components differed from TMTB in the Medium and High groups 
(36 and 33 at p < 1e-04, respectively). 
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5.4.5 Longitudinal (Slope) Differences between WM Profiles and Clinical Variables 
Generally, similarity between WM profiles and clinical functioning was much more 
apparent longitudinally than cross-sectionally (i.e., similarities between rates of change in WM 
profiles and clinical functioning variables were more readily detectable than similarities at 
baseline); the sole exception to this pattern of findings was the UHDRS-TMS. In Table 5.4—5 
we list regions within components that were most similar to clinical variables and in Table 5.4—
6 we display significant contrasts (indicating dissimilarity) as well as groups aligning most and 
least with each clinical variable in the study. These results are visualized in Figures 5.4—1 and 
5.4—2, and p-values for every contrast and group are provided in Appendices D.7-D.13. 
Table 5.4—5. WM profiles and clinical variables with similar change trajectories. 
Clinical 
variable 
Max. # 
NS 
contrasts  
Control Low Medium High Top regions 
UHDRS-
TMS 
2 G D, G, 
N, AH 
D, N, 
AH 
- cerebellum anterior lobe, culmen, vermis 4,5, 
superior occipital, cuneus, superior temporal, 
middle temporal 
SDMT 2 J A, D, E, 
F, I, J, 
P 
A, D, E, 
F, I, L, P 
L superior occipital, cuneus, postcentral, angular 
gyrus, middle temporal, corpus callosum, 
supplementary motor, premotor, medial 
frontal, precentral, precuneus 
SC 2 G A, D, E, 
F, M, P, 
R 
A, D, E, 
F, L, M, 
P, R, W 
L, W cerebellum anterior lobe, culmen, vermis 4,5, 
superior occipital, cuneus, angular gyrus, 
middle temporal, corpus callosum, 
supplementary motor, premotor, medial 
frontal, precentral, postcentral, BA18, middle 
occipital 
SI 2 J J B, V, AE B, V, 
AE 
postcentral, angular gyrus, inferior parietal, 
superior parietal lobule, calcarine, cuneus, 
BA18 
SW 3 A A, D, E, 
K, L, R 
A, D, E, 
K, L, R 
- superior occipital, cuneus, angular gyrus, 
middle temporal, corpus callosum, 
postcentral, BA18, middle occipital, 
precentral, middle frontal, DLPFC 
TMTA 2 J A, B, E, 
F, J, K, 
M, P, U 
A, B, E, 
F, K, M, 
P, U 
- postcentral, angular gyrus, middle temporal, 
corpus callosum, supplementary motor, 
premotor, medial frontal, precentral, middle 
frontal, DLPFC, putamen 
TMTB 3 B, G B, C, G, 
H, U, V 
B, C, H, 
U, V 
- cerebellum anterior lobe, culmen, vermis 4,5, 
angular gyrus, inferior parietal, superior 
parietal lobule, putamen, cuneus, middle 
occipital 
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The maximum number of non-significant contrasts (out of four) observed in at least one component 
is listed for each test, and components with two or more NS contrasts for a given clinical measure 
are listed for each group. Regions most contributing to these effects are displayed in the far-right 
column and color-coded according to location (frontal = green, temporal = blue, parietal = 
purple, occipital = red, sub-gyral/other = black).   
 
 
Table 5.4—6. Significant component - clinical variable trajectory differences 
Significant 
associations 
Control Low Medium High Most 
alignment 
Least 
alignment  
UHDRS-
TMS 
34 / 22 18 / 9 22 / 14 36 / 34 Low  High 
SDMT 35 / 33 26 / 17 25 / 14 29 / 15 Medium Control 
SC 35 / 30 26 / 16 23 / 15 30 / 17 Medium Control 
SI 35 / 31 35 / 14 28 / 15 19 / 10 High Control 
SW 32 / 21 24 / 13 26 / 13 32 / 22 Low High 
TMTA 35 / 25 24 / 15 25 / 12 27 / 13 Low Control 
TMTB 35 / 33 21 / 12 30 / 16 30 / 17 Low Control 
Significant differences between component and clinical variable trajectories, presented as: (# of 
significant differences) / (# significant at p < e-4). Bold denotes the most similarity with a given 
group, as significant differences indicate less similarity. The two rightmost columns list groups 
showing the most and least alignment with each clinical variable in the study. 
 
 
 
 Control (Green) Low (Blue) Medium (Purple) High (Red) 
UHDRS-TMS 28P  
 
17F  
 
22T  
 
4PUT  
 
SDMT 28P  
 
6F, 7CC  
 
31P, 45P,T  
 
34P,O  
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SC 28P  
 
5F, 18O, 27CER  
 
7CC  
 
33P, 41P  
 
SI 28P  
 
28P, 39P  
 
37P, 38O, 39P  
 
26T, 45P,T  
 
SW 27CER  
 
21O  
 
18O  
 
4PUT  
 
TMTA 28P 
 
6 F, 7CC  
 
29, 11P  
 
33P, 34P,O, 41P 
 
TMTB 28P 
 
9P  
 
37P  
 
4PUT  
 
Figure 5.4-1. Component and clinical variable slopes. 
 Components with trajectories of change that were most similar to change in clinical functioning 
variables. Dashed lines are clinical variables, and solid lines are components. Baseline (intercept) 
values are at the Y-intercept. X axis = duration (years) and Y axis = value (score or component 
weight). Components in bold exhibited robust effects for more than one clinical variable or group. 
Multiple components are listed in cases where more than one component comparably resembled 
a clinical variable, with the strongest effect and its corresponding component underlined. CCcorpus 
callosum; CERcerebellum; Ffrontal; Ooccipital; Pparietal; PUTputamen; Ttemporal. 
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 Control Low Medium High 
TMS     
SDMT 
 
 
 
 
SC 
    
SI 
 
 
  
SW 
   
 
TMTA 
 
 
 
 
TMTB 
    
Figure 5.4-2. WM changes most coinciding with clinical functioning changes. 
Rows are clinical variables and columns are components thresholded to show effects (z-scores) of 
p = 0.05 or less. These components correspond to the plots in Figure 5.4—1 (solid lines). 
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5.5 Discussion 
5.5.1 Cross-sectional (Intercept) Differences in WM Profiles 
Like previous studies, our analyses detected widespread WM differences inclusive of 
regions in every lobe of the brain. Components most sensitive to differences between Controls 
and all three CAP groups (i.e., those significant in all three Control group contrasts: X, N, O, 
AB, and C) were most commonly parietal. Areas of overlap among these components included 
angular gyrus (in three of the five components), superior temporal gyrus, superior and middle 
occipital, and inferior parietal lobule. Notably, component X included premotor, primary motor, 
and supplementary motor cortices, which exhibited the most robust effects in the largest 
longitudinal study of prodromal WM tract changes to date (24). Differences between CAP 
groups were best represented by components T (cerebellar), Q (parietal), and A 
(temporal/parietal), which yielded significant differences in every CAP group comparison (Low 
vs. Medium, Low vs. High, and Medium vs. High); component Q (inferior parietal, 
supramarginal gyrus) differed the most across CAP-group comparisons. These substantive cross-
sectional results suggest a pattern in which the most reliable group differences begin in superior 
temporal and parietal (Control > Low) and later extend into inferior parietal in the middle and 
late prodrome.  
Three components (T, Q, and N) exhibited the most robust intercept effects across 
prodromal and control group comparisons, with significant differences in five out of six contrasts 
(no component was significant in every intercept contrast). These components had few 
overlapping regions; component T most strongly represented cerebellar posterior lobe (along 
with cerebellum crus 1 and uvula), component Q sub-gyral inferior parietal WM, and component 
N superior and middle temporal WM (with weaker parietal and occipital contributions). These 
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three components are superimposed in Figure 5.5—1. Although the non-significant contrast was 
different among the three components (Control vs. Low for component T, Control vs. Medium 
for component Q, Low vs. Medium for component N), it reassuringly never included the High 
group (i.e., the High group was always different from the other groups for these components). 
Across components, significant differences were also most common in comparisons with the 
High group, conforming with the expectation that the most robust cross-sectional differences 
would be observed in the group closest to HD-onset.  
 
Figure 5.5-1. Components with the strongest cross-sectional group differences 
Superimposition of the three components with the strongest cross-sectional (intercept) effects 
across groups (components T, Q, and N, thresholded at p = 0.05). These components were 
significant in all but one of the possible CAP-group comparisons, highlighting differences across 
prodromal groups. Primary regions represented in each component are listed along with 
corresponding MNI coordinates (x, y, z).  
 
5.5.2 Longitudinal (Slope) Differences in WM Profiles 
The longitudinal analysis also highlighted parietal component Q, which was significant in 
every slope contrast, indicating differences in the rate of change in these regions at each 
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prodromal time point. As expected, the most rapid prodromal change occurred in the High group 
and the slowest change in the Low group, with change in the Control group lagging behind that 
of any prodromal group. Areas within component Q, including the inferior parietal lobe and 
lobule, supramarginal gyrus/BA40, frontal lobe, and postcentral gyrus, may most readily 
undergo WM changes throughout the prodrome. Other components with prominent group 
differences in trajectory of change (components AF, T, F, AA and H, which were significant in 
five out of six contrasts) either: (1) showed robust group differences both cross-sectionally and 
longitudinally or (2) had a strong slope/longitudinal effect but only one or no significant baseline 
effect.  
(1) In addition to inferior parietal component Q, components T (cerebellum posterior 
lobe, cerebellum crus 1, uvula, and other cerebellar areas) and AA (left middle frontal gyrus 
and other frontal regions) showed robust effects in both cross-sectional and longitudinal 
analyses, suggesting that group differences, as well as changes, are detectable in these 
regions.  
(2) Thalamic component AF (significant only in the High vs. Control intercept contrast) 
and premotor/supplementary motor/frontal component F (significant only in the Low vs. Control 
intercept contrast) displayed robust longitudinal effects despite few cross-sectional differences 
(Figure 5.5—2), suggesting that WM changes in these regions occur throughout the prodrome 
but may be challenging to detect cross-sectionally.  
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Figure 5.5-2. Components exhibiting significant change but not baseline differences 
Examples of white matter profiles that changed at significantly different rates among groups but 
did not exhibit significant group differences at baseline  
 
Although several components with longitudinal group differences had no intercept 
differences, the reverse was rarely true; only occipital component AB (cuneus, left calcarine, 
BA17/V1) lacked slope but not intercept effects (component AB was significant in four intercept 
contrasts). Fascinatingly, other components with maximum signals from these regions (e.g., 
components Z and AE) also had fewer slope than intercept effects, which was not a common 
occurrence across components. In each of these cases, significant differences were observed at 
baseline but little change was seen over time across groups. 
Regarding comparisons with the Control group, frontal components that were most 
significant longitudinally were least likely to show prominent cross-sectional effects (e.g., 
components AC and K), and conversely other components like striatal component S and parietal 
component Q did show significant intercept effects. The comparison with the Control group 
suggests that prodromal differences from controls in striatal and parietal WM may be 
easier to detect cross-sectionally than some frontal changes, even though changes in all 
these areas occur throughout the prodrome. This is in keeping with the prominence of these 
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regions in previous studies, and is consistent with our findings in gray matter, where SBM 
probed frontal differences that were not detected by a similar univariate analysis (23). 
The suggested patterns of most robust change among the intercept and slope results is 
similar for the Medium and High groups but distinct for the early prodrome. In other words, 
cross-sectional and longitudinal findings highlighted many of the same regions in the Medium 
and High groups, whereas areas most implicated in the Low group differed in the intercept 
compared to slope results.  All results highlighted inferior parietal component Q as strongly 
representative of changes in the middle and late prodrome. However, the most prominent early 
(Control and Low) cross-sectional differences manifested in temporal and superior parietal 
regions, whereas the longitudinal results singled out the most substantial early changes in 
premotor, supplementary motor and middle frontal component AC (in addition to 
commonly reported striatal and sub-gyral areas in component S) and highlighted many 
other frontal components in this early contrast. Cross-sectional effects were also weaker 
overall, but it is comforting for the sake of study feasibility everywhere that similar 
interpretations become apparent across cross-sectional and longitudinal analyses, especially at 
later prodromal phases when intercept and slope results shared more regional overlap. 
 
5.5.3 Summary – Prodromal WM Differences and Changes 
Taken together, these results suggest strong early prodromal changes in premotor, 
supplementary motor and middle frontal gyral GM-adjacent-WM, in agreement with previous 
reports of robust changes in these regions. These findings illustrate a widespread prodromal 
pattern of WM change that becomes increasingly sub-gyral with prodromal progression (with 
steeper WM changes in cingulum, thalamus, and other sub-gyral and striatal regions). Cerebellar 
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component T, inferior parietal component Q, and frontal component AA (inclusive of premotor 
and supplementary motor cortices and frontal eye fields) were highly and commonly significant 
in both intercept and slope contrasts, hinting that these regions may show the most robust group 
differences and changes over time. The parietal and frontal regions within these components are 
in complete agreement with striatal connectivity findings (24, 171). Parietal projections to striatal 
convergence zones begin in the inferior parietal lobule (the primary contributor to component Q) 
and angular gyrus (another prominent region highlighted in our results), and two prefrontal 
connectivity clusters that displayed prodromal group differences in an independent study 
included middle frontal gyrus and superior frontal gyrus, respectively. If longitudinal data 
collection is not possible, measures from these regions (in addition to the striatum) may offer the 
most insight into disease progression. In all tests, WM in the High group displayed the most 
robust differences and changes, consistent with predictions. 
 
5.5.4 Baseline (Intercept) Comparisons of WM Profiles and Clinical Variables 
To recapitulate, the stacked analysis compared change in clinical (motor and cognitive) 
functioning measures with change in WM profiles/components; thus, the components that lacked 
significant slope differences from clinical variables likely change along the most similar 
trajectories with those of clinical variables. Ergo, we somewhat counterintuitively discuss mostly 
the non-significant stacked results. 
The intercept (cross-sectional) portion of the stacked analyses suggest that only the motor 
performance measure (UHDRS-TMS) aligned well with WM structure, and this alignment was 
weakest in the High group. Cross-sectionally, TMS performance may be the best indicator of 
prodromal WM integrity, even and perhaps especially at earlier prodromal phases. In the 
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Control group and early and middle prodromal stages, UHDRS-TMS alignment with WM 
components was widespread, observed in over half the components in the Control and Low 
groups and nearly half the components in the Medium group. In the High phase, similarities were 
more isolated and observed in components outside the frontal lobe, especially in parietal regions 
(but also temporal, occipital, and cerebellar areas, in that order of prominence). The dearth of 
prominent results in the High group may be explained by the rapid deterioration of motor 
symptoms in groups closest to onset, which may overshadow structural changes detectable by 
MRI scanners. Of the cognitive measures, TMTA was most similar to WM cross-sectionally. 
Like many of the other clinical variables, TMTA aligned most with Low group WM profiles and 
least with those of the High group, in which no non-significant relationships were observed. 
Baseline WM profiles that were most consistently similar to cross-sectional cognitive 
scores differed from those that aligned with motor scores (UHDRS-TMS) and were mostly 
temporal and parietal (with some occipital influence). These included components A (peak signal 
from angular gyrus, middle temporal gyrus), C (angular gyrus, supramarginal gyrus) and H 
(cuneus, middle occipital). Other components with prominent similarities to cognitive measures 
(components B, D-I, and X) overlapped in superior occipital (in four of these components), 
superior parietal lobule/BA7, BA19, precuneus (each in three components), middle and superior 
frontal gyrus, V2/BA18, inferior parietal, and middle occipital (each in two components). By 
contrast, component I (peak signal from precuneus) was most similar to UHDRS-TMS, 
indicating that in cross-sectional snapshots, distinct brain regions appear to most underlie 
cognitive compared to motor functioning, even at early prodromal stages. However, parietal 
regions, such as the precuneus, are strongly implicated in both motor and cognitive functioning 
at baseline. 
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5.5.5 Longitudinal (Slope) Comparisons of WM Profiles and Clinical Variables 
Change in UHDRS-TMS aligned well with WM changes in the Low and Medium 
prodromal stages (and in fact did so better than any of the cognitive measures). However, 
consistent with the baseline findings, UHDRS-TMS changed at a different rate than WM in the 
High group, in which it underperformed in its similarity to WM compared to all the cognitive 
measures. In fact, UHDRS-TMS was the only clinical variable with no non-significant High 
slope differences from WM components. This different presentation in the High group 
reinforces the cross-sectional finding of similarities between UHDRS-TMS and WM that 
exceed those observed with any of the cognitive variables until the late prodrome.  
More surprisingly, TMTA also exhibited strong similarity to WM both cross-sectionally 
and longitudinally. Like UHDRS-TMS, TMTA changes were most similar to earlier prodromal 
WM changes. However, unlike UHDRS-TMS, TMTA slope also aligned well with High 
component slopes, indicating that TMTA may be the most reliable cognitive measure for 
representing ongoing prodromal WM changes. Notably, of the cognitive variables, Stroop 
Interference shared the most similarities with High group WM changes; however, WM changes 
were more consistent with TMTA change overall (i.e., robust similarities were observed at 
various prodromal stages). 
The overall patterns of alignment among component and clinical variable 
trajectories suggest that distinct regional changes accompany changes in different clinical 
functioning domains (Figure 5.5—3) and that these underlying changes differ across the 
prodrome (especially in the late prodrome). Throughout prodromal progression, different 
regions are associated with motor compared to cognitive performance, and the results overall 
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suggest that parietal areas may change the most steadily with both cognitive and motor 
functioning across the prodrome.  
  
Figure 5.5-3. WM Changes and Clinical Functioning across the Prodrome 
Simplified schematic depicting areas in which rates of change are most similar to changing motor 
(UHDRS-TMS) and cognitive functioning in each CAP group (yellow = Low, orange = Medium, 
red = High). 
 
Some components reflected changing function in multiple clinical variables at certain 
prodromal stages (Figures 5.4.5—1 and 5.4.5—2), the most poignant example of which was seen 
in the Control group; postcentral gyral component J’s trajectory of change did not differ from 
that of any clinical measure in Controls, and was either the only effect (SDMT, SC, SI, TMTA) 
or the most robust effect (UHDRS-TMS, TMTB) observed in Controls. This postcentral 
component displayed a relatively flat slope across control and prodromal groups, whereas the 
clinical functioning slopes revealed minimal change in controls (as expected) but substantial 
prodromal change; these discrepancies between Control and prodromal clinical change are the 
basis of the selective similarity between component J and clinical change trajectories in the 
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Control group. The Low group overall exhibited clinical changes that aligned well with parietal 
changes (components A, B, and D), but similarity was also observed in occipital (components A, 
B, and D) and temporal (components A and U) regions, as well as in the striatum (component U), 
corpus callosum (component E), cingulum (component E), and limbic lobe (components E and 
U). By the Medium prodromal stage, many of the same parietal, occipital, and temporal areas 
were changing at a rate similar to clinical measure changes, with more frontal areas (component 
K) changing similarly as well. By the High stage, fewer occipital components changed with 
clinical functioning, whereas many parietal, some frontal and more striatal components aligned 
with clinical changes. In the High group, the strongest WM-cognition links were observed in the 
absence of significant effects in any other group, indicating that regions most strongly 
underlying cognitive changes may differ in the late compared to early and middle prodrome. 
 
5.5.6 Summary  
There were overlaps and differences among WM regions that most readily changed with 
prodromal progression (unstacked analyses) and those most implicated in cognitive and motor 
functioning across the prodrome (stacked analyses). Two components (A and B) stood out in 
both sets of analyses (Figure 5.5—4). One of these (A) is a mixture of parietal, temporal 
(especially middle) and to a lesser extent, occipital areas; the other (B) is mostly parietal 
(superior and inferior) and occipital (superior and middle). Notably, both of these components 
have strong representation from angular gyrus, the site of most parietal projections to striatal 
convergence zones (171). These components displayed prominent differences and changes 
across the prodrome as well as similarity with clinical changes. 
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Figure 5.5-4. Components with Robust Effects Across Analyses 
Two WM profiles containing angular gyrus exhibited robust baseline and longitudinal group 
differences in addition to reliably aligning well with clinical functioning measures.  
 
WM components that aligned most with clinical functioning typically also exhibited many 
significant group differences cross-sectionally and over time, indicating that areas essential for 
prodromal clinical functioning also differ across prodromal stages as well as between prodromal 
and control individuals.  
 
5.6 Conclusions 
Overall, these results support the hypothesis that largely distinct regions most underlie 
cognitive compared to motor impairments in the HD prodrome, and further suggest that regions 
underlying these processes differ at different prodromal stages. 
These findings portray a widespread prodromal pattern of WM changes marked by 
intense, early motor cortical and middle frontal gyral (in additional to striatal) changes that 
increasingly extend sub-gyrally with increased prodromal progression. 
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The results are also in keeping with previous reports highlighting UHDRS-TMS as the 
best indicator of prodromal WM changes. However, at the High prodromal stage, cognitive 
variables (particularly Stroop Interference) outperformed UHDRS-TMS, and TMTA exhibited 
the most similarity to WM profiles overall across groups (especially cross-sectionally). 
Many observations were in keeping with predictions; WM in the High and Low groups 
respectively differed most and least drastically from the Control group, and the most robust 
longitudinal changes in clinical functioning were also observed in the High group. The prediction 
that motor performance would most resemble striatal and motor-implicated frontal change was 
partially supported, but indicated a stronger frontal involvement in the early prodrome; 
supplementary motor and striatal component changes most agreed with changing UHDRS-TMS 
performance in the Low and High groups, respectively. 
Other findings contradicted predictions. Frontal WM changes did not align most with 
cognitive changes across the prodrome. Instead, many components that best reflected changing 
clinical functioning highlighted regions with prominent striatal connections as well as essential 
roles in cognition, such as the angular gyrus and middle frontal gyrus. 
 
5.7 Limitations 
Because HD is a rare condition, there is an unavoidable tradeoff between maximizing 
power (afforded by a large sample) and data homogeneity (enabled by uniform data collection). 
Like most studies involving many participants with an uncommon condition, PREDICT-HD 
collected data from multiple sites using unique MRI scanners. Several steps were taken to 
minimize the complications of analyzing multi-site data. Before data collection, PREDICT-HD 
established uniform protocols across sites. Following data collection, sites were examined for 
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outliers and unbalanced participant demographics. For analyses, random site intercepts were 
included to account for correlations due to inherent scanner or site-specific features. Notably, the 
SBM method itself has also been shown to eradicate site effects (100), and the reliability of DWI 
data collected across these sites has also been previously demonstrated (172). 
 
5.8 Future Directions 
Reports regarding the chronology of brain structural changes in prodromal HD are 
conflicting, and it is still unclear whether WM and gray matter (GM) changes occur mostly 
simultaneously or if robust changes in WM precede those in GM (or vice versa); thus, a 
promising future direction for this work is to directly compare WM changes with those in GM, 
which could be achieved by applying SBM to the GM segmentations extracted in the first phase 
of this study and performing similar stacked LMM analyses to compare WM and GM trajectories 
from the same participants and scans. It is also possible that prodromal GM change more aptly 
reflects cognitive or motor changes, which could similarly be addressed in an analogous LMM 
study assessing GM in conjunction with clinical variables.  
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6 DISCUSSION 
6.1 Brain Structure Throughout the HD Prodrome 
These experiments elucidated many notable features of prodromal brain structure. In both 
GM and WM analyses, the most substantial atrophy was observed in the High prodromal group 
(closest to onset) and the most modest differences presented in the Low group, consistent with 
the expected low-to-high prodromal disease gradient. Additionally, widespread GM and WM 
loss was observed across the brain, rather than being restricted to the striatum. The pattern of 
atrophy generally followed a superior-inferior gradient of effectuation across the prodrome, a 
phenomenon that has not been explicitly reported outside of the striatum, where a dorso-ventral 
pattern has been described (173-175). 
Across analyses, regions co-occurring within components (or brain structural patterns) 
were frequently structural or functional neighbors. In both GM and WM, a prominent structural 
pattern that contained co-occurring signal from supplementary motor and premotor cortices 
exhibited highly significant differences and changes throughout the prodrome (Figure 6.1-1). 
These regions also exhibited the most robust effects in the largest longitudinal study of 
prodromal WM tract changes to date (24). 
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Figure 6.1-1. Supplementary motor components 
Components maximally representing supplementary motor cortex across SBM (GM and 
WM) and pICA studies, each of which exhibited robust effects. Images thresholded at p < 0.05, 
with cross-hairs placed at the global maxima. Coordinates and Z-scores corresponding to the 
global maximum are shown in boxes to the right of each component. 
 
The supplementary motor GM SBM component (Figure 6.1-1: A, top) was among five 
components with the most significant overall group differences (p < 0.0001) in the GM study, 
and was significantly different between the High group and every other group (Control, Low, 
and Medium). The supplementary motor GM-adjacent-WM SBM component (Figure 6.1-1: B, 
middle) was also among the components with the strongest overall group effects; its trajectory of 
change differed in every group contrast except Control vs. Low, and it was significantly different 
in the cross-sectional comparison of the Control and Low groups. The trajectory of change in this 
profile resembled that of SDMT, TMTA, and Stroop Color in the Low and Medium groups, 
TMTB and UHDRS-TMS in the Low group, and Stroop Interference in the High group. At 
baseline, it was similar to UHDRS-TMS in the Control, Low, and Medium groups and TMTA in 
the Control and Low groups. The supplementary motor pICA component (Figure 6.1-1: C, 
bottom) was the only GM component that significantly correlated with a genetic profile after 
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controlling for multiple comparisons. This profile significantly differed in prodromal individuals 
with a high or low level of the NTRK2-driven genetic profile, and the GM profile was also 
associated with performance on TMTA, Stroop Color, Stroop Interference, and UHDRS-TMS. 
These prominent effects across modalities and analyses provide compelling and converging 
evidence that these regions (including supplementary motor cortex, premotor cortex, and 
superior and middle frontal gyri) change across the prodrome and likely play a key role in both 
early and late prodromal symptoms. This supplementary motor profile was also unique in its 
relevance to both cognitive and motor functioning (which otherwise was evident only in parietal 
regions) and its sensitivity to both early and late prodromal differences.   
This prominence of inferior frontal regions is in agreement with known roles of these 
regions in planning and coordinating complex movement (supplementary motor) and selecting 
and timing motor sequences (premotor cortex), and aligns with previous studies suggesting 
involvement of these regions in HD pathology. For example, cortical thinning in inferior frontal 
regions (but not the striatum) differed between HD patients with more prominent bradykinesia, 
rigidity, and dystonia and those with more prominent chorea, indicating that cortical thinning 
may underlie clinical heterogeneity in HD that has previously been attributed to the striatum 
(46). 
Although secondary analyses performed on GM and WM components were different, the 
grouping of covarying regions into GM and WM components is more directly comparable 
because the same technique (SBM) was used to obtain the components, and in many cases was 
applied to GM and WM parcellations from the same participants and images. The co-occurrence 
of regions within GM and WM components may provide clues about the progressive 
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deterioration of these cell types. Although components are not synonymous with networks, co-
occurrence of regional differences suggests network-level changes.  
Notably, in WM compared to GM, different regions of the striatum were highlighted; 
WM changes were most prominent in the putamen, whereas striatal GM effects were most 
evident in the caudate; this is consistent with reportedly greater WM connectivity disruption 
with the putamen than the caudate (24). In both GM and WM, striatal effects were largely 
concentrated in one or two components, rather than widely distributed in a variety of networks. 
In GM, striatal signal manifested in a component containing mostly caudate, thalamus 
(especially dorsomedial and anteroventral subdivisions), rectus, and putamen, in that order of 
contribution. In WM, striatal signal came mostly from two components; one of these was similar 
to the striatal GM component except that the putamen contributed more than the caudate, and the 
other co-localized with temporal regions (including the amygdala and parahippocampal gyrus) 
and lacked contributions from the caudate. 
 In contrast to thalamic GM, which co-occurred with striatal GM (especially in the 
caudate), thalamic WM was fairly isolated, appearing in a single component that exhibited early 
prodromal differences. Like the striatal GM component, maximum thalamic signal came from 
the mediodorsal and ventroanterior nuclei as well as the ventrolateral nucleus, thalamic groups 
that innervate the basal ganglia and are involved in movement. The mediodorsal partition is 
strongly connected to frontal gyri, the temporal pole, the cingulate gyrus, and the basal ganglia, 
with its anterior region projecting pre-frontally and its posterior region innervating 
supplementary and premotor cortices; mediodorsal thalamus is most implicated in working 
memory (176). Ventroanterior thalamus also has strong connections to frontal cortex and the 
temporal pole, as well as the basal ganglia and amygdala, and has ascribed involvement in basal-
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ganglia-related movements. Ventrolateral thalamus preferentially connects to primary motor 
cortex, frontal gyri, the frontal pole, the striatum and brainstem, and comprises a major relay 
circuit with the cerebellum and motor cortex (176). 
Other regional groupings were more similar across GM and WM. Frontal and temporal 
regions were most commonly isolated in components (i.e., paired with other frontal and temporal 
regions, respectively), whereas parietal and occipital areas were frequently grouped together 
within components; this suggests that frontal and temporal WM and GM changes occur 
relatively independently of changes in other lobes of the brain, whereas occipital and parietal 
changes are more interdependent. Across the brain, inferior and superior regions of the same 
lobe were rarely paired (with the exception of the superior and inferior parietal lobules), however 
middle lobar regions were usually grouped with inferior or superior regions of the same lobe, 
rather than appearing alone. 
 
Early striatal differences: interestingly, striatal WM differences were evident cross-
sectionally even at the earliest prodromal stage, whereas the caudate-dominated GM differences 
were not detected until the middle prodrome (i.e., Medium CAP stage). Specifically, the striatal 
WM component containing putamen, parts of the frontal lobe, cingulate cortex, and the caudate 
differed as early as the Control and Low contrast, but the striatal WM component containing 
putamen (but not caudate) and temporal (especially limbic) areas did not exhibit significant 
differences until the High prodromal phase. The observation that striatal WM but not GM 
exhibited cross-sectional group differences raises the possibility that striatal WM is affected 
earlier, and furthermore that early changes in the putamen may be more robust than those in 
the caudate and occur in conjunction with changes in other functionally-related areas. 
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Although the caudate is generally thought to be affected before the putamen in HD (177), greater 
atrophy in the putamen (50.1% reduction compared to control volumes) relative to the caudate 
(27.7% reduction compared to controls) has also been reported (178), and putamen volumes have 
been identified as a more reliable indicator of disease progression than caudate volumes (1, 179). 
Although the striatal findings in the present study mesh with other reported literature, it is also 
possible that methodological differences caused distinctions between the GM and WM findings. 
Thus, duplicating the LMM WM analysis using the GM components, or setting up the model to 
compare GM and WM longitudinally, is an essential next step that is already underway (see 
Future Directions). 
 
Early extra-striatal differences: in these studies, the angular gyrus and precuneus were 
consensus areas for early prodromal differences in both GM and WM, possibly reflecting an 
early disruption of the default mode network (DMN). The striatum is structurally and 
functionally connected to DMN hubs, including the precuneus, posterior cingulate cortex, and 
anterior cingulate (putamen and ventral striatum), inferior parietal and DLPFC (anterior 
caudate). The precuneus has displayed some of the most robust early prodromal changes (46), 
and DMN disturbances have been reported in both prodromal and diagnosed HD during rest as 
well as task performance. Examples of reported DMN dysfunction include increased DMN 
connectivity that was evident before volumetric loss (180), intrinsic functional connectivity 
increases (181), and greater M1 connectivity with a posterior cingulate DMN hub (which was 
associated with cognitive and motor dysfunction) (88).  
In GM, the most common early prodromal differences presented in superior frontal, mid 
frontal, angular gyrus, and inferior temporal, with the most robust early effects being frontal. 
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Other strongly affected regions included the cuneus, precuneus, and superior temporal gyrus. In 
WM, by contrast, the most robust and early cross-sectional effects were parietal. Regions most 
commonly exhibiting cross-sectional differences in the early contrast included the inferior 
parietal lobule, angular gyrus, precuneus, superior parietal, and superior occipital. Early cross-
sectional effects in middle and superior frontal were also observed in WM but were not nearly as 
common as similar changes in GM. However, in the longitudinal analysis, the strongest early 
changes were observed in premotor, supplementary motor and middle frontal gyral WM, and 
many other frontal regions were also significant in the earliest contrast; this is more in agreement 
with what was found cross-sectionally in GM, suggesting that frontal changes in GM may be 
easier to detect cross-sectionally than those in WM. Other distinctions between early GM and 
WM results included strong early differences in occipital GM (but not WM) and thalamic 
differences that were evident in GM-adjacent-WM before manifesting in GM. 
 
Structural change throughout the prodrome: components exhibiting significant 
differences between controls and each prodromal group were more common in WM than GM, 
which again could be attributable to either more extensive WM changes or simply to 
methodological differences. In GM, two components containing precentral, mid frontal, medial 
frontal, superior frontal, and supplementary motor exhibited differences between controls and 
each prodromal group. In WM, these regions also exhibited robust group differences, and other 
commonly affected regions included angular gyrus, followed (in no particular order) by superior 
temporal gyrus, superior and middle occipital, and inferior parietal lobule.  
Notably, the angular gyrus exhibited prominent early prodromal effects, group 
differences across the prodrome, and alignment with cognitive and motor variable change over 
146 
time in these studies. Although the angular gyrus is not typically reported as a primary region of 
change in prodromal HD, one study examining post-mortem brain tissue from HD patients found 
a 55% reduction in angular gyrus pyramidal neurons, and the authors suggested that HD may 
disproportionately affect posterior cortical regions (182).  
 
Later prodromal differences: some late prodromal differences occurred the absence of 
earlier differences, indicative of brain regions where disruption is delayed. While the specific 
regions most evident in these contrasts were distinct in WM compared to GM, it was clear across 
analyses that subcortical regions became increasingly affected with progression. Evidence of 
late cross-sectional GM and WM changes in the absence of early changes overlapped in the 
lingual gyrus and cingulum, highlighting a trend across both datasets in which selectively late 
differences appear in more sub-gyral/lobar regions. In GM, paracentral, mid temporal, inferior 
frontal, vermis (4, 5, 9), and cerebellum crus 2 also exhibited selectively late differences. In 
WM, other exclusively late differences were primarily seen in the thalamus (and its 
subdivisions), calcarine, cuneus, limbic lobe, BA17/V1, amygdala, BA13/insula, 
BA30/agranular retrolimbic area, BA41,42/primary auditory cortex, parahippocampal gyrus, and 
pallidum. The delayed atrophy of movement-related regions is in keeping with motor impairment 
as the primary instigator of diagnosis and the non-linear prodromal pattern of motor dysfunction 
that rapidly steepens near diagnosis.  
 
Discrepancies between GM and WM results: the GM and WM results differed most 
distinctly in inferior areas. For example, inferior frontal and parietal effects were fairly common 
in WM, even in early prodromal contrasts, despite being relatively absent in GM. Additionally, 
147 
inferior temporal and occipital results were common in GM contrasts but scarce in WM results. 
However, results in both GM and WM are mostly in keeping with a superior-to-inferior gradient 
of degradation across the prodrome. 
 
Longitudinal structural changes: although longitudinal results are only available for WM, 
slopes for WM components followed the pattern observed cross-sectionally in both GM and 
WM, wherein the most rapid changes occur in the High group (near diagnosis) and the most 
modest changes in the Low and Control groups (with the control group exhibiting the fewest 
changes). In WM, longitudinal effects were also more prominent than cross-sectional effects, 
further highlighting the need for an analogous analysis in GM.  
 
Hemispheric effects: the GM results suggested regionally-variable hemispheric effects; 
significant olfactory and lingual findings were solely in the left hemisphere, and some inferior 
(frontal, occipital) and subcortical (putamen, thalamus) regions showed stronger left-hemispheric 
effects in the early prodrome. Conversely, mid frontal, superior temporal, and cerebellar effects 
were measured only in the right hemisphere, and effects were stronger in the right hemisphere in 
early contrasts for middle and inferior temporal gyrus and hippocampus. This supports a L → R 
pattern of degradation in inferior, thalamic, and striatal GM, with the opposite pattern of atrophy 
(R → L) in other, more superior regions. However, in WM, the left hemisphere seemed overall 
more affected, particularly by the late prodrome. Few prior studies have actually directly 
addressed brain asymmetry in HD outside of the striatum, where left-hemispheric asymmetry is 
often reported (31, 183). One volumetric meta-analysis reported converging evidence for left-
biased atrophy (31) and an additional study reported bilateral GM atrophy that became more left-
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lateralized with prodromal progression (183). Our results suggest that WM atrophy may proceed 
with more uniformly left-hemispheric bias than that of GM; this may in part reflect connectivity 
increases that have been observed in right hemispheric regions (such as the DLPFC), particularly 
in the late prodrome, which have been proposed as possible compensatory mechanisms (103).  
 
6.2 Clinical Functioning and Brain Structure Throughout the Prodrome 
The research examining how WM profiles change with clinical functioning across the HD 
prodrome revealed that different WM regions decline at a rate similar to motor, as opposed to 
clinical, functioning across the prodrome. There was also overlap among regions most 
implicated in clinical tests in superior occipital (SC, SI, SW TMTA TMTB), precuneus (SC, SI, 
TMTA, TMTB), superior parietal lobule (SC, SI, TMTA, TMTB), angular gyrus (SI, TMTB, 
UHDRS-TMS), middle occipital (SDMT, SI, TMTB), associative visual cortex (SW, TMTA, 
TMTB), supramarginal gyrus (SI, TMTB), cuneus (SW, TMTA), and inferior parietal lobule (SI, 
TMTB). 
Additionally, clinical functioning is best reflected by different brain regions depending 
on prodromal stage, although there is some overlap among regions implicated at different 
prodromal stages. Parietal regions (including precuneus, superior parietal lobule, and angular 
gyrus) appear to play a strong role in clinical functioning throughout the prodrome, with the 
angular gyrus standing out as the only region strongly involved in both cognitive and motor 
functioning.  
The strong involvement of parietal and frontal regions in cognitive functioning during 
early stages of (and throughout) the prodrome is consistent with compensatory mechanisms 
involving increased recruitment of parietal and frontal cortical regions during movement (e.g., 
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the Simon button press task) in HD patients (184). Alterations in intrinsic neural activity have 
been observed in the precuneus and angular gyrus of HD patients, and significant correlations 
between cognitive performance and precuneus activation and cortical thinning have been 
reported (185, 186). Furthermore, parietal regions BA 5 and 7 contain neurons that selectively 
respond to specific hand and mouth movements (187), and these regions were both present in 
components with prominent clinical effects in our studies. 
Frontal regions implicated in movement (premotor, supplementary motor, and middle 
frontal) showed some of the strongest similarities with clinical functioning in the early prodrome. 
In a positron emission tomography (PET) study comparing brain activation during hand 
movements in HD patients and controls, HD patients exhibited abnormal movement-related 
activation in the supplementary motor cortex, premotor cortex, and anterior cingulate, as well as 
the striatum, in conjunction with enhanced parietal activity that may reflect compensatory 
mechanisms (188). Similarly, an additional PET study reported frontal lobe and putamen activity 
alterations in HD patients during a movement task, with inadequate activation in supplementary 
and premotor cortices, in addition to the cingulum, that correlated with performance accuracy 
(187); here, enhanced activation in left parietal cortex was associated with improved 
performance in HD patients. 
In the middle prodrome, the angular gyrus, limbic lobe, and middle occipital play a more 
pivotal role in clinical functioning, with comparatively diminished involvement of frontal 
regions. Many of these regions have been previously identified in studies of neural correlates of 
clinical functioning. Middle occipital diffusivity changes can distinguish prodromal stages, and 
poorer Stroop Word performance has been associated with increased diffusivity in superior and 
middle occipital gyrus (189). An additional study found that the only diffusivity changes that 
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distinguished prodromal groups were in the superior fronto-occipital fasciculus, with the greatest 
changes in the group closest to diagnosis. Diffusivity increases in the superior fronto-occipital 
fasciculus were also associated with worsening motor functioning over time (i.e., motor 
symptom increases) (41).  
By the late prodrome, parietal areas implicated in early prodromal clinical functioning 
(including the precuneus and superior parietal lobule) again align well with clinical 
functioning, and change in the angular gyrus continues to strongly resemble changes in both 
cognitive and motor functioning. Other regions that appear to play an increasing role in clinical 
functioning in the late prodrome include superior occipital gyrus and inferior parietal lobule. 
Occipital involvement in clinical functioning shifts across the prodrome, with associative visual 
cortex being most implicated in the early prodrome, followed by middle occipital later in the 
prodrome and superior occipital at the latest prodromal stage.  
 
Sensitivity of clinical variables: across clinical variables, WM aligned most with clinical 
functioning in the Low group and least with that of the High group. Overall, the UHDRS-TMS 
was the best indicator of prodromal WM integrity, both at baseline and over time, until the late 
prodrome. At the late prodromal stage, cognitive measures, especially Stroop Interference and 
TMTA, aligned most with WM. Of the cognitive variables, TMTA showed the most promise for 
capturing cross-sectional WM differences at each stage of the prodrome. 
 
6.3 Genetic Modifiers of Prodromal Symptoms 
Results from the genetic analyses agree with previous reports indicating that a substantial 
amount of variability in prodromal functional decline cannot be explained by CAG-number and 
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age, the primary indicators of prodromal progression. This work pinpoints several genes that 
may act upon brain structure and clinical functioning, even before the onset of diagnosis-
associated motor symptoms. Furthermore, these findings indicate that these genetic factors can 
eventually influence onset, and support GM variation (both in the context of CAG and 
independent of CAG) as a suitable phenotype for examining genetic influences on prodromal HD 
progression and onset. The following genes (or variants) were identified as promising candidates 
for future research: NTRK2 (rs11140810, rs4877289, rs10868241, rs2277193), CDK14 
(rs7801922), FAM114A1 (rs7655305), HEATR4 (rs8012614), LRRC55 (rs548321), and 
MIR181A1 (rs427790), NCOR1, and ADORA2B. Additionally, this work provided converging 
evidence supporting previously identified genetic modifiers, including MTMR10 and FAN1 (58). 
 
NTRK2, brain structure, and clinical functioning: the hypothesis-driven study examining 
BNDF-signaling-genes indicated that NTRK2, which encodes BDNF’s high-affinity TrkB 
receptor, may influence prodromal GM and clinical functioning, particularly in individuals with 
certain genotypes. Fascinatingly, this genetic profile was associated with a GM network that 
included regions frequently grouped together and highly significant across the GM and WM 
findings, namely precentral gyrus, supplementary motor cortex, and superior, middle, and 
medial frontal gyrus. This frontal GM profile was associated with both motor and cognitive 
functioning in the prodromal cohort, with the strongest effects being observed for clinical tests 
that were most linked to cross-sectional and longitudinal change in WM (including TMTA, 
Stroop Interference, and UHDRS-TMS, in addition to Stroop Color). Furthermore, one of the 
top NTRK2 SNPs in the genetic profile was protectively associated with TMTB performance. 
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 Each of the four most implicated NTRK2 SNPs were situated near alternative stop codons 
for truncated TrkB variants; the truncated variants lack the catalytic tyrosine kinase domain and 
are not associated with rapid intracellular signaling in neurons, whereas the full length version is 
implicated in rapid BDNF and neurotrophin 4/5 (NT-4/5) neuronal signaling. In astrocytes, the 
truncated TrkB-T1 variant is the most commonly expressed TrkB variant, and its interaction with 
BDNF evokes calcium release (190). TrkB-T1 also has alleged roles in BDNF sequestering and 
translocation, cytoskeletal restructuring, and neurite outgrowth (191). In Parkinson’s Disease 
(PD) patients, post-mortem tissue revealed that the distribution of truncated and full length TrkB 
differed between PD patients and controls in the striatum and substantia nigra. Alternative TrkB 
splicing has also been implicated in cancer pathology (192), and NTRK2 has been a target of 
recent clinical trials for cancer treatments (193, 194). 
Furthermore, in the brain, these SNPs exert the most pronounced effects on expression in 
frontal regions, aligning with the coupling of this genetic profile with frontal GM in this study; 
they also exert disproportionate effects on other regions affected in HD (including the putamen, 
cerebellum and thalamus). NTRK2 and the genes these SNPs act upon have roles in several 
cellular functions that are aberrant in HD, including apoptosis, smooth muscle cell proliferation, 
mRNA splicing, neurotransmission, translational control, SUMOylation, Golgi and ER 
retrograde transport, and shortening of long polyglutamate chains.  
 Other, un-hypothesized variants also contributed to the genetic profile, with many of 
these being implicated in cancer regulation, and these merit further investigation. Among the 
most interesting of these variants was an intronic HEATR4 (HEAT Repeat Containing 4) SNP 
known to influence DNAL1 (an HD-pathway gene encoding dynein axonemal light chain 4, a 
component of the molecular motor that is disrupted by mutant Huntingtin, which impedes BDNF 
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microtubule transport). Another top contributor of interest was a variant in CDK14 (Cyclin 
Dependent Kinase 14), which was the strongest overall contributor to the SNP profile and may 
thus be a particularly promising avenue for future research. Although CDK14 has not been 
previously implicated in HD pathology, it is involved in processes that are aberrant in HD, 
including Wnt signaling and glucose transport (153, 195-197). For instance, in HD-patient-
derived induced pluripotent stem cells (iPSCs), abnormal Wnt signaling has been associated with 
impaired cerebrovascular and blood-brain barrier development (195). 
There was also some overlap between hypothesized and novel variants. Top SNPs in both 
NTRK2 and MIR181A1 affect the same ZEC regulatory motif, a DNA-binding transcriptional 
activator (198), as well as two Fox transcription factors, Foxj1 and Foxa. Foxj1 has a role in the 
formation of motile cilia (199), and Foxa is required for organ development and is among 
“pioneer” transcription factors that enhance gene activation via chromatin binding during early 
development (200, 201). SNPs in both NTRK2 and LRRC55 alter GR (glucocorticoid receptor) 
and Pax (paired box) regulatory motifs (Pax-4 and Pax-6). Pax genes play a crucial role in tissue 
development during embryogenesis, and Pax-6 is involved in both pre- and post-natal 
neurogenesis (202). Although HD is typically described as neurodegenerative and diagnosis 
occurs in middle-to-late life, mounting evidence demonstrating an essential role of huntingtin in 
prenatal development has led to HD being increasingly described as neurodevelopmental as well 
(203, 204). 
 
CAG-independent genetic effects: in the genetic analyses, genes outside of HTT were 
associated with differences in GM profiles that were related to cognition and motor functioning 
in a CAG-independent manner; the relationships between these variants and GM was also not 
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influenced by CAG, providing converging evidence for extra-HTT genetic effects on prodromal 
disease progression. Additionally, SNPs in MTMR10 and FAN1, located in a region previously 
associated with delayed HD-onset (ch15q13.3) (58), were associated with GM increases as well 
as improved motor functioning, indicating that genes and variants outside of HTT that influence 
HD-onset also confer CAG-independent effects on prodromal phenotypes thought to reflect 
disease progression (e.g., brain structure, cognition, and motor functioning). 
 
6.4 Future Directions 
These experiments helped characterize the multifaceted interactions among the genome, 
brain, and cognitive and motor functioning throughout the HD prodrome, establishing 
fundamental framework for future research endeavors. Beyond testing existing hypotheses 
regarding the roles of BDNF, REST, and its interactors, these experiments highlighted 
previously identified as well as heretofore unreported genetic variants that appear to play a role 
in prodromal brain structure and clinical functioning. In the future, it will be important to fully 
elucidate the roles of these genes and variants in HD and prodrome, as well as determine the 
generalizability of these findings to other conditions that share landmark features with HD (e.g., 
delayed onset, selective atrophy, and abnormal protein folding and accumulation), such as 
schizophrenia and Alzheimer’s and Parkinson’s diseases. 
Ultimately, it is also important to causally assess the strongest associations observed in 
large, comprehensive human datasets via carefully controlled experiments in non-human 
animals. An appropriate starting point for this work is to test promising candidates in one or 
more of the several available strains of HD Drosophila (fruit flies), for which there is a multitude 
of techniques that enable rapid, inexpensive testing of variants and genes of interest in the 
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context of different genotypes. Following these experiments, genetic factors with the most 
therapeutic potential can be focused on in further studies in mammals and, hopefully, eventual 
clinical trials. In keeping with this, our group has begun a collaborative study investigating how 
over-expression and knock-down of various forms of the Drosophila BDNF ortholog (DNT1: 
full-length, pro, and mature) and its receptor (Toll-7) affect brain structure, motor functioning, 
and longevity in Drosophila lines expressing various human HTT CAG-lengths (46Q, 72Q, 96Q, 
128Q). 
Beyond characterizing genetic influences on HD and the prodrome, future researchers 
would be well-served to identify protective and detrimental epigenetic marks, which can alter 
gene expression. Epigenetic differences between prodromal patients and controls have already 
been uncovered (205), but relatively little is known about how these changes contribute to HD 
progression and how they could be exploited to delay onset. This approach may be especially 
promising because epigenetic marks can change across the lifespan, respond to the environment, 
and in some cases are reversible. It would also be useful to examine the influence of genetic and 
epigenetic factors longitudinally, as they may influence clinical decline or onset rapidity, and 
these findings could be incorporated into therapies to halt or delay symptoms and onset. As 
genetic and epigenetic contributors to disease burden continue to be identified, the potential for 
effective gene therapies (such as DNA-methylating drugs and histone-deacetylase inhibitors) 
expands as well.  
Regarding brain structure, GM differences outlined in this paper also merit longitudinal 
examination, an analysis that is currently underway in our lab. The GM and WM datasets used in 
these analyses could also be analyzed concurrently to compare the chronology and extent of 
prodromal GM and WM changes. In particular, it is still unclear whether GM or WM is affected 
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first in the HD prodrome, and this information could be highly useful for therapeutic 
development; this comparison could be made using a stacked LMM analysis with the WM and 
GM segmentations, similar to what was used to compare WM and clinical trajectories. 
Examining longitudinal GM changes in conjunction with the clinical variables could also provide 
some insight on the relative involvement of GM and WM in clinical functioning at various stages 
of the HD prodrome.  
Finally, and perhaps most importantly, actual rates of HD-conversion should be 
compared to estimated rates of conversion (based on CAG and age) to enable identification of 
protective and detrimental genotypes, epigenetic marks, and brain structural profiles, among 
other factors. PREDICT-HD researchers have already examined rates of conversion in a subset 
of participants who received a diagnosis during the study, and have used this information to 
designate “slow”, “normal”, and “fast” HD converters. Assessing this information in conjunction 
with the wealth of available genomic and phenotypic data could be highly useful for pinpointing 
promising intervention targets. 
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APPENDICES  
Appendix A 
Appendix A.1.  
Significant SBM Components in Supplemental CAPD-Group Contrasts. Significant SBM 
components in Low > Medium, Low > High, and Medium > High CAP-group contrasts (p<0.05) 
A-T. Comparisons labeled with a single asterisk (*) are significant at p <0.05; Two asterisks (**) 
denotes significance of p<0.001. 
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Appendix A.2.  
VBM significant group effects (ANCOVA T contrasts). Pairwise effects of CAP group 
on VBM, showing regions that vary throughout the prodrome (p<0.05). The colored bar legend 
codes the T-statistic at each voxel, with white areas denoting voxels with the highest significance 
levels. 
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Appendix A.3.  
SBM Component Descriptions. Summary of each SBM component, including 
MANCOVA CAP-group significance, Control > Low, Control > Medium, and Control > High 
Sidak pairwise contrast significance, regions most substantially contributing to SBM components 
(Z-scores of at least 4.0), and left- and right- hemisphere maximum z scores. 
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Appendix A.4.  
Site Demographics. Scan site information, including site number and scanner field 
strength in tesla (T) (column 1). Also presented are \ numbers of control and low-, medium-, and 
high-prodromal subjects at each scan site, and total participant numbers for each site.  
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Appendix B 
Appendix B.1. Cognitive and Motor Variables 
SDMT = Symbol Digit Modalities Test. The SDMT measures working memory, complex 
scanning, and processing speed, and is an adaptation of the Wechsler Digit Symbol subtest (136, 
137). For SDMT, participants are provided with a key of symbols paired with numbers (at the 
top of the test page). On the same test sheet, a series of numbers are presented in a horizonal row, 
and the task is to fill in the symbols matching each number in the sequence as quickly and 
accurately as possible. Raw scores represent the number of correctly completed items within 90 
seconds (109). 
Stroop Color = Stroop Color and Word Test – color condition. The color condition is a 
color identification task that measures basic attention, and is the first of three 45-second trials in 
the Stroop Color and Word Test (110). The task is to identify colors presented on stimulus cards, 
and raw scores reflect the number of correct responses (138). 
Stroop Word = Stroop Color and Word Test – word condition. For the Stroop Color and 
Word test word condition, participants are tasked with reading color names presented in black 
ink. The word condition is the second of three 45-second trials in the Stroop Color and Word 
Test (110). Like the color condition, the word condition measures basic attention, and raw scores 
represent the number of correct responses (138).  
Stroop Interference = Stroop Color and Word Test – interference condition. The Stroop 
Interference task is the third 45-second trial of the three-part Stroop Color and Word Test (110). 
For the Interference task, participants inhibit an overlearned response by naming the color that 
color-names are presented in rather than reading the color name itself (e.g., for the word “blue” 
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printed in green ink, the correct response is “green”). Like the other two conditions, raw scores 
reflect the number of correct trial responses (138). 
TMTA = Trail Making Test, Part A. For TMTA, the task is to sequentially connect a 
series of numbered circles (e.g., 1-2-3-4) as quickly as possible. Raw scores reflect time (in 
seconds) taken to complete the task. Thus, higher scores reflect poorer performance (111, 206).  
TMTB = Trail Making Test, Part B. For TMTB, participants are asked to connect 
consecutive numbers and letters in ascending/alphabetical order, alternating between numbers 
and letters (e.g., 1-A-2-B-3-C). Like TMTA, raw scores reflect completion time in seconds, and 
higher scores reflect poorer performance (111, 206).  
TMS = total motor score (TMS) from the Unified Huntington Disease Rating Scale 
(UHDRS). TMS is a standardized measure of oculomotor function, dysarthria, chorea, dystonia, 
gait and postural stability, and is part of the UHDRS (108). 
Oculomotor = ocular subscale from the UHDRS. The ocular-motor subscale of the 
UHDRS assesses eye motion and tracking ability (1, 108). 
Bradykinesia = bradykinesia subscale from the UHDRS. The bradykinesia subscale of the 
UHDRS measures the level of movement rigidity or slowness (1, 108). 
Chorea = chorea subscale from the UHDRS. The chorea subscale of the UHDRS assesses 
the frequency and severity of abnormal involuntary movements in the face, mouth, trunk, and 
extremities. Chorea symptoms are scored from 0 (absent) to 4 (marked/prolonged) in each 
region, and the sum of the scores is the chorea-motor score (1, 108). 
Dystonia = dystonia subscale from the UHDRS. The dystonia subscale from the UHDRS 
measures the occurrence and severity of involuntary muscle contractions and twisting in the 
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trunk and extremities of the body. Like chorea, dystonia symptom scores range from 0-4 for each 
bodily region, and the sum of these scores is the dystonia score (1, 108). 
  
Appendix B.2. Association test results for individual motor and cognitive variables 
Eleven motor and cognitive variables were tested for association with CAP using a 
regression model: a cognitive or motor variable = age + sex + CAP. Poisson regression was used 
for motor variables and linear regression was used for cognitive variables, due to the distribution 
patterns of each variable. Appendix B.3 lists the association p values and percentage of variance 
explained by the model. For individual variables, the association with CAP was significant (p < 
0.01 for dystonia and p < 1e-11 for the others). These results are consistent with those reported in 
the main text using representative variables. 
  
Appendix B.3. Individual Variable Associations with Age, Sex and CAP. 
Association of individual motor and cognitive variables with GM components was tested 
using a regression model: a cognitive or motor variable = age + sex + CAP + GM network 
loadings. Poisson regression was used for motor variables and linear regression was used for 
cognitive variables. One GM component out of 15 represented artifacts and was not further 
analyzed. Appendix B.4 lists the association p values (uncorrected) and bold indicates p values 
passing FDR correction. GM component 6 consists of cuneus, lingual gyrus, and middle occipital 
gyrus, and is associated with overall working memory/attention performance (see main text). 
Here, this component was associated with SDMT, Stroop Color, and Stroop Interference. 
Component 11 includes GM in bilateral inferior parietal and superior/middle temporal gyri, and 
was associated with the binary dystonia variable in the main text. Here, it was associated with 
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original dystonia scores. GM component 14 consists of bilateral insula and superior temporal 
gyrus.  This component was associated with SDMT, but not with any other individual cognitive 
measure nor any representative measure from the main text. A further association test between 
component 14 GM loadings and genomic SNPs, pathway SNPs and candidate SNPs also 
revealed no significant SNP association. Due to the relatively sparse association, we believe 
further validation of the component 14 result is necessary. Overall, the results from individual 
variables are highly consistent with those derived from representative variables reported in the 
main text.  
 Age_p Sex_p CAP_p variance  explained % 
TMS 1.72E-02 2.40E-01 <1E-15 18.36% 
oculomotor 1.37E-02 4.79E-02 5.95E-12 10.21% 
bradykinesia 7.25E-02 2.70E-02 <1E-15 14.89% 
chorea 9.46E-02 1.74E-01 <1E-15 9.32% 
dystonia 1.05E-01 6.48E-01 6.19E-03 2.22% 
SDMT 3.84E-02 4.54E-01 <1E-15 21.45% 
stroop_color 1.86E-01 1.95E-01 <1E-15 13.60% 
stroop_word 6.45E-01 5.95E-01 <1E-15 11.96% 
stroop_interference <1E-15 4.49E-01 <1E-15 15.24% 
TMTA 3.51E-02 9.25E-01 <1E-15 13.29% 
TMTB 2.20E-01 7.38E-01 <1E-15 14.88% 
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Appendix B.4. Association P-Values of Individual Variables with GM Components 
Association of motor and cognitive variables with SNPs was tested using a regression 
model: a motor or cognition variable = age + sex + CAP + SNP + top ten MDS scores. Poisson 
regression was used for motor variables and linear regression was used for cognitive variables. 
The tests, genomic level and pathway level, were FDR corrected at p < 0.05 for all tested 
variables and SNPs. No significant associations were observed. For candidate SNP analyses, 
SNPs in chromosome 15 (in high LD) showed associations with motor variables. Using rs11293 
as an example, this SNP was related to TMS (p = 0.02), oculomotor (p = 0.02), and chorea (p = 
0.05), with more minor alleles being linked to lower scores; this is consistent with the overall 
motor function association reported in the main text. Three identical SNPs in chromosome 8, 
(rs16869295, rs11777942, and rs11778107) were associated with chorea score (p = 0.003) but 
not with other scores. Here, greater minor allele numbers were associated with higher chorea 
scores, in keeping with a hastening of onset that is in line with previous reports (58).  
GM 
network 
TMS oculo brady chorea 
dystoni
a 
SDMT 
Stroop 
color 
Stroop 
word 
Stroop 
Inter-
ference 
TMTA TMTB 
1 
7.96E-
01 
3.67E-
01 
8.31E-
01 
6.03E-
01 
4.38E-
01 
7.60E-
01 
6.59E-
01 
6.11E-
01 
4.22E-
01 
3.93E-
01 
5.47E-
01 
2 
9.99E-
01 
5.13E-
01 
2.26E-
01 
4.27E-
01 
2.34E-
01 
4.38E-
01 
2.74E-
01 
8.78E-
01 
8.55E-
01 
3.01E-
01 
4.15E-
02 
3 
9.91E-
01 
3.10E-
01 
9.30E-
01 
1.99E-
01 
7.37E-
01 
5.09E-
01 
7.79E-
01 
7.99E-
01 
4.39E-
01 
4.13E-
01 
7.24E-
01 
4 
8.70E-
01 
6.87E-
01 
3.75E-
01 
7.47E-
01 
3.94E-
01 
2.56E-
01 
2.93E-
01 
2.09E-
01 
3.15E-
02 
8.27E-
01 
1.21E-
02 
5 
9.63E-
01 
8.41E-
01 
6.59E-
01 
9.30E-
01 
3.67E-
01 
9.52E-
01 
8.63E-
01 
5.87E-
01 
5.94E-
01 
7.00E-
01 
2.54E-
01 
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6* 
5.48E-
03 
9.79E-
02 
3.94E-
02 
5.02E-
03 
3.40E-
01 
1.31E-
04 
2.34E-
04 
9.07E-
03 
1.16E-
04 
6.73E-
03 
3.64E-
03 
7 
9.12E-
01 
8.59E-
01 
7.38E-
01 
4.33E-
01 
8.34E-
01 
2.86E-
01 
4.02E-
01 
6.43E-
01 
6.98E-
02 
5.09E-
01 
3.29E-
01 
8 
5.99E-
01 
2.39E-
01 
8.92E-
01 
8.06E-
01 
8.41E-
01 
4.96E-
01 
1.55E-
01 
4.18E-
01 
3.97E-
02 
7.65E-
01 
3.85E-
02 
10 
8.71E-
02 
5.77E-
01 
2.13E-
02 
4.83E-
01 
7.27E-
01 
5.75E-
02 
1.81E-
01 
2.55E-
02 
2.73E-
01 
5.41E-
01 
1.41E-
01 
11** 
1.22E-
02 
2.49E-
01 
9.07E-
02 
2.16E-
02 
2.54E-
06 
2.44E-
01 
3.55E-
01 
6.93E-
01 
6.72E-
01 
6.21E-
01 
3.26E-
01 
12 
5.01E-
01 
5.39E-
01 
2.32E-
01 
5.61E-
01 
1.54E-
02 
1.05E-
01 
8.92E-
01 
3.31E-
01 
6.52E-
01 
6.99E-
02 
1.36E-
01 
13 
4.04E-
01 
6.96E-
01 
2.10E-
01 
6.00E-
01 
5.30E-
01 
6.46E-
01 
5.15E-
01 
6.21E-
01 
2.58E-
01 
6.26E-
01 
2.71E-
01 
14*** 
1.73E-
02 
1.02E-
01 
2.86E-
02 
2.09E-
01 
1.63E-
02 
2.19E-
04 
5.69E-
01 
2.24E-
01 
2.65E-
01 
1.71E-
02 
1.06E-
02 
15 
6.70E-
01 
8.46E-
01 
6.91E-
01 
6.86E-
01 
4.70E-
01 
6.10E-
01 
5.93E-
01 
6.26E-
01 
2.46E-
01 
2.48E-
01 
9.77E-
01 
*cuneus, lingual gyrus, middle occipital gyrus component. **bilateral inferior parietal 
and superior/middle temporal network. ***bilateral insula and superior temporal gyrus 
component.  
 
Appendix B.5.  
In an extended analysis focusing on the SNP rs71358386 in NCOR1 (similar results were 
obtained for rs78804732 in ADORA2B), we found it was marginally correlated with one GM 
component consisting of caudate, insula, and superior temporal gyrus (STG) (p = 0.069, r = -
0.065) and positively related to overall motor function (p = 0.05) and dystonia (p = 0.04). Very 
encouragingly, the caudate/insula/STG component showed a negative relationship with overall 
motor function (p = 0.02) and problem-solving processing (p = 0.007). Even though these p 
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values did not pass FDR correction, the overall association pattern is very appealing; i.e., greater 
minor allele numbers are linked to less GM volume in the caudate/insula/STP component as well 
as higher motor scores and dystonia signs, and less GM in this component is linked to higher 
motor scores and slower problem-solving processing. This result warrants further exploration.   
 
Appendix B.6. Cross correlation among cognitive and motor function variables.  
Cross correlation among cognitive and motor function variables. The diagonal auto-
correlation was ignored. 
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Appendix B.7. QQ plots for genomic association tests 
QQ plots for genomic association tests with A: cuneus GM component, B: inferior 
parietal GM component, C: working memory/attention, D: problem solving, E: overall motor 
function, and F: dystonia. 
 
A) 
B) 
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Appendix B.8. Figures of all GM components (|Z|>2.5) 
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Appendix C 
Appendix C.1. Regression Influence Analysis 
Regression influence analysis in R to identify participants driving the significant frontal 
GMC - NTRK2 SNP profile correlation. Circles denote observations proportional to Cook’s 
distances, with vertical reference lines at two and three times the average hat value and 
horizontal reference lines at -2, 0, and 2 on the studentized-residual scale. Numbers within the 
chart area (e.g., 4, 713, 124) are identifiers that denote individuals driving the significance of the 
correlation 
 
 
Appendix C.2. Top 61 SNPs contributing to the NTRK2 component.  
For each SNP, rs ID, weight in the component, direction of contribution to the component 
(positive or negative), associated gene, and variant type are displayed 
SNP Weight 
(||) 
+/- Ranking  Gene dbSNP func 
annot 
rs7801922 1.29 + 1 CDK14 intronic 
rs11140810 1.20 + 2 NTRK2 intronic 
rs4877289 1.08 + 3 NTRK2 intronic 
rs548321 1.03 + 4 70kb 5' of LRRC55 
 
rs112140519 1.01 + 5 53kb 3' of NUS1 
 
rs427790 1.00 + 6 20kb 5' of RP11-382E9.1 
 
rs10868241 1.00 + 7 NTRK2 intronic 
rs7655305 0.99 + 8 FAM114A1 intronic 
186 
rs2277193 0.98 + 9 NTRK2 intronic 
rs8012614 0.98 + 10 HEATR4 intronic 
rs921184 0.98 + 11 ANK2 intronic 
rs7851762 0.97 + 12 433bp 3' of NCS1   
rs1846464 0.97 + 13 CNTN6 intronic 
rs9921192 0.97 + 14 16kb 5' of GLIS2 
 
rs3772327 0.96 + 15 CNTN6 intronic 
rs11745541 0.96 + 16 RP11-281O15.3 intronic 
rs4888761 0.96 + 17 WWOX intronic 
rs1882077 0.96 + 18 ELMO1 intronic 
rs17204453 0.96 + 19 14kb 3' of RP11-524C21.2   
rs4673374 0.95 + 20 9.9kb 5' of CCNYL1   
rs11140831 0.95 + 21 8.9kb 3' of NTRK2   
rs1940659 0.95 + 22 RP11-161I6.2   
rs35947825 0.94 + 23 7.1kb 3' of CACNA2D1   
rs6022607 0.94 + 24 ZNF217 intronic 
rs1929185 0.94 - 25 GPC5 intronic 
rs2933573 0.94 + 26 58kb 5' of MSX1   
rs4732179 0.93 + 27 AC009784.3 intronic 
rs7957137 0.93 + 28 TMEM132D intronic 
rs55962532 0.93 + 29 37kb 3' of TAS1R2   
rs2099533 0.93 + 30 502kb 5' of ALCAM   
rs12146299 0.92 + 31 196kb 5' of AL356154.1 
 
rs10920230 0.92 + 32 NAV1 intronic 
rs10933554 0.92 + 33 2.2kb 5' of OR6B2   
rs564011 0.91 + 34 ARRB1 intronic 
rs1873127 0.91 + 35 22kb 3' of U7   
rs1078962 0.91 + 36 ZNF444 intronic 
rs7868631 0.91 + 37 11kb 5' of AL442639.1 
 
rs8006593 0.91 + 38 2.7kb 3' of CTD-2552B11.4   
rs717952 0.90 + 39 RP11-185P18.1 intronic 
rs1463883 0.90 + 40 MB21D2 intronic 
rs12371144 0.90 + 41 PPM1H intronic 
rs4867981 0.89 + 42 KCNIP1 intronic 
rs2275458 0.89 + 43 SPSB1 3'-UTR 
rs100840 0.89 + 44 PTPRN2 intronic 
rs12873665 0.89 + 45 RASA3 intronic 
rs2478467 0.89 + 46 CLPSL2 intronic 
rs6854255 0.89 + 47 73kb 3' of RP11-399F2.2   
rs11971401 0.88 + 48 PTPRN2 intronic 
rs2443426 0.88 + 49 OR9Q1 intronic 
rs28713361 0.88 + 50 1.2kb 3' of FAM19A5   
rs12125200 0.88 + 51 RP11-16L9.4 intronic 
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rs6743142 0.88 + 52 9kb 5' of AC097517.2   
rs877118 0.88 + 53 ARVCF intronic 
rs1461303 0.88 + 54 LINC01246 intronic 
rs6956508 0.88 + 55 HUS1   
rs66499509 0.88 + 56 KCNIP1 intronic 
rs1867283 0.88 + 57 NTRK2 intronic 
rs4475412 0.88 + 58 CDK14 intronic 
rs7080094 0.87 + 59 109kb 3' of Y_RNA   
rs2070373 0.87 + 60 HUNK 3'-UTR 
rs13164430 0.87 + 61 KCNIP1 intronic 
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Appendix C.3. Top SNPs Outside of NTRK2 
Descriptions of genes affected by top contributing component SNPs outside of NTRK2. 
Sources: GeneCards human gene database (142) and UniProt (153) 
Gene  Full name 
Associated 
SNP(s)  
Description Type 
Related 
pathways 
GO 
annotations 
CDK14 
Cyclin-
dependent 
kinase 14 
rs7801922 
Eukaryotic cell cycle 
progression/proliferation
, cell-cycle regulation of 
Wnt signaling pathway, 
meiosis, neuronal 
differentiation, indirect 
negative regulation of 
insulin-responsive 
glucose transport 
Protein 
coding, 
CDC2 
(MIM 
116940)-
related 
protein 
kinase  
Transcriptional 
misregulation 
in cancer 
Transferase 
activity, 
transferring 
phosphorus-
containing 
groups, 
protein 
tyrosine 
kinase 
activity 
FAM114A
1 
Family 
with 
Sequence 
Similarity 
114 
Member 
A1 
rs7655305 
Neuronal cell 
development 
Protein 
coding 
Associated 
with mixed 
germ cell 
cancer 
  
HEATR4 
HEAT 
repeat-
containing 
protein 4 
rs8012614 Lipid transport 
Protein 
coding 
  Binding 
LRRC55 
Leucine 
Rich 
Repeat 
Containing 
55 
rs548321 
Axonogenesis, positive 
regulation of voltage-
gated potassium channel 
activity, potassium ion 
transmembrane transport  
Protein 
coding 
    
MIR181A1 
MicroRN
A 181a-1 
rs427790 
Antioncogenic gene, 
dual function miRNA 
involved in 
tumorigenesis in cancer 
cell lines 
RNA 
gene, 
miRNA 
class 
Respiratory 
electron 
transport, ATP 
synthesis by 
chemiosmotic 
coupling, heat 
production by 
uncoupling 
proteins, 
MicroRNAs in 
cancer 
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NR5A2 
Nuclear 
Receptor 
Subfamily 
5 Group A 
Member 2 
rs427790 
Encodes a DNA-binding 
zinc finger transcription 
factor involved in 
hepatitis B virus and 
cholesterol biosynthesis 
gene expression, may 
regulate pancreas-
specific genes and 
embryonic development 
Protein 
coding 
Regulation of 
beta-cell 
development, 
Nuclear 
Receptor 
transcription 
pathway 
Transcription 
factor 
activity, 
sequence-
specific 
DNA 
binding, 
RNA 
polymerase 
II core 
promoter 
proximal 
region 
sequence-
specific 
DNA 
binding 
 
 
Appendix C.4. Top NTRK2 SNPS and Histone Modifications  
Associated active histone modifications contributing to chromatin states in the brain at 
top component SNPs outside of NTRK2. H3K27ac = enhancer/promoter-associated, H3K4me1 = 
enhancer-associated, H3K36me3 = transcription-associated. Data from HaploReg v4.1 (152) 
SNP Anterior 
Caudate 
Middle 
Hippocampus 
Regulatory motifs 
altered 
rs7801922     Evi-1, GATA, Irf, 
SEF-1 
rs7655305   H3K36me3 CTCF, Tel2 
rs548321 H3K27ac, 
H3K4me1 
  GR, Pax-4 
rs427790     DuxI, Foxj1, Zec 
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Appendix C.5. Rs7801922 Gene Regulation 
Reported gene regulation by rs7801922, the top SNP contributing to the frontally-related 
SNP component, in and outside of brain tissue. With the exception of the DLPFC, brain regions 
listed do not represent eQTLs but instead depict the strongest effects on gene expression in the 
brain. avia exon skipping, specific to disease and not control LIBD sample 
Gene Primary regions affected Source(s) 
C7orf63 DLPFCa, Hippocampus, Thalamus LIBD eQTL, Braineac 
STEAP2 Cerebellum, WM, Thalamus Braineac 
STEAP1 Occipital cortex Braineac 
GTPBP10 Lung, Tibial nerve GTEx portal eQTL 
DPY19L2P4 Thyroid, Substantia nigra 
GTEx portal eQTL, 
Braineac 
CDK14  Tibial artery, Substantia nigra 
GTEx portal eQTL, 
Braineac 
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Appendix D 
Appendix D.1. Group differences in age, sex, and education. 
Differences in age, sex, and years of education among groups. Asterisks denote 
significant results. The High group was older than the Medium and Low groups, and the Medium 
group was older than the Low group. The Low and Medium groups were also younger than the 
Control group. The High group had fewer years of education than the Control and Medium 
groups, and the Low group had fewer years of education than the Control group. Significant 
CAP-group differences in gender were also observed (there were more female participants 
overall) but were driven by the High vs. Low contrast. 
 Age Sex Education 
ANOVA F P F P F P 
Group 198.96 < 0.0001* 3.84 0.009* 9.40 < 0.0001* 
Sidak Post-
Hoc 
Diff P Diff P Diff P 
Low vs. HC -11.63 < 0.0001* 0.04 .64 -0.43 0.008* 
Med vs. HC -4.13 < 0.0001* -0.004 1.0 -0.26 0.16 
High vs. HC 0.31 0.95 -0.041 0.51 -0.56 < 0.0001* 
Med vs. Low 7.49 < 0.0001* -0.041 0.51 0.17 0.76 
High vs. Low 11.94 < 0.0001* -0.08 0.007* -0.13 0.88 
High vs. Med 4.45 < 0.0001* -0.04 0.38 -0.30 0.03* 
 
Appendix D.2. Full list of SBM components. 
Column I contains the component name (A-AJ) and number of gray matter (GM) and 
white matter (WM) voxels in the cluster with maximum representation in the component. 
Column II denotes the primary direction of the component (positive or negative). The remaining 
columns list the most prominent positive and negative regions in the component, maximum z-
scores and corresponding coordinates. Regions are listed in order of voxel-number in the cluster 
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(from greatest to fewest voxels). Bolded regions correspond to the maximum z-scores and 
respective coordinates. All images were thresholded at p = 0.05 in Xjview with a minimum 
cluster size of 5 unless otherwise specified; cases where no regions were represented at p = 0.05 
are indicated, and only the maximum effects from those clusters are listed. WM = White matter; 
GM = Gray Matter; L = Left; R = Right, BA = Brodmann Area, CSF = Cerebrospinal Fluid. 
Compone
nt 
+/
- 
Positive Regions Ma
x. + 
Stat
. 
Max. 
Coordi
nates 
Negative Regions Max
. – 
Stat. 
Max. 
Coordi
nates 
A 
GM: 168 
WM: 222 
- Frontal WM, Inferior 
Parietal Lobule, 
Postcentral Gyrus, 
Parietal Lobe, 
Supramarginal 
7.1 x: 48  
y: -24 
z: 29 
Angular Gyrus/BA39, 
Temporal Lobe WM, Middle 
Temporal Gyrus, Parietal 
Lobe, Superior Temporal 
Gyrus, Middle Occipital  
-9.0 x: -41  
y: -62  
z: 27       
B 
GM: 456 
WM: 
1860 
- Superior Parietal, 
Precuneus, Parietal 
WM, BA7 
 
6.4 x: -21      
y: -60        
z: 46 
Parietal WM, Angular 
Gyrus/BA39, Inferior Parietal 
Lobule, Precuneus, Middle 
Occipital, Superior Parietal 
Lobule/BA7, Superior 
Occipital, BA19, Inferior 
Parietal, Supramarginal 
Gyrus/BA40 
-
18.2 
x: 32      
y: -60        
z: 39 
C 
GM: 92 
WM: 
1284 
+ Parietal WM, Angular 
Gyrus/BA39, 
Supramarginal 
Gyrus/BA40, Superior 
Temporal Gyrus, Inferior 
Parietal Lobule, Middle 
Temporal Gyrus 
16.
5 
x: 39 
y: -55 
z: 31 
Parietal WM, Angular 
Gyrus, Inferior Parietal 
Lobule, Inferior Parietal, 
Supramarginal Gyrus/BA40, 
Superior Parietal Lobule 
-
14.5 
x: 34  
y: -54  
z: 40 
D 
GM: 62 
WM: 6 
- None @ p<0.05, peak in 
R Postcentral Gyrus WM 
3.6 x: 28       
y: -44         
z: 62 
None @ p<0.05, peak in L 
Superior Occipital, Cuneus, 
BA19, BA7, BA18, 
Precuneus, BA31 
-4.6 x: -18 
y: -85 
z: 29 
E 
GM: 45 
WM: 
1209 
+ Corpus Callosum WM, 
Sub-lobar, Inter-
Hemispheric, Extra-
Nuclear, Limbic Lobe, 
CSF, Lateral Ventricle, 
Cingulate Gyrus/BA23, 
Posterior Cingulate 
13.
1 
x: -1 
y: -19 
z: 24 
None @ p<0.05, peak in 
Caudate WM 
-5.0 x: -17 
y: 4 
z: 18 
F 
GM: 468 
WM: 953 
- None @ p<0.05, peak in 
L Angular Gyrus WM 
1.4 x: -38        
y: -66         
z: 30 
Supplementary Motor 
Area/BA6, Medial Frontal 
Gyrus WM, Superior Frontal 
Gyrus, Sub-Gyral, BA8 
-
11.7 
x: 10       
y: -7         
z: 64 
G - 
 
None @ p<0.05, peak in 
R Inferior Temporal Sub-
Gyral WM 
4.2 x: 47      
y: -19        
z: -22 
Cerebellum Anterior Lobe, 
Culmen, Cerebellum, Vermis 
4,5, Cerebellum 4,5, 
Cerebellum Posterior Lobe, 
-9.5 x: -1      
y: -56        
z: -14 
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Declive, Vermis 3, Cerebellar 
Lingual, Midbrain, 
R Brainstem, Cerebellum 3, 
Vermis 6 
H 
GM: 98 
WM: 360 
- Medial Frontal Gyrus, 
Supplementary Motor 
Area/BA6  
 
7.2 x: -10 
y: -11  
z: 63 
Cuneus, Occipital WM, 
Superior Occipital, Middle 
Occipital Gyrus, BA18, 
BA19, Temporal Lobe 
-
10.3 
x: -24 
y: -86  
z: 21         
I 
GM: 348 
WM: 
1181 
- None @ p<0.05, peak in 
R Precuneus, BA7 
4.8 x: 11 
y: -62 
z: 38 
Precuneus, Parietal WM, 
BA7, Superior Parietal, 
Superior Occipital, Cuneus 
-
15.8 
x: 17 
y: -67 
z: 46 
J 
GM: 275 
WM: 
2256 
+ Parietal WM, 
Postcentral Gyrus, 
Inferior Parietal, Inferior 
Parietal Lobule, 
Supramarginal/BA40, 
Superior Parietal, 
Paracentral Lobule, BA7, 
BA5, Precuneus 
23.
6 
x: 30       
y: -39        
z: 41 
Superior Parietal 
Lobule/BA7, 
Angular Gyrus, Superior 
Parietal, Precuneus, Inferior 
Parietal Lobule, Inferior 
Parietal 
 
-7.5 x: 28      
y: -55        
z: 44 
K 
GM: 230 
WM: 
1056 
- Middle Frontal Gyrus 
WM, Frontal Inferior 
Operculum, Frontal 
Inferior Trigeminal, BA9 
17.
4 
x: -35 
y: 17 
z: 31 
L Precentral, Middle 
Frontal Gyrus, Inferior 
Frontal Gyrus, BA9, Sub-
Gyral, Precentral Gyrus, BA6, 
Frontal Inferior Operculum 
-
25.3 
x: -36 
y: 7 
z: 38 
L 
GM: 39 
WM: 
1154 
+ Parietal WM, 
Postcentral 
Gyrus/BA2/BA3, 
Inferior Parietal, Inferior 
Parietal Lobule, BA40 
17.
7 
x: -30       
y: -36         
z: 45 
Inferior Parietal, Inferior 
Parietal Lobule, 
Supramarginal Gyrus/BA40, 
Angular Gyrus 
-
10.7 
x: -27       
y: -49         
z: 46 
M 
WM: 
1008 
GM: 69 
+ Middle Temporal 
WM/BA21, Inferior 
Temporal  
9.5 x: -55 
y: -18 
z: -12 
None @ p<0.05, peak in R 
Angular Gyrus, Supramarginal 
Gyrus WM 
-4.4 x: 41 
y: -52 
z: 33 
N 
GM: 709 
WM: 
1886 
+ Temporal WM, 
Superior Temporal 
Gyrus/BA22, L Middle 
Temporal, Angular 
Gyrus/ BA39, Middle 
Occipital 
24.
1 
x: -42       
y: -58        
z: 19 
Middle Temporal WM, 
Occipital Lobe, Sub-Gyral, 
Middle Occipital 
 
-9.9 x: -40      
y: -64     
z: 11 
O 
GM: 559 
WM: 
1932 
+ Parietal Lobe WM, 
Precuneus, Angular 
Gyrus, Superior Parietal 
Lobule/BA7, Superior 
Parietal, Inferior Parietal, 
Inferior Parietal Lobule, 
Superior Occipital 
23.
9 
 
x: 26       
y: -56        
z: 45 
Sub-Gyral WM, Parietal 
Lobe, Supramarginal 
Gyrus 
 
-6.9 x: 30       
y: -41         
z: 41 
P 
GM: 607 
WM: 
1218 
- None @ p<0.05, peak in 
Precentral (Sub-Gyral 
Frontal) 
3.1 x: 17        
y: -20         
z: 64 
Frontal WM, Medial Frontal 
Gyrus, Supplementary Motor 
Area/BA6, Sub-Gyral, 
Precentral Gyrus/BA4, 
Middle Frontal Gyrus, 
Paracentral Lobule, 
Postcentral Gyrus/BA3, 
Superior Frontal Gyrus 
-
10.4 
x: 17        
y: -20         
z: 64 
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Q 
GM: 410 
WM: 
1541 
+ Parietal Lobe WM, 
Inferior Parietal Lobule, 
Sub-Gyral, 
Supramarginal 
gyrus/BA40, Inferior 
Parietal, Frontal Lobe, 
Postcentral 
25.
8 
x: 38 
y: -40 
z: 39 
Supramarginal WM/BA40, 
Inferior Parietal Lobule, 
Angular Gyrus 
 
-
14.4 
x: 45 
y: -44 
z: 31 
R 
GM: 1336 
WM: 
1461 
- None @ p<0.05, 
maximum at R Precentral 
GM, BA9, Inferior 
Frontal Gyrus 
3.5 x: 46        
y: 2         
z: 32 
Cuneus, Superior Occipital, 
BA18, Middle Occipital 
Gyrus, BA19, Calcarine, 
BA17, Lingual Gyrus 
-
11.9 
x: -11        
y: -99         
z: 10 
S 
GM: 576 
WM: 
1128 
+ Rectus, Medial Frontal 
Gyrus, Anterior 
Cingulate, Limbic Lobe, 
Subcallosal Gyrus, 
Frontal Medial Orbital, 
Olfactory, Putamen, 
Caudate, Lentiform 
Nucleus, BA25, Caudate 
Head, BA11, BA47, 
BA32, Inferior Frontal 
Gyrus, Insula, Anterior 
Cingulum, Frontal 
Superior Orbital 
10.
2 
x: 8 
y: 23 
z: -12 
None @ p<0.05, peak in R 
Supramarginal Gyrus (Parietal 
Lobe) 
-3.1 x: 37 
y: -55 
z: 37 
T 
 
- None @ p<0.05, peak in 
Midbrain 
2.6 
 
x: -1 
y: -35 
z: 13 
Cerebellum Posterior Lobe, 
Declive, Cerebellum 6, 
Cerebellum Anterior Lobe, 
Cerebellum Crus 1, Culmen, 
Dentate, Uvula, Pyramis 
-
10.9 
 
x: 26         
y: -70          
z: -32 
 
U 
GM: 548 
WM: 740 
+ Putamen, WM, Extra-
Nuclear, GM, Lentiform 
Nucleus, Pallidum, 
Amygdala, Temporal 
Lobe, 
Claustrum, Limbic Lobe, 
Parahippocampal Gyrus 
14.
4 
x: 31       
y: -6         
z: -7 
None @ p<0.05, peak in L 
Middle Temporal Gyrus WM 
-5.4 
 
x: -38       
y: -61         
z: 17 
V 
GM: 424 
WM: 
1928 
- Parietal Lobe WM, 
Sub-Gyral, Inferior 
Parietal, Inferior Parietal 
Lobule, BA40, 
Postcentral 
8.3 x: -34        
y: -38         
z: 39 
Inferior Parietal GM, 
Superior Parietal, Precuneus, 
Superior Parietal 
Lobule/BA7, Inferior Parietal 
Lobule, Middle Occipital, 
Angular Gyrus, 
Supramarginal Gyrus/ BA40 
-
28.2 
x: -27        
y: -54         
z: 44 
 
W 
GM: 11 
WM: 674 
+/
- 
Parietal WM, Sub-
Gyral, Inferior Parietal, 
Postcentral Gyrus, 
Inferior Parietal Lobule, 
BA40, Superior Parietal, 
Frontal Lobe 
10.
1 
x: -32       
y: -39      
z: 42 
Frontal WM, Postcentral 
Gyrus, Precentral Gyrus/BA4, 
Parietal Lobe, Supramarginal, 
Inferior Parietal 
-
14.7 
x: -50      
y: -19       
z: 32 
X 
GM: 350 
WM: 
1573 
- Middle Frontal Gyrus 
WM, BA9, Frontal 
Inferior Operculum, 
Precentral, Inferior 
Frontal Gyrus, Frontal 
Inferior Trigeminal 
19.
1 
x: -36 
y: 12 
z: 36 
Frontal WM, L Precentral, 
Middle Frontal Gyrus, 
Inferior Frontal Gyrus, BA6, 
BA9, Precentral Gyrus, BA8 
-
24.5 
x: -36       
y: 3        
z: 38 
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Y 
GM: 86 
WM: 
1613 
+ Frontal WM, Middle 
Frontal Gyrus, BA9, 
Frontal Inferior 
Trigeminal, BA8, 
Superior Frontal  
12.
9 
x: 30       
y: 23         
z: 35 
Frontal WM, Frontal 
Inferior Trigeminal, Frontal 
Inferior Operculum, Middle 
Frontal Gyrus 
-
10.9 
x: 35       
y: 18         
z: 28 
Z 
GM: 867 
WM: 646 
+ Parietal Lobe, 
Precuneus, Superior 
Occipital, WM, Cuneus, 
Occipital Lobe, BA19, 
Superior Parietal, Middle 
Occipital, Superior 
Parietal Lobule/BA7 
14.
6 
x: -19       
y: -80         
z: 37 
None @ p<0.05, peak in 
Superior Parietal, Precuneus 
WM 
-6.1 x: -17       
y: -64        
z: 48 
AA 
GM: 25 
WM: 224 
+ L Middle Frontal Gyrus 
WM, BA8, BA6 
7.8 x: -32       
y: 14       
z: 45 
None @ p<0.05, peak in 
Supplementary Motor Area, 
Medial Frontal Gyrus WM  
5.3 x: 9       
y: -3         
z: 59 
AB 
GM: 874 
WM: 
1424 
- None @ p<0.05, peak in 
R Inferior Frontal 
Orbital, Inferior Frontal 
Gyrus WM 
4.2 x: 30      
y: 24        
z: -10 
Occipital Lobe, Cuneus, L 
Calcarine, BA17, Lingual 
Gyrus, BA18, Superior 
Occipital, BA23, Posterior 
Cingulate, Limbic Lobe, 
BA30, Middle Occipital 
Gyrus, 
BA19, BA31 
-
10.0 
x: -8      
y: -91        
z: 2 
AC 
GM: 812 
WM: 861 
- Medial Frontal Gyrus 
WM, Supplementary 
Motor Area/BA6 
    
 
9.7 x: 12        
y: -4         
z: 58 
Supplementary Motor 
Area/BA6, Medial Frontal 
Gyrus WM, Superior Frontal 
Gyrus, Middle Frontal Gyrus, 
Precentral Gyrus 
-
24.3 
x: 10 
y: -15 
z: 66 
AD 
GM: 244 
WM: 
1260 
- Frontal WM, Sub-
Gyral, Middle Frontal 
Gyrus, Precentral, BA6, 
Superior Frontal  
14.
4 
x: 28 
y: -4         
z: 44 
Frontal WM, R Precentral 
Gyrus, Inferior Frontal Gyrus, 
Middle Frontal Gyrus, BA9, 
BA6, Frontal Inferior 
Operculum 
-
19.7 
x: 36       
y: 1        
z: 35 
AE 
GM: 615 
WM: 386 
- Cuneus, Occipital WM, 
BA19 
7.1 x: 11      
y: -87        
z: 23 
R Calcarine, Cuneus, BA18, 
BA31, Posterior Cingulate, 
Limbic Lobe, Precuneus, 
Temporal Lobe, Parietal Lobe, 
Superior Occipital 
-
20.3 
x: 16      
y: -72       
z: 16 
AF 
GM: 2015 
WM: 101 
+ Thalamus GM, Medial 
Dorsal Nucleus, Ventral 
Lateral Nucleus, Ventral 
Anterior Nucleus, 
Pulvinar, Lateral 
Ventricle, CSF, Lateral 
Posterior Nucleus, WM, 
Extra-Nuclear, Lateral 
Dorsal Nucleus, Midline 
Nucleus 
20.
7 
x: 11        
y: -15         
z: 15 
 
None @ p<0.05, peak in R 
Sub-Gyral Temporal WM 
-1.3 
 
x: 41 
y: -57 
z: 2 
AG 
GM: 838 
WM: 
1075 
- Parietal Lobe WM, 
Sub-Gyral, Angular 
Gyrus, Superior Parietal 
Lobule/BA7 
7.6 x: 28      
y: -57        
z: 42 
Inferior Parietal, Inferior 
Parietal Lobule, 
Supramarginal Gyrus/BA40, 
Angular Gyrus 
 
-
16.3 
x: 38      
y: -52        
z: 40 
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AH 
GM: 238 
WM: 747 
+ Superior Temporal 
Gyrus, Temporal WM, 
Insula/BA13, Parietal 
Lobe, Inferior Parietal 
Lobule, BA41, BA40, 
BA42, Middle Temporal  
11.
4 
x: -55      
y: -38        
z: 15 
Frontal WM, Precentral, 
Middle Frontal Gyrus, Inferior 
Frontal Gyrus 
 
-7.1 x: 36      
y: 1        
z: 36 
AI 
GM: 400 
WM: 269 
+ Cuneus, Calcarine, 
BA17, BA18, BA23, 
Limbic Lobe, Posterior 
Cingulate, Lingual 
Gyrus, BA30, BA31 
9.0 x: 6      
y: -84         
z: 5 
None @ p<0.05, peak in L 
Inferior Temporal, Middle 
Temporal Gyrus WM 
6.3 x: -50       
y: -40        
z: -14 
AJ - None @ p<0.05, peak in 
L Occipital and Middle 
Temporal WM 
3.5 x: 40 
y: -66 
z: 12 
Brainstem, Pons, L 
Cerebellum 9, Cerebellar 
Tonsil, Cerebellum Posterior 
Lobe, Medulla, Cerebellum 
Anterior Lobe, Vermis 10, 
Nodule, Sub-lobar, Fourth 
Ventricle, CSF, Vermis 9  
-
21.0 
 
x: -1        
y: -50        
z: -52 
 
Appendix D.3. REFERENCE GLOSSARY OF COMPONENT REGIONS  
FRONTAL 
BA4 (Brodmann area 4): precentral gyrus (primary motor cortex) 
BA6 (Brodmann area 6): premotor cortex, supplementary motor cortex 
BA8 (Brodmann area 8): frontal eye fields 
BA9 (Brodmann area 9): dorsolateral prefrontal cortex 
BA10 (Brodmann area 10): anterior prefrontal cortex 
BA11,12 (Brodmann area 11 and 12): orbitofrontal area (orbital gyri, gyrus rectus, rostral 
gyrus and part of the superior frontal gyrus) 
BA46 (Brodmann area 46): dorsolateral prefrontal cortex 
BA47 (Brodmann area 47): pars orbitalis and part of the inferior frontal gyrus 
 
TEMPORAL 
BA21 (Brodmann area 21): middle temporal gyrus 
BA22 (Brodmann area 22): superior temporal gyrus (including Wernicke area) 
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BA41,42 (Brodmann area 41 and 42): primary auditory cortex (Heschl gyrus) 
 
PARIETAL 
BA1,2,3 (Brodmann areas 1, 2 and 3): postcentral gyrus (primary somatosensory cortex) 
BA5 (Brodmann area 5): superior parietal lobule (somatosensory association cortex)  
BA7 (Brodmann area 7): superior parietal lobule (visuo-motor coordination) 
BA39 (Brodmann area 39): angular gyrus 
BA40 (Brodmann area 40): supramarginal gyrus 
Precuneus 
 
OCCIPITAL 
BA17 (Brodmann area 17): primary visual cortex (V1) 
BA18 (Brodmann area 18): secondary visual cortex (V2) 
BA19 (Brodmann area 19): associative visual cortex (V3, V4 & V5) 
Cuneus 
 
OTHER 
BA13,16 (Brodmann area 13 and 16: insular cortex 
BA23,24,28-33 (Brodmann area 23, 24, and 28-33): cingulate cortex 
BA25: subgenual cingulate 
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Appendix D.4. Intercept contrast pairwise results for each component and contrast  
Intercept contrast pairwise results (un-stacked) for each component and contrast (t-
value/p-value). Significant p-values are displayed in bold black font, and the strongest results (p 
< 1e-04) are also underlined. Results were not calculated for components with non-significant 
Chi-square values; thus, these fields are shaded gray in lieu of these results. 
Component Low vs 
Control 
Medium vs 
Control 
High vs 
Control 
Medium vs 
Low 
High vs Low High vs 
Medium 
A 3.68/2e-04 0.56/0.57 -1.25/0.21 -3.36/8e-04 -5.24/<1e-4 -1.96/0.05 
B -0.63/0.53 1.81/0.07 2.08/0.04 2.52/0.01 2.80/0.01 0.28/0.78 
C -3.36/1e-3 -2.96/3e-3 -3.73/2e-4 0.57/0.57 -0.18/0.86 -0.80/0.42 
D 3.04/2e-3 -0.05/0.96 -1.40/0.16 -3.29/1e-3 -4.69/<1e-4 -1.46/0.14 
E 2.59/0.01 -1.15/0.25 -1.91/0.06 -3.93/1e-04 -4.73/<1e-4 -0.82/0.41 
F -2.02/0.04 -0.79/ 0.43 -1.52/0.13 1.35/0.18 0.63/0.53 -0.78/0.44 
G 0.12/0.90 0.83/0.41 -0.14/0.89 0.71/0.48 -0.27/0.79 -1.05/0.30 
H -0.81/0.42 0.43/0.67 0.96/0.34 1.30/0.19 1.85/0.06 0.57/0.57 
I -3.19/1e-3 -0.04/0.97 1.72/0.09 3.36/8e-04 5.17/<1e-4 1.90/0.06 
J 2.16/0.03 0.60/0.55 1.04/0.30 -1.70/0.09 -1.27/0.20 0.47/0.64 
K -0.06/0.95 -0.72/0.47 -2.74/0.01 -0.66/0.51 -2.72/0.01 -2.18/0.03 
L 2.47/0.01 0.81/0.42 1.44/0.15 -1.81/0.07 -1.19/0.23 0.67/0.50 
M 1.91/0.06 1.06/0.29 1.49/0.14 -0.95/0.34 -0.54/0.59 0.46/0.65 
N 3.96/1e-04 3.69/2e-04 7.56/<1e-4 -0.47/0.64 3.43/6e-04 4.16/<1e-4 
O 3.94/1e-04 2.59/0.01 5.42/<1e-4 -1.58/0.11 1.27/0.20 3.05/2e-3 
P -0.29/0.78 -1.14/0.25 -0.31/0.76 -0.86/0.39 -0.01/0.99 0.91/0.37 
Q -2.34/0.02 1.57/0.12 9.20/<1e-4 4.09/<1e-4 11.89/<1e-4 8.23/<1e-4 
R 1.56/0.12 -1.01/0.31 1.29/0.20 -2.70/0.01 -0.37/0.71 2.50/0.01 
S 3.35/1e-3 2.73/0.01 1.92/0.06 -0.80/0.43 -1.65/0.10 -0.90/0.37 
T -0.96/0.34 2.55/0.01 8.76/<1e-4 3.62/3e-04 9.95/<1e-4 6.70/<1e-04 
U 0.66/0.51 0.18/0.86 2.13/0.03 -0.52/0.60 1.46/0.15 2.10/0.04 
V -0.79/0.43 0.08/0.94 0.42/0.68 0.92/0.36 1.27/0.20 0.37/0.71 
W 0.44/0.66 0.11/0.92 1.15/0.25 -0.36/0.72 0.70/0.49 1.13/0.26 
X -3.37/1e-3 -2.35/0.02 -1.96/0.05 1.21/0.23 1.65/0.10 0.45/0.65 
Y 0.36/0.72 -2.21/0.03 -0.96/0.34 -2.63/0.01 -1.37/0.17 1.37/0.17 
Z -1.56/0.12 -0.80/0.42 1.19/0.24 0.85/0.40 2.89/4e-3 2.16/0.03 
AA 1.14/0.25 3.87/1e-04 5.21/<1e-4 2.72/7e-3 4.07/<1e-4 1.42/0.16 
AB 2.03/0.04 3.01/3e-3 4.80/<1e-4 0.90/0.37 2.71/7e-3 1.91/0.06 
AC -0.38/0.71 0.94/0.35 0.81/0.42 1.36/0.17 1.23/0.22 -0.15/0.88 
AD -2.10/0.04 -0.02/0.10 1.20/0.23 2.22/0.03 3.50/1e-3 1.32/0.19 
AE -0.27/0.79 -0.52/0.60 -2.71/0.01 -0.25/0.81 -2.47/0.01 -2.36/0.02 
AF 1.49/0.14 0.80/0.42 2.16/0.03 -0.78/0.44 0.60/0.55 1.47/0.14 
AG 1.27/0.20 2.14/0.03 7.26/<1e-4 0.82/0.41 6.01/<1e-4 5.52/<1e-4 
AH 1.07/0.29 -0.39/0.69 2.52/0.01 -1.54/0.12 1.42/0.16 3.16/2e-3 
AI 0.17/0.86 1.51/0.13 3.27/1e-3 1.35/0.18 3.14/2e-3 1.89/0.06 
AJ -0.56/0.57 -0.17/0.87 -0.78/0.43 0.43/0.67 -0.19/0.85 -0.66/0.51 
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Appendix D.6. Slope contrast pairwise results for each component and contrast  
Significant t-values/p-values are displayed in bold, and the strongest results (p < 1e-04) 
are also underlined.  
Component Low vs 
Control 
Medium vs 
Control 
High vs 
Control 
Medium vs 
Low 
High vs Low High vs 
Medium 
A -0.13/0.90 2.92/4e-3 3.73/2e-04 3.10/2e-3 3.89/1e-04 0.93/0.35 
B 0.65/0.52 0.35/0.73 2.96/3e-3 -0.36/0.72 2.29/0.02 2.87/4e-3 
C 2.96/3e-3 1.69/0.09 -0.36/0.72 -1.51/0.13 -3.52/4e-4 -2.23/0.03 
D -0.69/0.49 2.36/0.02 1.50/0.13 3.16/2e-3 2.26/0.02 -0.92/0.36 
E -1.33/0.18 1.06/0.29 1.35/0.18 2.52/0.01 2.78/0.01 0.33/0.74 
F -1.82/0.07 2.04/ 0.04 3.99/1e-04 4.02/1e-04 5.93/<1e-4 2.17/0.03 
G 2.83/0.01 0.25/0.80 2.94/3e-3 -2.82/0.01 -0.07/0.95 2.95/3e-3 
H 0.40/0.69 -4.71/<1e-4 -1.92/0.05 -5.19/<1e-4 -2.35/0.02 2.99/3e-3 
I 2.97/3e-3 0.68/0.50 -0.67/0.50 -2.55/0.01 -3.87/1e-04 -1.48/0.14 
J 0.98/0.33 1.52/0.13 3.93/1e-4 0.46/0.64 2.89/4e-3 2.66/0.01 
K -2.69/0.01 -2.39/0.02 -2.36/0.02 0.50/0.62 0.49/0.63 -0.003/1.0 
L -1.17/0.24 -0.04/0.97 2.10/0.04 1.23/0.22 3.36/1e-3 2.35/0.02 
M -0.68/0.50 2.20/0.03 1.44/0.15 2.95/3e-3 2.17/0.03 -0.80/0.42 
N -1.15/0.25 1.09/0.27 2.19/0.03 -1.00/0.32 0.05/0.96 -1.97/0.05 
O -0.36/0.72 1.97/0.05 -0.17/0.86 2.38/0.02 0.21/0.83 -2.32/0.02 
P -2.51/0.01 1.81/0.07 0.62/0.54 4.55/<1e-4 3.30/1e-3 -1.28/0.20 
Q 3.16/2e-3 8.86/<1e-4 13.43/<1e-4 5.50/<1e-4 10.11/<1e-4 5.14/<1e-4 
R -1.66/0.10 0.73/0.47 1.10/0.27 2.53/0.01 2.88/4e-3 0.42/0.68 
S -3.12/2e-3 -2.47/0.01 -2.78/0.01 0.89/0.37 0.53/0.60 -0.38/0.71 
T 2.77/0.01 3.83/1e-04 6.70/<1e-4 0.87/0.38 3.81/1e-04 3.21/1e-3 
U -0.67/0.50 0.41/0.68 1.83/0.07 1.14/0.25 2.55/0.01 1.56/0.12 
V 1.52/0.13 -0.08/0.94 3.41/1e-3 -1.73/0.08 1.80/0.07 3.82/1e-4 
W 0.18/0.86 -0.13/0.90 2.78/5e-3 -0.32/0.75 2.61/9e-3 3.19/1e-3 
X 0.58/0.57 0.76/0.45 -2.4/0.02 0.14/0.89 -3.03/2e-3 -3.46/1e-3 
Y 1.57/0.12 3.80/1e-4 2.61/0.01 2.17/0.03 0.96/0.34 -1.27/0.21 
Z -1.23/0.22 -2.30/0.02 -0.72/0.47 -0.98/0.33 0.59/0.55 1.70/0.09 
AA -2.45/0.01 -5.53/<1e-4 -2.69/7e-3 -2.96/3e-3 -0.10/0.92 3.04/2e-3 
AB 0.32/0.75 -1.27/0.20 -0.73/0.47 1.63/0.10 -1.07/0.29 0.57/0.57 
AC 3.91/1e-04 5.05/<1e-4 3.48/5e-04 0.85/0.40 -0.67/0.50 -1.65/0.10 
AD -0.78/0.44 -1.21/0.23 0.91/0.37 -0.39/0.70 1.75/0.08 2.31/0.02 
AE 0.35/0.73 -0.60/0.55 1.46/0.15 -0.99/0.32 1.10/0.28 2.25/0.03 
AF 1.35/0.18 3.86/1e-04 7.49/<1e-4 2.44/0.01 6.12/<1e-4 4.05/1e-04 
AG 0.97/0.33 5.38/<1e-4 3.97/1e-04 4.42/<1e-4 2.98/3e-3 -1.48/ 0.14 
AH -0.49/0.62 1.91/0.06 0.46/0.65 2.47/0.01 0.99/0.32 -1.57/0.12 
AI -1.14/0.25 -1.07/0.29 3.04/2e-3 0.16/0.87 4.30/<1e-4 4.50/<1e-4 
AJ -2.08/0.04 -1.75/0.08 1.15/0.25 0.49/0.63 3.42/1e-3 3.17/2e-3 
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Appendix D.7. Stacked analysis SDMT results 
Stacked analysis SDMT results comparing component intercepts and slopes with SDMT 
intercepts and slopes in each group (Control, Low CAP, Medium CAP, and High CAP). 
Intercept results are displayed in blue and slope results in green. Significant results are displayed 
in bold black font. 
Component C_int Low_int Med_int High_int C_slope L_slope Med_slope High_slope 
A 6e-4 0.42 2e-4 <1e-4 <1e-4 0.55 0.71 0.02 
B <1e-4 8e-4 <1e-4 <1e-4 1e-4 0.29 6e-4 <1e-4 
C 0.02 0.02 1e-4 <1e-4 <1e-4 7e-4 0.04 <1e-4 
D <1e-4 0.02 <1e-4 <1e-4 <1e-4 0.82 0.15 0.02 
E <1e-4 0.04 <1e-4 <1e-4 <1e-4 0.97 0.62 6e-4 
F 1e-4 6e-4 <1e-4 <1e-4 <1e-4 0.56 0.33 2e-4 
G <1e-4 8e-4 <1e-4 <1e-4 6e-4 0.40 <1e-4 <1e-4 
H 6e-4 0.01 <1e-4 <1e-4 <1e-4 6e-4 <1e-4 <1e-4 
I <1e-4 0.02 <1e-4 <1e-4 <1e-4 0.82 0.15 0.02 
J <1e-4 <1e-4 <1e-4 <1e-4 0.11 0.11 <1e-4 <1e-4 
K <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.02 0.56 9e-4 
L <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.01 0.77 0.34 
M <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.02 0.56 9e-4 
N <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-4 3e-4 0.35 
O <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.55 
P <1e-4 1e-4 <1e-4 <1e-4 <1e-4 0.95 0.10 <1e-4 
Q <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
R <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.03 0.63 0.01 
S <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 4e-4 0.14 0.03 
T <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
U <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.34 0.01 <1e-4 
V <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-3 3e-3 <1e-4 
W <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.01 2e-3 0.10 
X <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.10 
Y <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.02 
Z <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.01 0.92 
AA <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
AB <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.02 0.10 
AC <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.01 1e-3 
AD <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-3 
AE <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 5e-4 
AF <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
AG <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
AH <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 2e-3 0.04 
AI <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-4 <1e-4 
AJ <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
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Appendix D.8. Stacked analysis Stroop Color results 
Stacked analysis Stroop Color results comparing component intercepts and slopes with 
Stroop Color intercepts and slopes in each group (Control, Low CAP, Medium CAP, and High 
CAP). Intercept results are displayed in blue and slope results in green. Significant results are 
displayed in bold black font. 
Component C_int Low_int Med_int High_int C_slope L_slope Med_slope High_slope 
A 0.09 0.02 1e-3 <1e-4 <1e-4 0.01 0.13 <1e-4 
B <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-4 0.50 0.23 
C 0.01 0.01 5e-4 <1e-4 <1e-4 0.01 <1e-4 <1e-4 
D 1e-4 0.02 <1e-4 <1e-4 5e-4 0.97 0.08 0.01 
E 5e-4 0.03 <1e-4 <1e-4 <1e-4 0.80 0.86 1e-4 
F 2e-3 6e-4 1e-4 <1e-4 <1e-4 0.90 0.76 <1e-4 
G <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 2e-4 4e-4 0.01 
H <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
I 9e-4 <1e-4 <1e-4 <1e-4 2e-4 <1e-4 0.40 <1e-4 
J 2e-4 8e-4 <1e-4 <1e-4 0.03 0.91 <1e-4 <1e-4 
K <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.05 0.81 2e-4 
L <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
M <1e-4 2e-4 <1e-4 <1e-4 <1e-4 0.71 0.37 <1e-4 
N <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.10 0.36 1e-3 
O <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.07 
P 1e-4 1e-4 <1e-4 <1e-4 <1e-4 0.49 0.31 <1e-4 
Q <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
R <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.01 
S <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-3 0.07 0.01 
T <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-4 
U <1e-4 <1e-4 <1e-4 <1e-4 0.58 0.03 <1e-4 <1e-4 
V <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.01 0.02 <1e-4 
W <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.01 0.03 
X <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.03 
Y <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.02 0.47 0.15 
Z <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.92 
AA <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.76 0.03 <1e-4 
AB <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-3 0.65 
AC <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 4e-3 2e-4 
AD <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.05 
AE 2e-4 7e-4 1e-4 <1e-4 3e-3 0.58 3e-3 <1e-4 
AF <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
AG <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 3e-3 
AH <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
AI <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 2e-4 1e-4 0.16 
AJ <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
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Appendix D.9. Stacked analysis Stroop Interference results 
Stacked analysis Stroop Interference results comparing component intercepts and slopes 
with Stroop Interference intercepts and slopes in each group (Control, Low CAP, Medium CAP, 
and High CAP). Intercept results are displayed in blue and slope results in green. Significant 
results are displayed in bold black font. 
Component C_int Low_int Med_int High_int C_slope L_slope Med_slope High_slope 
A 5e-3 0.84 0.01 <1e-4 <1e-4 0.01 8e-4 0.86 
B 1e-4 0.01 5e-4 <1e-4 1e-4 1e-3 0.84 0.12 
C 0.08 0.09 4e-3 <1e-4 <1e-4 <1e-4 0.10 <1e-4 
D 1e-4 0.08 <1e-4 <1e-4 <1e-4 0.03 1e-4 0.52 
E 3e-4 0.14 <1e-4 <1e-4 <1e-4 0.04 0.03 0.12 
F 2e-3 0.01 3e-4 <1e-4 <1e-4 2e-3 2e-3 0.55 
G 1e-4 7e-3 1e-4 <1e-4 7e-4 1e-3 0.10 <1e-4 
H 0.01 0.07 2e-3 <1e-4 <1e-4 <1e-4 0.14 2e-4 
I 6e-4 7e-4 1e-4 <1e-4 <1e-4 <1e-4 0.19 3e-4 
J <1e-4 3e-4 <1e-4 <1e-4 0.08 0.33 0.03 <1e-4 
K <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.03 0.16 
L <1e-4 1e-4 <1e-4 <1e-4 <1e-4 <1e-4 7e-4 0.26 
M <1e-4 3e-3 <1e-4 <1e-4 <1e-4 6e-4 0.01 2e-3 
N <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.42 
O <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.01 
P <1e-4 2e-3 <1e-4 <1e-4 <1e-4 0.01 0.01 2e-4 
Q <1e-4 <1e-4 <1e-4 <1e-4 4e-4 0.01 0.04 2e-3 
R <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 3e-4 0.64 
S <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-4 0.72 
T <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
U <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-3 0.27 0.01 
V <1e-4 5e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.18 0.18 
W <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 5e-4 0.13 
X <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.64 
Y <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 2e-4 
Z <1e-4 1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.01 
AA <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
AB <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.49 
AC <1e-4 1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.61 
AD <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
AE 1e-4 0.01 5e-4 <1e-4 1e-4 1e-3 0.84 0.12 
AF <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
AG <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
AH <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.90 
AI <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
AJ <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
 
  
203 
Appendix D.10. Stacked analysis Stroop Word results 
Stacked analysis Stroop Word results comparing component intercepts and slopes with 
Stroop Word intercepts and slopes in each group (Control, Low CAP, Medium CAP, and High 
CAP). Intercept results are displayed in blue and slope results in green. Significant results are 
displayed in bold black font. 
Component C_int Low_int Med_int High_int C_slope L_slope Med_slope High_slope 
A 2e-4 0.09 1e-4 <1e-4 0.16 0.16 0.39 <1e-4 
B <1e-4 <1e-4 <1e-4 <1e-4 0.32 0.23 <1e-4 <1e-4 
C 0.01 2e-3 1e-4 <1e-4 0.03 0.33 4e-4 <1e-4 
D <1e-4 1e-3 <1e-4 <1e-4 0.04 0.22 0.73 <1e-4 
E <1e-4 3e-3 <1e-4 <1e-4 0.01 0.10 0.09 <1e-4 
F 1e-4 <1e-4 <1e-4 <1e-4 1e-3 0.02 9e-3 <1e-4 
G <1e-4 <1e-4 <1e-4 <1e-4 0.78 0.03 <1e-4 <1e-4 
H 2e-4 7e-4 <1e-4 <1e-4 <1e-4 0.37 <1e-4 <1e-4 
I <1e-4 <1e-4 <1e-4 <1e-4 0.02 2e-3 0.03 <1e-4 
J <1e-4 <1e-4 <1e-4 <1e-4 0.08 <1e-4 <1e-4 <1e-4 
K <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.54 0.07 <1e-4 
L <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.47 0.29 4e-3 
M <1e-4 <1e-4 <1e-4 <1e-4 0.02 0.08 2e-3 <1e-4 
N <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.02 0.01 0.01 
O <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.23 
P <1e-4 <1e-4 <1e-4 <1e-4 0.01 3e-3 8e-4 <1e-4 
Q <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
R <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.98 0.38 <1e-4 
S <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.05 0.75 2e-4 
T <1e-4 <1e-4 <1e-4 <1e-4 1e-4 <1e-4 1e-3 5e-3 
U <1e-4 <1e-4 <1e-4 <1e-4 0.02 0.09 <1e-4 <1e-4 
V <1e-4 <1e-4 <1e-4 <1e-4 2e-3 0.73 <1e-4 <1e-4 
W <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.02 0.24 0.01 
X <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 2e-4 3e-4 
Y <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-4 <1e-4 0.46 
Z <1e-4 1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.01 
AA <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-4 1e-3 
AB <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.39 2e-4 
AC <1e-4 <1e-4 <1e-4 <1e-4 3e-4 1e-3 0.30 <1e-4 
AD <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 2e-3 0.09 
AE <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-4 0.07 
AF <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-4 <1e-4 <1e-4 
AG <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
AH <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.03 0.05 1e-4 
AI <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.01 <1e-4 
AJ <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
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Appendix D.11. Stacked analysis TMTA results 
Stacked analysis TMTA results comparing component intercepts and slopes with TMTA 
intercepts and slopes in each group (Control, Low CAP, Medium CAP, and High CAP). 
Intercept results are displayed in blue and slope results in green. Significant results are displayed 
in bold black font. 
Component C_int Low_int Med_int High_int C_slope L_slope Med_slope High_slope 
A 0.21 0.48 0.20 <1e-4 0.01 0.69 0.06 0.03 
B 0.03 0.07 0.05 <1e-4 0.01 0.51 0.35 4e-4 
C 0.89 0.45 0.16 <1e-4 3e-4 0.01 0.77 <1e-4 
D 0.01 0.36 3e-3 <1e-4 2e-3 0.88 0.01 0.01 
E 0.05 0.56 1e-3 <1e-4 4e-4 1.0 0.32 6e-4 
F 0.12 0.06 0.03 <1e-4 <1e-4 0.75 0.13 0.01 
G 0.03 0.07 0.02 <1e-4 0.04 0.62 0.01 <1e-4 
H 0.27 0.39 0.13 1e-4 <1e-4 0.01 0.01 <1e-4 
I 0.07 0.02 0.02 <1e-4 1e-3 1e-4 0.74 <1e-4 
J 1e-4 0.01 <1e-4 <1e-4 0.57 0.17 0.002 <1e-4 
K <1e-4 1e-4 <1e-4 <1e-4 <1e-4 0.06 0.28 1e-3 
L <1e-4 2e-3 <1e-4 <1e-4 <1e-4 0.03 0.05 0.26 
M 1e-3 0.04 5e-4 <1e-4 3e-4 0.53 0.35 <1e-4 
N <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 7e-4 <1e-4 0.23 
O <1e-4 2e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.87 
P 0.01 0.03 3e-4 <1e-4 <1e-4 0.93 0.35 <1e-4 
Q <1e-4 <1e-4 1e-4 1e-4 1e-4 <1e-4 0.01 <1e-4 
R <1e-4 1e-4 <1e-4 <1e-4 <1e-4 0.12 0.03 0.01 
S <1e-4 8e-4 <1e-4 <1e-4 <1e-4 3e-3 0.01 0.02 
T <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 8e-4 
U <1e-4 2e-4 <1e-4 <1e-4 2e-4 0.50 0.86 <1e-4 
V 0.01 0.01 1e-3 <1e-4 <1e-4 0.02 0.85 4e-4 
W <1e-4 6e-4 <1e-4 <1e-4 <1e-4 4e-4 0.04 0.44 
X 3e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.08 
Y 3e-4 4e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.14 
Z 3e-3 3e-3 1e-4 <1e-4 <1e-4 <1e-4 1e-4 0.98 
AA <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 3e-4 
AB <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 2e-4 0.10 
AC 9e-4 3e-3 2e-4 <1e-4 <1e-4 <1e-4 1e-4 0.01 
AD 4e-4 2e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.02 
AE <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.01 
AF <1e-4 1e-3 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
AG <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
AH <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 8e-4 <1e-4 0.06 
AI <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-4 <1e-4 
AJ <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
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Appendix D.12. Stacked analysis TMTB results 
Stacked analysis TMTB results comparing component intercepts and slopes with TMTB 
intercepts and slopes in each group (Control, Low CAP, Medium CAP, and High CAP). 
Intercept results are displayed in blue and slope results in green. 
Component C_int Low_int Med_int High_int C_slope L_slope Med_slope High_slop
e 
A 4e-3 0.40 9e-4 <1e-4 0.05 0.56 3e-3 3e-3 
B 1e-4 8e-4 <1e-4 <1e-4 0.10 0.72 0.95 <1e-4 
C 0.07 0.02 5e-4 <1e-4 0.01 0.10 0.19 <1e-4 
D <1e-4 0.02 <1e-4 <1e-4 0.02 0.51 3e-4 3e-3 
E 3e-4 0.03 <1e-4 <1e-4 4e-3 0.35 0.05 <1e-4 
F 2e-3 6e-4 <1e-4 <1e-4 3e-4 0.34 0.01 <1e-4 
G 1e-4 8e-4 <1e-4 <1e-4 0.36 0.47 0.05 <1e-4 
H 5e-3 0.01 2e-4 <1e-4 <1e-4 0.12 0.09 <1e-4 
I 4e-4 <1e-4 <1e-4 <1e-4 0.01 1e-3 0.23 <1e-4 
J <1e-4 <1e-4 <1e-4 <1e-4 0.56 0.01 0.01 <1e-4 
K <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.30 0.05 1e-4 
L <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.18 2e-3 0.06 
M <1e-4 4e-4 <1e-4 <1e-4 0.01 0.58 0.04 <1e-4 
N <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.01 <1e-4 0.08 
O <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.64 
P <1e-4 1e-4 <1e-4 <1e-4 1e-3 0.15 0.04 <1e-4 
Q <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.05 <1e-4 
R <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.49 9e-4 6e-4 
S <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.03 2e-4 4e-3 
T <1e-4 <1e-4 <1e-4 <1e-4 1e-4 <1e-4 <1e-4 2e-3 
U <1e-4 <1e-4 <1e-4 <1e-4 3e-3 0.62 0.44 <1e-4 
V <1e-4 <1e-4 <1e-4 <1e-4 7e-4 0.22 0.39 <1e-4 
W <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.01 2e-3 0.10 
X <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.01 
Y <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-4 <1e-4 0.24 
Z <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.32 
AA <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 7e-4 
AB <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.01 
AC <1e-4 <1e-4 <1e-4 <1e-4 1e-4 4e-4 <1e-4 1e-4 
AD <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.03 
AE <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.03 
AF <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 2e-4 <1e-4 <1e-4 
AG <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
AH <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.01 <1e-4 0.01 
AI <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
AJ <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 
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Appendix D.13. Stacked analysis UHDRS-TMS results 
Stacked analysis UHDRS-TMS results comparing component intercepts and slopes with 
UHDRS-TMS intercepts and slopes in each group (Control, Low CAP, Medium CAP, and High 
CAP). Intercept results are displayed in blue and slope results in green. Significant results are 
displayed in bold black font. 
Component C_int Low_int Med_int High_int C_slope L_slope Med_slope High_slope 
A 0.26 4e-3 0.37 0.06 0.03 0.18 1e-3 <1e-4 
B 0.88 0.82 0.91 0.04 0.04 0.25 <1e-4 <1e-4 
C 0.02 0.17 0.43 0.08 2e-3 0.40 <1e-4 <1e-4 
D 0.89 0.21 0.44 1e-4 0.01 0.13 0.06 <1e-4 
E 0.69 0.11 0.22 2e-4 2e-3 0.09 1e-4 <1e-4 
F 0.47 0.94 0.84 0.01 1e-4 0.11 <1e-4 <1e-4 
G 0.98 0.85 0.70 6e-3 0.15 0.16 <1e-4 <1e-4 
H 0.20 0.21 0.52 0.16 <1e-4 0.50 <1e-4 <1e-4 
I 0.44 0.81 0.95 0.15 5e-3 0.02 <1e-4 <1e-4 
J 0.09 0.41 0.01 <1e-4 0.93 9e-4 <1e-4 <1e-4 
K 0.03 0.06 5e-4 <1e-4 <1e-4 0.86 2e-4 <1e-4 
L 0.03 0.27 3e-3 <1e-4 <1e-4 0.63 9e-4 <1e-4 
M 0.27 0.84 0.11 2e-4 2e-3 0.20 <1e-4 <1e-4 
N <1e-4 4e-3 <1e-4 <1e-4 <1e-4 0.08 0.96 <1e-4 
O 1e-3 0.08 1e-4 <1e-4 <1e-4 <1e-4 0.08 <1e-4 
P 0.75 0.74 0.09 3e-4 4e-4 0.03 <1e-4 <1e-4 
Q 0.16 0.02 0.18 0.32 <1e-4 <1e-4 <1e-4 <1e-4 
R 5e-3 0.03 <1e-4 <1e-4 <1e-4 0.78 2e-3 <1e-4 
S 0.01 0.18 2e-3 <1e-4 <1e-4 0.20 0.03 <1e-4 
T 0.04 0.03 0.06 0.07 <1e-4 6e-4 0.78 <1e-4 
U 0.02 0.05 1e-3 <1e-4 2e-3 0.21 <1e-4 <1e-4 
V 0.69 0.55 0.23 1e-3 2e-4 0.60 <1e-4 <1e-4 
W 0.04 0.11 2e-3 <1e-4 <1e-4 0.07 4e-4 <1e-4 
X 0.17 0.01 2e-4 <1e-4 <1e-4 <1e-4 0.51 <1e-4 
Y 0.22 0.14 2e-3 <1e-4 <1e-4 3e-3 0.05 <1e-4 
Z 0.46 0.28 0.04 2e-4 <1e-4 1e-4 0.09 <1e-4 
AA 0.005 0.04 2e-3 <1e-4 <1e-4 <1e-4 0.35 <1e-4 
AB 1e-3 0.02 4e-4 <1e-4 <1e-4 <1e-4 0.07 <1e-4 
AC 0.25 0.26 0.08 <1e-4 <1e-4 0.01 0.09 <1e-4 
AD 0.22 0.08 0.01 <1e-4 <1e-4 <1e-4 0.62 <1e-4 
AE <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 0.42 <1e-4 
AF 0.04 0.28 0.01 <1e-4 <1e-4 0.01 0.19 <1e-4 
AG <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-4 
AH 2e-3 5e-3 <1e-4 <1e-4 <1e-4 0.10 0.45 <1e-4 
AI 0.03 0.03 3e-3 <1e-4 <1e-4 4e-4 0.79 <1e-4 
AJ 0.01 0.03 <1e-4 <1e-4 <1e-4 <1e-4 <1e-4 1e-4 
 
 
